oxkdesign_portfolio by oxkdesign

KING HO GRAPHIC DESIGNER

MY PORTFOLIO

H 3

CLIENT OPTION C1

Logo

OPTION C2

shapin OPTION C4

3ye0 ars t 30 brate Cele splan Tran

う ELT 日を祝

3ye0 ars 0 brez lant 3 p s Tran

ELT MS

Count on

3ye0 ars t 30 rn Feie splan Tran OPTION C4 B5 OPTION

OPTION C5

Concept ‘Talk to the ELT’ breakfast meetings

Benecol ACADEMY

ETING

T ME

Red Door Unlimited 01.03.2017

Application

OPTION A3 Print & Web Media

OPTION C6

OPTION B6

CANCER

Count on

THE Benecol ACADEMY Time to hangeBenecol

programme partnerships

ELT

KFAS

BREA

Job Description Logo Design and Development for Astellas as a informal chat/meeting in a cafe during breakfast

CANCER: Count on

Count on

ELT

breakfast meetings

s A OPTION3yeF0arA2 ggia 30 este ianto

Trap

TATLHKE

Job Des Logo De Genzym

Benecol

programme partnerships

Client Astellas

Concept Combining spider graphs, polygons and data analysis representing the many facets of MS

Count on

Benecol

programme partnerships

Client Genzyme

breakfast meetings

Talk to the

OPTION C3

Count on

Benecol

ELT

breakfast meetings

3ye0 0 arsELT es 3 bre Cele plant as rMEETINGS TBREAKFAST

OPTION C2

Talk to the

SHAPING

OPTION B3 Talk to the

OPTION CéC1lé

THE

Talk to the

breakfast 0 移植3meetings

OPTION B2

OPTION A1

Talk to the

3ye0 ars

OPTION C5

Time to Change

THE

ACADEM

programme partnerships

Count on

Benecol OPTION A5

Client Benecol

Concept check/tick meaning test, exam correct answer, solution, Food +/ more than food

Time to Change C-Change

nisms

THE

ACADEMY

PROJECT

CANCER Healthcare

Logo design and development

Client RDU

C-Change OPTION A4

Print and digital media

Concept C-Change (see, sea, C, look, view) Vision.change.direction.process

Job Description Logo Design and Development

C Client RDC

Concept Modular Based Digital

Time to Change

Compliance

WORK TYPE

OPTION A3

TimeCompliance to Change

ACADEMY

C-Change

Client Astellas

OPTION C3

CANCER Healthcare Free

Red Door Communications OPTION C2 16.08.2012

Application OPTION A2 OPTION C1 Print & Web Media

Application Print & Web Media

Date 22.02.2016

red door unlimited www.reddoorunlimited.com

Concept Healthcare Compliance (HCC) Compliance is in our DNA

Job Description Logo Design and Development for

Years

Red Door Communications 10.04.2013

Application Print & Web Media

Healthcare Cancer: Compliance

C-Change Job Description OPTION A1 Logo Design and Development for AstraZeneca

OPTION A6

Job Description Logo Design and Development for Count on Benecol/Cholesterol counts

5 5

OPTION A4

Years Free The

Years

Academe

CANCERFree Time to Change

Healthcare Compliance

Years Free

OPTION C4

Job Description Logo Design and Development

Application Print & Web Media

Date 29.02.2016

red door unlimited www.reddoorunlimited.com

CLIENT

Logos OPTION D2

OPTION D3

DIFFICULT TO

DIFFICULT

CHEMIA TO

REACH

CONNECTED TO HEALTH

REACH

OPTION A1 OPTION D5

OPTION D6

DIFFIC U LT

REACH DIP TO

DIFFIC ULT

INTO DIGITAL

REACH TO

CHEMIA Application CONNECTED TO HEALTH Print & Web Media

velopment

Red Door Communications 08.11.2012

Client RDC

Concept Reaching out and helping the hard to reach

Job Description Logo Design and Development for ‘Difficult to Reach’

OPTION A1

Red Door Communications 13.09.2012

Application Print & Web Media

OPTION A2

OPTION B

Concept Connections, health

Job Description Logo Design and Development for Chemia - connected in health

FAMILIAL

EVERYTHING

FAMILIAL SEE ME

HYPERCHO LESTEROLEMIA

OPTION B2

S H A P E D dip INTO digital

CROWD SHAPED

OPTION B1

OPTION B2

OPTION D2

OPTION D3 OPTION A4

FAMILIAL

HYPERCHOLESTEROLEMIA

OPTION B3

Client Sanofi

SORE THROAT SMART

HYPERCHOLESTEROLEMIA

EVERYTHING HEART OF THE

OPTION B4

HEART OF THE

FAMILY OPTION A1

Concept Familial Hypercholesterolemia

OPTION A5

FAMILIAL

Job Description Logo Design and Development

OPTION B3

FAMILY RALLY HEART OF THE

FAMILY SEE ME

Application Print & Web Media

OPTION DateA2

20.02.2015

OPTION A3

red door unlimited www.reddoorunlimited.com

OPTION D5

Sore

Client Sanofi

Client Sirukumab

CROWD

Concept

SHAPED

SMART

Job Description Logo Design and Development

WORK TYPEFamilial Hypercholesterolemia

Logo design and development Throat Print and digital media

ConceptOPTION • Everything RA • RAlly

Client RDC

CROWD

OPTION B4

SHAPED

PROJECT

LLY

C R O W D

H Y P E R C H O L ESTEROLEMIA

OPTION B1

Red Door Communications 24.10.2013

Application Print & Web Media

Concept CrOwd shaPeD SMART

Date 12.03.2015

Application Print & Web Media

Date 02.12.2015

red door www.reddoorunl

red door unlimited www.reddoorunlimited.com

Job Description Logo Design and Development

Application Print & Web M

CLIENT

Logos OPTION A1

Get

OPTION A2

Get

COMFORTABLE

PSORIASIS CONVERSATIONS OUT OF THE

COMFORTABLE

PSORIASIS CONVERSATIONS

SHADOWS

OUT OF THE

OPTION B1

OPTION B2

OPTION C1

OPTION A3

PSORIASIS OUT OF THE

SHADOWS

Communications Network

Communications Network 2017 Copenhagen Meeting

OPTION A5 OPTION B2

OPTION A6

OPTION B3

OPTION C4

get comfortable conversations

HIV START PSORIASIS ACTION

HIV HYGIENE PSORIASIS Get Comfortable Conversations START

Client Canesten

GETTING

OUT OF THE ACTION GROUP SHADOWS Concept Get Comfortable Conversations

n Group

ACTION

GROUP

2017 Copenhagen Meeting SHADOWS Date 03.04.2016

Application Print & Web Media

Client Astellas

Communications Network PSORIASIS BETTER OUT OF THE 2017 Copenhagen Meeting rest, liquids & painkillers SHADOWS

red door unlimited www.reddoorunlimited.com

Concept Hygge (a Danish word that can be vaguely translated with cosiness)

OPTION B5 HYGIENE

Job Description Logo Design and Development for The Astellas Communications Network meeting in Copenhagen

Job Description Logo Design and Development for Psoriasis: Out of the shadows

GROUP

Power To Move

HIV

Red Door Communications 10.04.2013

Application Print & Web Media

GROUP

Start Getting

Job Description Hygiene Action Group Logo Design and Development for

Concept HIV: start getting personal.

02 PROJECT

WORK TYPE

Logo design and development

Print and digital media

Client RDC

Kivexa pitch

Concept Lighthouse Direction

Client Treat yourself better

Power To Move

Concept To encourage consumers to self treat cold and flu symptoms, seeking pharmacy advice

HIV:PERSONAL

PERSONAL Hygiene Action Group

PERSONAL

Red Door Unlimited 23.01.2017

Application Print & Web Media

OPTION B6

ACTION

Concept Shadows, skin, positivity. Shifting out of the shadows

GETTING

Client RDC/Kivexa

OUT OF THE

Job Description Logo Design and Development

HIV START

Action Group

GETTING Communications Network

OPTION B4

OPTION B4 HYGIENE Client RDC Novartis

TART HIVGSTREAT TTING E YOURSELF

HYGIENE

Personal

OPTION B3

with rest & cold & flu medicines

SHADOWS

2017 Copenhagen Meeting

OPTIONB1 A4 OPTION

TREAT YOURSELF BETTER

START GETTING

Application Print & Web Media

Job Description Logo Design and Development for ViiV Healthcare DTG/Trii LOC

POWER TO MOVE

Red Door Communication 18.02.201

Application Print & Web Media

CLIENT

Infographics

COFFEE IN THE UK 79% of consumers drink coffee (either ground or instant)1,

What is breathlessness?

COFFEE HEALTH It's reassuring to know that caffeine is one of the most heavily researched compounds in the world today and the overwhelming weight of scientific information suggests that moderate caffeine consumption of four to five cups per day is safe and may even confer some health benefits3.

A common symptom of COPD is breathlessness. Breathlessness is when you feel short of breath or have trouble breathing. This is because your lungs have to work harder than normal to inhale and exhale.

What causes breathlessness?

With COPD there are 2 common conditions that cause breathlessness:

Chronic bronchitis

This makes it more difficult to inhale and exhale and can leave you feeling short of breath. Normal airway

79%

Airway with chronic bronchitis

Emphysema

For pregnant women guidelines issued by the Food Standards Agency recommend a safe upper limit of 200mg caffeine per day from all sources4.

Normal alveoli

meaning that as a nation we consume approximately

COFFEE & HYDRATION 10 MILLION 20 MILLION 30 MILLION 40 MILLION 50 MILLION 60 MILLION 70 MILLION

70 million cups of coffee per day2.

THE UK

Alveoli with emphysema

Research has shown that the amount of caffeine consumed throughout the day in a couple of cups of coffee is no more a diuretic than water5.

Therefore evidence shows that when consumed in moderation, coffee is not in fact dehydrating and can contribute to your daily fluid intake6.

With chronic bronchitis, airways in the lungs become inflamed and narrow and produce extra mucus.

Emphysema affects the alveoli, air sacs at the end of airways. With emphysema the air sacs are damaged or destroyed and cannot be repaired. With fewer air sacs, less inhaled oxygen can reach the bloodstream. This leads to breathlessness in the later stages of COPD. Emphysema also causes the lungs to lose their springiness, which means that the lungs are not emptied each time you exhale. Eventually the lungs expand too much (hyperinflation). As a result, the lungs must work harder to breathe.

Tell your doctor if you are feeling breathless. It is important to begin treatment right away to control symptoms.

How can I stay active?

17%

25%

Coffee market is continuing to grow, with sales already increasing by 17% between 2005 and 2009 and the market is forecast to continue to grow by almost a quarter by 20142.

0.5l

1.0l

1.5l

2.0l

2.5l

In the early stages of COPD, breathlessness may be felt during activities that need extra effort. These activities may include walking or running up stairs. Everyone’s lungs weaken over time, but it happens faster in people who have COPD. As COPD worsens, everyday actions like getting dressed may cause breathlessness.

Adults 19-70 years

Males

2.5 L/day

19-70 years

Females

2.0 L/day

You may think you are too breathless to exercise, but regular exercise can actually make you feel less breathless over time.

Special cases

25%

47%

Pregnant women

2.3 L/day

Lactating women

2.7 L/day

COFFEE & CANCER In 2008, coffee shop openings actually increased by 25%.

In 2009 the six biggest chains in the UK increased their retail space by 47% according to a study from the Local Data Company1.

AT PRESENT almost half the population (47%) drink coffee in coffee shops and cafés, the majority of whom are from a younger demographic1. Coffee shops also have a much stronger appeal for women, whilst men are more likely to drink and buy coffee at work1.

Data published in BioMed Central Cancer suggests that coffee consumption may reduce total cancer incidence7.

This study builds on the World Cancer Research Fund’s advice that coffee has no significant relationship with the risk of cancer at any site7.

COFFEE & HEART HEALTH Evidence has shown that moderate coffee consumption of four to five cups a day does not significantly affect people’s risk of coronary heart disease or stroke, and instead may in fact have a protective effect9.

6 Go to physical therapy if recommended by your doctor

Walk around the house

Stay mobile and participate in activities like going for a walk

See how far you can walk in 6 minutes and try to go farther next time

Consult your doctor for advice on what you can do to relieve your symptoms.

How do I talk to my doctor about my breathlessness? If at any point you discover a new symptom or if your symptoms get worse, you should call your doctor. Keep track of when your breathlessness started and how long it lasted. Also take note of what makes you feel better or worse.

How do I treat breathlessness?

47% THE COFFEE MARKET The coffee market is therefore continually expanding, revealing the entrenched love of cafe culture, dining out and the importance of coffee shops as a place for socialising and conducting business meetings and out of office work1.

The British Heart Foundation also states that moderate amounts of caffeine do not lead to arrhythmias, coronary heart disease or effect an individual’s blood pressure10.

REFERENCES 1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce venenatis tristique enim, at suscipit tellus lobortis at. 2. Sed commodo scelerisque nulla, ullamcorper condimentum tortor sollicitudin at. 3. Nunc tincidunt ultricies aliquam. Nam sit amet feugiat turpis. Morbi eu dolor sed arcu accumsan mollis eu eu eros. 4. Mauris in nunc velit, eget tristique eros. Nulla facilisi. Sed vel justo leo, eu semper odio. 5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce venenatis tristique enim, at suscipit tellus lobortis at. 6. Sed commodo scelerisque nulla, ullamcorper condimentum tortor sollicitudin at. 7. Nunc tincidunt ultricies aliquam. Nam sit amet feugiat turpis. Morbi eu dolor sed arcu accumsan mollis eu eu eros. 8. Mauris in nunc velit, eget tristique eros. Nulla facilisi. Sed vel justo leo, eu semper odio.

Breathlessness caused by COPD can be treated. It’s important to start COPD treatment when you first feel breathless as this will help control other symptoms. Quitting smoking is the best way to improve the way your lungs work. There are a number of things you could do to help your lungs and help yourself feel better:

Tips on eating and energy Eating a healthy diet is important for everyone, especially if you have COPD. The muscles used for breathing in a person with COPD may need 10 times more calories than those of a person without COPD. Here are some things you could do to get the right nutrients while maintaining a healthy weight:

Drink non-caffeinated or non-alcoholic drinks

Eat high-fiber foods like vegetables and whole grains

Consult your doctor for advice on what you can do to relieve your symptoms.

Job Number: XXX/XXX/XXXXXX Date of preparation: January 2015

PROJECT

WORK TYPE

Infographic design and development

Print and digital media

Use herbs instead of salt

Stay away from foods that cause bloating (soda or fried foods)

CLIENT

Cholesterol By Numbers*

Infographics INFLUENZA AND VACCINATION

Hepatitis C (HCV) in the UK

Cholesterol affects 3 out of 5 adults in the UK1

IN CHILDREN

FACT SHEET Flu Strikes*

HCV in numbers

HEALTH AND WELLBEING

1CASES BILLION OF FLU EACH

300,000 & 500,000

3-5 MILLION ANNUAL CASES OF SEVERE ILLNESS WORLDWIDE1

YEAR GLOBALLY1

EACH YEAR UP TO AN ESTIMATED

EACH YEAR BETWEEN

RESULTING IN

14,000

DEATHS ATTRIBUTED TO FLU IN THE UK.2

DEATHS GLOBALLY

*Extrapolated from estimated figures for the USA

FLU

Impact of Flu

10%

CAN LEAD TO

Young children

In England, flu* affects approximately 10% of children aged 0 –14 years in an average season3

are more likely to suffer complications and hospitalisations from flu adding substantial pressures on the NHS.4,5

Bacterial lnfection

Pneumonia6 Ear infection6

*defined as influenza like illness (ILI)

94%

2nd

of people over 45 years old say maintaining their heart health is “extremely important” to them

39% 39

Heart disease ranks second among this groups health concerns

are worried about cholesterol which is a major risk factor in the development of heart disease

CHOLESTEROL AWARENESS 29% of over 45s

Almost 45% of over 45s have no idea what their cholesterol level is

have never had a cholesterol test,

216,000

Hepatitis is a general term meaning inflammation of the liver

45%

x100

For every

8% said they weren’t currently doing anything about their cholesterol level

subsequently will become ill8* * Based on a U.S kindergarten study

195

Accidental exposure to infected blood (such as needle stick injury in healthcare workers)4 Via blood transfusion before 1992 (pre blood screening)5 Baby boomers (adults born between 1945 – 1965) are five times more likely to have HCV6, as they were adults when HCV infection rates were at the highest7

50% Genotype 2/3

People of South Asian origin1

Signs and symptoms

8 household members

influenza-infected children under 3 years old,

However, there are other prevalent transmission groups in the UK, who may have been infected with HCV and some are traditionally underreported:

45% of patients in the UK with HCV are genotype 1 which is the most challenging genotype to treat: 50% of patients in the UK are genotypes 2/34

45% Genotype 1

missed school because of a flu-associated illness,

were children under 17 years of age.7

Failure to treat people currently living in the UK with HCV will cost the NHS an estimated £156 million annually2

HCV is transmitted through contact with infected blood. Stereotypically, HCV has been associated with those who share needles e.g. people who inject drugs (PWID).

Hepatitis can be caused by several mechanisms, including viral infection. Hepatitis C is caused by infection with the Hepatitis C virus (HCV) – of which there are 6 different forms (genotypes)3

rising to 40% in the 45 to 54 year old population

10 children who

243

Only 1-2% of people in the UK diagnosed with HCV will receive treatment2

What is HCV?

Data suggests for every

906

Out of the hospitalised cases reported

Almost 90% of people living with HCV remain unaware, undiagnosed and untreated2

HCV is a global public health issue. In the UK HCV is estimated to affect 216,000 adults1

parental work days were lost9

WHO IS YOUR PLUS-ONE

20 -30 YEARS

People infected by HCV may not experience any symptoms for 20 – 30 years8

The signs and symptoms of HCV are often asymptomatic until the disease has progressed to liver failure6

Common symptoms include: drowsiness; headaches; nausea; and abdominal pain (focussed in the liver area)9

Consequences of HCV

Flu Symptoms Symptoms appear 1 to 4 days after the virus enters the body10

of women

High fever11

Muscle aches and pains11

Tiredness11

Flu Spreads

Headaches11

Cough (usually dry)11

Sore throat11

only 19% of men said they were

said they were more worried about their partner’s cholesterol than their own

In contrast,

more worried about their partner’s cholesterol than their own

>7 days -

Children, particularly those of school age, are the main transmitters of flu12

Untreated, the consequences of HCV are very serious and have a significant impact on mortality and morbidity10.

raised cholesterol affects

men and women over 45 equally2

One in four of those aged 45 and over already take between 3 and 6 prescription meds every day

the time that children may pass on the virus10

UP TO 2 METRES13 All children aged 2, 3 and 4 years old and children in

The Annual Flu Vaccination

school years 1&2

will be eligible for the annual vaccination programme5

47%

The optimal time to get vaccinated is from September to early November14

According to the independent advisory committee to the Department of Health, the benefits of the influenza vaccination programme for all individuals in the UK could be as many as:

Flu vaccination helps cut down flu-related missed school days by over 56%15 *

11,000 fewer hospitalisations a year16

vs not vaccinating

72% say they would prefer to lower their cholesterol through diet and exercise alone

72%

Almost a third

of people infected with HCV will go on to develop cirrhosis (scarring of the liver)11

There has been a 20% increase in deaths in the UK from chronic liver disease and cirrhosis in the under 65s between 2000 and 2009

1–2% - The number of those infected and diagnosed with HCV who receive treatment in the UK2

RANKED

7th

DID YOU KNOW…? A daily intake of 1.5 –2.4g plant stanols is proven to lower LDL cholesterol by 7 – 10% in 2 to 3 weeks

World Health Organization. Immunization, Vaccines and Biologicals. Available at: http://www.who.int/immunization/topics/influenza/en/index.html [Last accessed: May 2015] Onmedica. Flu campaign extended to four-year-olds. Available at: http://www.onmedica.com/newsArticle.aspx?id=a70a003b-04e0-432a-b016-30afeab85af2 [Last accessed: April 2015] Paget J, Balderston C, Casas, I et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Paediatr. 2010;169(8):997–1008 Heikkinen T, Booy R, Campins M et al. Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatr. 2006;165: 223–228 Department of Health. Annual Flu Letter 2015/16. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418428/Annual_flu_letter_24_03_15__FINALv3_para9.pdf Last accessed July 2015 Patient UK. Influenza. Available at: http://www.patient.co.uk/doctor/influenza [Last accessed: April 2015] Public Health England. Surveillence of influenza and other respiratory viruses in the United Kingdom: Winter 2013/14. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/325203/ Flu_annual_report_June_2014.pdf [Last accessed: April 2015] Neuzil KM, Hohlbein C, Zhu, Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pedi 2002;156:986-991 Heikkinen T, Silvennoinen H, Peltola V et al. Burden of influenza in children in the community. J Infect Dis. 2004; 190:1369–1373. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15378427/ [Last accessed: April 2015] Centers for Disease Control and Prevention. How Flu Spreads. Available at: <http://www.cdc.gov/flu/about/disease/spread.htm> [Last accessed: April 2015] World Health Organisation. Fact Sheet No 211. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/ [Last accessed: April 2015] Esposito S et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 2006;30;24(5):629-35 World Health organization. Public health agenda for influenza 2010. Available at: http://www.who.int/influenza/resources/research/research_agenda_influenza_stream_2_limiting_spread.pdf [Last accessed July 2015] NHS Choices. Available at: http://www.nhs.uk/Livewell/winterhealth/Pages/Fluandthefluvaccine.aspx [Last accessed: April 2015] Families fighting flu. Resources. Available at http://www.familiesfightingflu.org/resources/ [Last accessed April 2015] National Health Service. Children to be offered annual flu vaccine. Available at: http://www.nhs.uk/news/2012/07July/Pages/All-children-to-be-offered-annual-flu-vaccine.aspx [Last accessed: April 2015] AstraZeneca Data on File: FLU-007-APR2015

According to the Euro Hepatitis Index, the UK ranks seventh for its capacity to handle the threat of hepatitis16

FOODS AND ACTIVITIES THAT HELP TO REDUCE CHOLESTEROL Eating cholesterol lowering functional foods that contain plant stanols or plant sterols is clinically proven to lower LDL cholesterol

Economic burden of HCV

Reducing dairy products Reducing red meats Eating more wholegrains & oats Eating more ﬁsh Eating more soya Exercise * Based on research undertaken by Redshift Research on behalf of Benecol amongst 2000 people over 45 in the UK

References: 1. Heart UK, ‘Cholesterol – The Silent Killer http://heartuk.org.uk/files/uploads/documents/HUK_memberapplicationform.pdf (Accessed 25th February 2014) 2. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J, Luengo-Fernandez R, Rayner M (2012). Coronary heart disease statistics 2012 edition. British Heart Foundation: London.

May 2014

Print and digital media

Number of local authorities that are aware of the number of patients with HCV in their area18

40% Number of local authorities that had an arrangement with commissioners to co-ordinate the management of the condition19

Screening and prevention

£500m The cost of HCV is directly related to the severity of the disease – if treated earlier, the subsequent cost to treating HCV-related disease will be significantly reduced13 The cost to the NHS of liver disease is at least £500m, with £156m resulting from the management of HCV-liver complications, and is rising by 10% annually2 The total lifetime cost of failing to tackle HCV has been estimated to be £4.3 billion,14 with an estimated rise to £8 billion over the next 25 years2

Screening programmes in the UK target those at a higher risk of developing HCV, including past or present PWID and South Asian communities1 Screening initiatives in Scotland have demonstrated a 50% increase in the number of patients being tested and treated during the active stage of the campaign (between 2007 and 2011)15 Awareness of HCV in the UK amongst the general public still remains low and, as a consequence, diagnosis and treatment also remains low among those infected with HCV1

For more information please contact Creston Health on Gilead@crestonhealth.co.uk or +44 (0)20 8392 8040

Eating more fruits and vegetables

Infographic design and development

25% Scotland is the only UK country with a mandatory HCV Action Plan within their National Healthcare strategy

£8 billion over 25 years

This document has been produced by AstraZeneca UK who have exercised full editorial control Date of preparation August 2015 Job number 732,633.011

WORK TYPE

92% The number of PCTs in 2006 in England that were not effectively implementing a HCV Action Plan17 An audit of commissioners and local authorities in England showed that:

believe flu is serious enough to warrant vaccination17

PROJECT

In the UK there has been a 300% increase in hospital admissions and deaths from HCV-related end-stage liver disease and liver cancer in the last 12 years, from 612 in 1998 to 1,979 in 201012

Management of HCV The UK has one of the lowest treatment rates for patients with HCV in Europe2

of mums do not

32%

Direct HCV-related death rates are rising. In the UK they have more than doubled between 1996 to 2010, increasing from 98 in 1996 to 323 deaths in 20101 In England, cirrhosis and HCC-related liver transplants have been increasing steadily over the past 15 years1, but demand for liver transplants is outweighed by the demand2

20%

25%

fewer deaths a year16

References

8. 9. 10. 11. 12. 13. 14. 15. 16. 17.

The main consequences of untreated HCV are cirrhosis and hepatocellular carcinoma (HCC) and it is predicted that in England 15,840 individuals will be living with HCV-related cirrhosis or HCC by 20201

20%

* Based on U.S data

But in a recent survey

1. 2. 3. 4. 5. 6. 7.

But 25% of people are unaware that (functional) foods and drinks containing Plant Stanols are proven to lower cholesterol

2,000

10%

But in fact,

References: 1

Health Protection Agency – Hepatitis C in the UK, 2012 report. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317135237219. [Accessed December 2013]

12 Hospitals Episode Statistics (HES). The NHS Information Centre for Health and Social Care, England: Patients Episode Database for Wales (PEDW). NHS Wales Informatics Service. Health protection Scotland un association with the Information Services Division

The Hepatitis C Trust. The UK vs. Europe – Losing the Fight Against Hepatitis C. http://www.hepctrust.org.uk/Resources/HepC/Migrated%20Resources/Documents/Other/213_ The%20UK%20vs.%20Europe.pdf [Accessed December 2013]

14 Chief Medical Officers Report 2011, volume 1 http://www.dh.gov.uk/health/2012/11/cmo/ [Accessed December 2013]

WHO. 2002. Available at http://www.who.int/csr/disease/hepatitis/Hepc.pdf [Accessed December 2013]

Cornberg et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International. 2011: 30-60

Volk ML. J Antimicrob Chemother 2010; 65:1327-1329

CDC. Available at http://www.cdc.gov/knowmorehepatitis/Media/PDFs/FactSheet-boomers. pdf [Accessed December 2013]

Razavi H et al. Hepatology 2013; 57(6):2164-2170

Toulouse, B. Hepatitis C Fact Sheet. HCV Advocacy - NATAP.

NHS Choices. Hepatitis C – symptoms. Available from http://www.nhs.uk/Conditions/Hepatitis-C/Pages/Symptoms.aspx. Accessed December 2013

13 El Khoury, et al. J Med Econ. 2012;15:887-896

15 The Economist Intelligence Limited, ‘The Silent Pandemic’ report, 2012. 16 Euro Hepatitis Index 2012. Health Consumer Powerhouse. 17 The All-Party Parliamentary Hepatology Group. A Matter of Choice. 2006 18 The Hepatitis C Trust. Opportunity Knocks? An audit of hepatitis C services during the transition. [Accessed December 2013] 19 Ipsos Healthcare Combined data from the Q2/3/4 2012 HCV EU5 Therapy Monitor Base: All untreated patients with specified reason for not being on therapy, excluding patients recent diagnosis.; Patients with barriers or delaying treatment. [Data on file]

10 van der Meer AJ, et al. JAMA. 2012; 308(24):2584-2593 11 Biggins SW et al. Liver Transplantation 2012; 18:1471-1478

XXXXXXXXX December 2013

CLIENT

Infographics Median age life expectancy if starting currently available cART regimens at age 20 years

67.4

82.2

10%

YEARS

Tolerability

25%

52%

DEPRESSION SYMPTOMATIC HIV AIDS ASYMPTOMATIC HIV MS ESRD GERD EPILEPSY US GENERAL POPULATION PROSTATE DISEASE DIABETES 10

YEARS

PLHIV*

Emotional well-being scores are worse for HIV patients compared to patients with other diseases, except for chronic depression

25.6

PLHIV

General population

LANTERN STUDY

10% of PLHIV* are expected to exhaust all currently available cART options after just 25.6 years

Only 52% of patients in a survey were satisfied with the tolerability of their medications

WEEK

STUDY

25% of PLHIV* have never spoken to their HCP about the side effects they are experiencing

Ultibro® Breezhaler® vs salmeterol/ﬂuticasone (SFC)* in patients with stable moderate-to-severe chronic obstructive pulmonary disease (COPD), with a history of one exacerbation or none in the previous year1

40% 60

efficacy + safety

PLHIV

RESULTS

40% of PLHIV* report that their sex life has been affected completely or to a major extent by treatment side effects. Patients also express concern with side effects related to sleep disturbances, fatigue, and depression or anxiety

Up to a third of HIV-related deaths are a consequence of late diagnosis and delayed initiation of cART

63%

Only 25% of PLHIV* in the US are estimated to be virologically suppressed

*People living with HIV

SECONDARY endpoint met

Ultibro Breezhaler

27.5% of treatment switches are accounted for by adverse events in a large retrospective cohort of patients on first line treatment

63% of patients surveyed rated either minimal side effects or minimal long-term impact on the body as the most important factors when choosing ART

Features of existing ARVs can limit their use in special patient populations, such as women of child-bearing potential and those with co-infections

PRIMARY endpoint met

27.5%

Demonstrated non-inferiority vs SFC in terms of lung function (as measured by trough FEV1) at Week 262

References:

Signiﬁcantly reduced the rate of moderateto-severe exacerbations by 31% compared to SFC2**

Showed superiority in improving lung function (as measured by trough FEV1; AUC0-4h) compared to SFC at Week 262

In this study, exacerbations were a pre-speciﬁed exploratory endpoint

WRAP AROUND AREA

STUDY CONDUCTED IN

744 patients

Argentina, Chile, China and Taiwan1

Chronic Obstruction Pulmonary Disease (COPD) is a chronic and highly debilitating pulmonary disease. COPD is characterised by persistent airflow limitation that makes it hard to breathe.

Ultibro Breezhaler

COPD patients suffer from day and night-time symptoms and they get worse when exercising or during an exacerbation (periods when there is a sudden increase in symptoms).

is a

There are effective treatment options available that can ease the symptoms of COPD and greatly improve a person’s quality of life. Whilst these treatments cannot reverse damage already done to the airways, early diagnosis and active management of the disease can make a real day-to-day difference.

COPD in the UK

hear

• COPD affects 3.7 million people in the UK, however less than 1 million are currently diagnosed.1 It is thought that this is a result of people not recognising the symptoms of COPD and instead dismissing these symptoms as result of getting older, or as just having a ‘smokers cough’ • One person dies from COPD in England and Wales every 20 minutes – equating to around 25,000 - 30,000 lives every year2

Day and night-time symptoms affect COPD patients at all levels of disease severity8

Almirall is committed to improving the quality of life of people with COPD through products from its own research and development.

see

References: 1. Clinicaltrials.gov. A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 (LANTERN). NCT01709903. Available at: http://clinicaltrials.gov/ct2/show/NCT01709903 [Accessed 17 July 2014]

4. Pavkov et al. Characteristics of a Capsule Based Dry Powder Inhaler for the Delivery of Indacaterol. CMRO 2010;26;11:2527-2533

UNDERSTANDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COPD is recognised as the only major cause of death among women that is rapidly increasing- but awareness amongst this audience remains low6

2. Zhong N et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study. [ERS abstract 700090; Session 281; Date: September 8 2014; Time].

3. EMA. 2012. Ultibro Breezhaler EU Summary of Product Characteristics. [Online] 3 October 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_-_Product_Information/human/002679/WC500151255.pdf [Accessed 17 July 2014].

No rest from COPD symptoms

Nearly 8 in 10 patients suffer from day and night-time disturbances as a result of COPD7

and

** RR [95% CI]: 0.69 [0.48, 1.00]; p=0.048)

44%

of patients are women5

The prevalence rate of COPD has been increasing nearly three times faster amongst women than men6

feel

* The LANTERN study used Seretide (salmeterol/ﬂuticasone) 50/500 mcg, which is indicated in the UK for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (prebronchodilator) and a history of repeated exacerbations, who have signiﬁcant symptoms despite regular bronchodilator therapy6. The patient population in the LANTERN study were stable moderate-to-severe COPD patients with a history of one exacerbation or none in the previous year2. Seretide is also known as Advair® and Accuhaler is also known as Diskus®. Seretide, Advair, Diskus and Accuhaler are registered trademarks of the GlaxoSmithKline group of companies.

• Emergency admissions for COPD are the second highest of any disease area in the UK, resulting in excess of 1 million bed days3

of those with COPD are less than 65 years old and

that they have taken the full dose correctly 4,5

• COPD is one of the most costly inpatient conditions treated by the NHS, with hospital admission costs related to COPD estimated at over £310 million per annum4

50%

once-daily

maintenance bronchodilator treatment approved in the EU to relieve symptoms in adult patients with COPD3

The Breezhaler® inhalation device allows patients

There is continued low public awareness of COPD. There is therefore a need to raise the profile of the disease among people in order to support accurate recognition of symptoms and to educate on effective ways COPD can be treated.

COPD has historically been seen as a disease that affects old men; recent estimates suggest that

56 sites

ACROSS

UNDERSTANDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The changing face of COPD

5. Onbrez® Breezhaler® (indacaterol) EU Summary of Product Characteristics. [Online] Available at: http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_-_Product_Information/human/001114/WC500053732.pdf [Accessed 17 July 2014] 6. Seretide® Summary of Product Characteristics [Online] Available at: https://www.medi cines.org.uk/emc/medicine/2317/SPC/Seretide+100,+250,+500+Accuhaler [Accessed 17 July 2014]

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and highly debilitating disease that affects the lungs. COPD is characterised by persistent airflow limitation, typically due to inflammation of the bronchi (airways) and damage to the alveoli (air sacs). Symptoms include: breathlessness, cough, tight chest, wheezing, and producing excess mucus.

Night-time symptoms are an under recognised unmet need of COPD. Patients with both day-time and night-time symptoms are more likely to have severe breathlessness, more exacerbations and receive a higher number of maintenance products than those with day-time symptoms only8

COPD patients suffer from day-and night-time symptoms, which become worse when exercising or during an exacerbation (a ’flare-up’ of symptoms). COPD affects many aspects of a patient’s daily life.

1. British Lung Foundation. Invisible Lives - Chronic Obstructive Pulmonary Disease (COPD) - finding the missing millions Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed August 2014 2. HSE. Chronic Obstructive Pulmonary Disease. Available at http://www.hse.gov.uk/statistics/causdis/copd/copd.pdf. Accessed August 2014 3. British Lung Foundation. Ready for home? - Improving hospital discharge care for people living with COPD. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed August 2014 4. National Institute for Health and Care Excellence. NICE Costing Report. Chronic Obstructive Pulmonary Disease. NICE CG 101. 2011 5. Rennard, S et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J. 2002. 20:799-805 6. British Lung Foundation. Femme-Fatality – The rise and rise of COPD in women. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed August 2014 7. Price D, Small M, Milligan G. Prevalence and impact of night-time symptoms in COPD patients-results of a cross-sectional study in five European countries. Presented at: 4th World Asthma & COPD Forum; 2011; Paris, France 8. Price D, Small M, Sayers J. Characteristics of COPD patients experiencing night-time symptoms-results of a cross-sectional study in five European countries. Presented at: 4th World Asthma & COPD Forum; 2011; Paris, France

Date of preparation: September 2014 Job code: UKACL2344a

There are effective treatment options available that can ease the symptoms of COPD and improve a person’s quality of life. Whilst these treatments cannot reverse damage already done to the lungs, early diagnosis and active management of the disease can make a real day-to-day difference. There is continued low public awareness and correct diagnosis of COPD. There is therefore a need to raise the profile of the disease among people in order to support accurate recognition of symptoms and to educate on effective ways COPD can be treated.

COPD in the UK • COPD is common. It affects approximately 3.7 million people in the UK, however less than 1 million are currently diagnosed1 • One person dies from COPD in England and Wales every 20 minutes – equating to around 25,000 deaths every year2 • Emergency hospital admissions for COPD are the second highest of any disease area in the UK, resulting in excess of 1 million ‘bed days’ in hospitals each year3 • COPD is one of the most costly in-patient conditions treated by the NHS, with hospital admission costs related to COPD estimated at over £310 million per annum4

DIABETES, A GLOBAL PANDEMIC.

A health problem that has unified the science community globally in order to find a solution. The International Diabetes Foundation predicts that by 2035 one in ten of the world’s population will be living with diabetes, the implications of which permeate every corner of society. Given the number of people currently being treated for Type 1 or Type 2 diabetes worldwide, it is often assumed that healthcare professionals are well-versed in the range of treatment options available, identifying which treatment is suitable for which patient, and understanding when to initiate and intensify insulin regimens.

case. The overwhelming theme from the feedback was that messaging around the positioning of diabetes treatments needs to be less complex. How does human insulin differ from analogues? What exactly are the clinical benefits of analogues and do these benefits justify the increased cost? Clear, simple messaging will ensure that GPs have confidence in prescribing the right treatment and can defend and rationalise their decision when challenged against a range of cost and guideline restrictions.

This situation analysis has been developed to collate the key interviews and media desk top research (including social media) undertaken by Red Door Communications (RDC) for However, having spoken with a broad the development of our strategic range of healthcare professionals across recommendations and considerations different markets and disciplines within for the Novo Nordisk Modern diabetes care as part of our research, Insulin brands and devices portfolio it appears that this is not always the communications activities.

PROJECT

WORK TYPE

Infographic design and development

Print and digital media

N MODELRIN INSOUUND AR ORLD: THE W

The changing face of COPD Diabetes Experts spoken to

KATRIN HERTRAMPF

PROFESSOR DR HELLMUT MEHNERT

Diabetes Nurse

Munich-Schwabing Hosptial

Germany

DEBBIE HICKS Senior Diabetes Specialist Nurse Hull Royal Infirmary, UK

DR MATTHEW CAPEHORN

PROFESSOR TONY BARNETT

Clinical Manager

Emeritus Chair of Medicine

Rotherham Institute of Obesity, UK

Birmingham Heartlands Hospital, UK

GWEN HALL Diabetes Specialist Nurse Solent NHS Trust, UK

• COPD has historically been seen as a disease that affects old men; however, recent estimates suggest that the mean age of those with COPD is less than 65 years old and around 44% of patients are women5 • The incidence rate of COPD has been increasing nearly three times faster amongst women than men6

No rest from COPD symptoms

SIGH PERT IN

DR ROGER HENDERSON

PROFESSOR MELANIE DAVIES

GP and Media Medic

Professor of Diabetes Medicine

Telford, UK

Leicester General Hospital, UK

DR MICHAEL FEHER

PAUL RYAN

DR MARCIA NERY

Consultant in Diabetes & Clinical Pharmacology

Deputy Head of Contracts

Supervising docator of the Endocrinology and Metabolism Hospital das Clinicas medical school of the University of São Paulo, Brazil

Hertfordshire, UK

Chelsea and Westminster, UK

• Nearly 8 in 10 patients suffer from day-and night-time disturbances as a result of COPD7 • Individual patients rank the importance of various COPD symptoms differently; however, in general, shortness of breath is the symptom that causes them the most concern8 • COPD patients at all levels of disease severity can be bothered by night-time symptoms9 • Night-time symptoms are an under-recognised unmet need of COPD. Patients with both day-time and night-time symptoms are more likely to have severe breathlessness, more exacerbations and receive a higher number of maintenance treatments than those with day-time symptoms only9

DR KAMINI D LAKHIANI Endo-Diabetologist Sadhana Proactive Clinic, India

GENERAL INSIGHTS:

DIABETES TREATMENT REGIME COST-EFFECTIVENESS:

HUMAN VS. ANALOGUE INSULIN

TYPE 1 DIABETES

TYPE 2 DIABETES

• There is a ‘honeymoon period’ straight after diagnosis, when an aggressive treatment regime is not always necessary

• Treatment regime is more variable for these patients and it is difficult to assess when to start insulin

• A basal bolus system is required, using a mix of rapid and intermediate treatment:

• Human insulin is prescribed more in countries where cost is an issue

– x2 injections taken daily taken at the start of treatment

• Countries such as India, China, Australia, Western Europe and Canada are richer, so analogues tend to be prescribed more. In addition:

– This will then increase to more aggressive treatment – x3 injections of rapid-acting insulin before each meal and a 4th injection of a longer- acting insulin taken before bedtime to provide background insulin • There is no pressure for HCPs to use older NPH insulin (which is cheaper) in T1D because hypos are a bigger problem (and this has a strong evidence base) – meaning the cost argument is a lot easier

– GLP1/basal treatment in combination tends to be prescribed more – T1D tends to be treated more aggressively in these countries

• In Germany, initiation on insulin happens much earlier than in France or the UK; it can take up to 10 years in the UK and even longer in France • NovoRapid is common in patients with T1D. In T2D its use is pushed back by GLP1 and basal combo – but the rapid component is often still required (some patients don’t respond well to long-acting and the disease is progressive) • Diabetes treatment regime in Canada, Australia and Turkey is similar to the UK • Most countries adhere to the ADA, EASD and IDF guidelines – Canada has its own guidelines (Canadian Diabetes Association)

Brazil: For type 2 diabetes, meta-analysis shows that the use of analogues is not cost- effective; in my opinion, it is only patients with type 2 diabetes under intensive insulin therapy and with high risk of hypoglycaemia who are recommended the analogous. Dr Marcia Nery

UK: There is more pressure to use NPH insulin (intermediate-acting) – it is known that older insulins increase hypos, but the recommendation from NICE is that patients should be switched only when hypos occur. Professor Tony Barnett

Germany: Unfortunately the German health system does not treat life quality as a “hard” factor. The factor that makes the most impact on the reimbursement of treatment costs is the Hba1c level. Katrin Hertrampf

Germany: Still the 'human' insulins are not worse than the insulin analogues, they are just more rigid and don’t allow as much flexibility. Especially for kids and young adults the insulin analogues are an advantage. Katrin Hertrampf

UK: The argument for MI versus HI is not that solid: HI is seen as moderately effective and cheaper. Paul Ryan

UK: When considering modern insulins, I would use the NICE guidance and have a look at what is best value for money, at what is the most cost effective for the patients and the NHS. Debbie Hicks

India: I very rarely prescribe human insulin; only for patients who cannot afford analogues as they are too costly. Kahmini D Lakhiani

Germany: In the beginning, and during the course of the insulin effect, analogues do have a major advantage over human insulin. Prof. Dr. Hellmut Mehnert

1. British Lung Foundation. Invisible Lives – COPD – finding the missing millions. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed November 2015 2. Health and Safety Executive. Chronic Obstructive Pulmonary Disease. Available at http://www.hse.gov.uk/statistics/causdis/copd/copd.pdf. Accessed November 2015 3. British Lung Foundation. Ready for home? – Improving hospital discharge care for people living with COPD. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed November 2015 4. National Institute for Health and Care Excellence. NICE Costing Report. COPD. NICE CG 101. 2011 5. Rennard, S. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799–805 6. British Lung Foundation. Femme-Fatality – The rise and rise of COPD in women. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed November 2015 7. Price D, et al. Prevalence and impact of night-time symptoms in COPD patients – results of a cross-sectional study in five European countries. Presented at: 4th World Asthma & COPD Forum; 2011; Paris, France 8. NICE Clinical Guidelines, No. 101. COPD. Available at: http://www.ncbi.nlm.nih.gov/books/NBK65029/ Accessed November 2015 9. Price D, et al. Characteristics of COPD patients experiencing night-time symptoms-results of a cross-sectional study in five European countries. Presented at: 4th World Asthma & COPD Forum; 2011; Paris, France

Date of preparation: November 2015 Job code: 930,527.011

CLIENT

Infographics

3.7 M LL ON people are estimated to be living with COPD in the UK, yet only 900,000 people have been diagnosed with the disease

IMPACT OF CVD IN THE UK 175,000

7 million

people estimated to be living with cardiovascular disease (CVD) in the UK British Heart Foundation. Cardiovascular Disease Statistics Factsheet. Available at https://www.bhf.org.uk/research/heart-statistics [last accessed March 2015].

minutes

British Heart Foundation. Cardiovascular Disease Statistics Factsheet. Available at https://www.bhf.org.uk/research/ heart-statistics [last accessed March 2015].

£19bn

British Lung Foundation. Invisible Lives – COPD – finding the missing millions. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed April 2015

The estimated total cost of premature death, lost productivity, hospital treatment and prescriptions relating to CVD each year in the UK

768,216.011 | May 2015

It is estimated that

heart attacks (MI) in the UK each year; that's one every three minutes

British Heart Foundation. Cardiovascular Disease Statistics Factsheet. Available at https://www.bhf.org.uk/research/heart-statistics [last accessed March 2015].

160,000

deaths caused by CVD in the UK each year

British Heart Foundation. Cardiovascular Disease Statistics Factsheet. Available at https://www.bhf.org.uk/research/heart-statistics [last accessed March 2015].

2.8 million

people in the UK are living with undiagnosed COPD

CVD is projected by World Health Organization (WHO) to remain a substantial contributor to global deaths, causing an estimated 22.2 million deaths in 2030

110,000 men and 65,000 women in the UK suffer a heart attack each year

World Health Organization. Global Status Report on Noncommunicable Diseases: 2014. Available at http://www.who.int/nmh/publications/ncd-status-report-2014/en/ [last accessed February 2015].

1/ 5

British Heart Foundation. Cardiovascular Disease Statistics Factsheet. Available at https://www.bhf.org.uk/research/heart-statistics [last accessed March 2015].

~1 in 5 patients who were event free for the first year post-MI suffered an MI, stroke or death within 3 years [APOLLO 4-country analysis]

Only half of patients with coronary heart disease use 3 or more of the recommended treatments 5 years after their cardiovascular event World Heart Federation. Secondary cardiovascular disease prevention and control. July 2014. http://tinyurl.com/pzvo2vn [Last accessed March 2015].

Rapsomaniki E, et al. ESC Late. Breaking Registry presentation 2014.

This document has been produced by AstraZeneca UK Date of preparation March 2015 | 705,713.011

minutes

One person dies from COPD in England and Wales every 20 minutes resulting in around 25,000 deaths every year Health and Safety Executive. Chronic Obstructive Pulmonary Disease. Available at: http://www.hse.gov.uk/statistics/causdis/copd/copd.pdf. Accessed April 2015

Tecfidera is a new oral treatment for adult patients with relapsing remitting multiple sclerosis (MS)1 – the most common type of MS2

Tecfidera is licenced for patients with relapsing remitting MS1

THE BENEFITS OF TECFIDERA

Tecfidera is taken twice daily with food1

Causes of prostate cancer The factors that determine the risk of developing prostate cancer are not well known, although a few have been identiﬁed. The well-established risk factors for prostate cancer are:4

Increasing age

Ethnic origin Genetic predisposition Unhealthy diet Smoking

about 80% of men who reach the age of 80 have prostate cancer cells in their prostate

Anxiety and depression, stress or loss of control, and problems in coping

Treatment options for prostate cancer Treatment options are based on the stage and grade of the disease. When the prostate cancer is more advanced, and has spread to other parts of the body, treatment includes reducing the level of testosterone (a male hormone). Prostate cancer cells need testosterone, an androgen, to grow. The cellular effects of androgens are mediated via the androgen receptor.7

Hormonal treatment is used to lower the level of a man’s testosterone (also known as androgen-deprivation). This in turn can shrink the cancer, reduce prostate-speciﬁc antigen (PSA) levels and control symptoms.8

The list price for Tecfidera will be £17,900 per annum

HOW TECFIDERA WORKS The mechanism of Tecfidera is not fully understood. It is believed to reduce inflammation via the Nrf2-dependent antioxidant pathway1

90%

Reduce the rate of MS relapses by 53% (0.17 vs. 0.36, p<0.001)3 and 44% (0.22 vs. 0.40, p<0.001)4 vs. placebo at 2 years

38%

Reduce the number of gadoliniumenhancing lesions on MRI by 90% (0.1±0.6 vs. 1.8±4.2, p<0.001)3 and 74% (0.5±1.7 vs. 2.0±5.6, p<0.001)4 vs. placebo at 2 years

SIDE EFFECTS

27%

Delay disability progression by up to 38% 38% (16% vs. 27%, p=0.005)3 and 21% (13% vs. 17%, p=ns)4 vs. placebo at 2 years

27% of patients on Tecfidera had an MS relapse in 2 years, vs. 46% of patients treated with placebo (p<0.001)3

The most common side effects of Tecfidera are flushing and gastrointestinal problems (e.g. diarrhoea, nausea and abdominal pain)1

1 million

These side effects tend to begin early in the course of treatment and may continue to occur intermittently throughout treatment1

TF-GBR-0068 January 2014

Burden of Chronic Spontaneous Urticaria (CSU)

CSU is a serious, chronic and distressing skin condition that is difficult to diagnose and manage.

SYMPTOMS

1-4

‘bed days’ in hospitals each year

768,216.011 | May 2015

most common cause of cancer death in Europe

In two pivotal phase lll studies, Tecfidera has been shown to:

53%

British Lung Foundation. Ready for home? – Improving hospital discharge care for people living with COPD. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed April 2015

90,000 deaths every year3

every minutes

TECFIDERA (DIMETHYL FUMARATE)

768,216.011 | May 2015

Emergency hospital admissions for COPD are the second highest of any disease area in the UK, resulting in excess of

resulting in more than

one man

Men with advanced prostate cancer often report feelings of:5,6

British Lung Foundation. Invisible Lives – COPD – finding the missing millions. Available at: http://www.blf.org.uk/Page/Special-Reports. Accessed April 2015 768,216.011 | May 2015

is the

with a mortality rate of at least

Prostate cancer

! !! ! !! ! ! !

How can Red Door Communications’ Consumer Health experience benefit

GSK’s Consumer Healthcare Product Portfolio? Red Door’s consumer health team comprises outstanding consultants who have worked at some of the UK’s leading agencies supporting some of the UK’s best known consumer brands with innovative, impactful and award winning campaigns

Extensive experience of running busy press offices including the generation of newshooks and media content, the creation and development of social media communities and online engagement, media events and briefings

COMPLICATIONS

There is no specific external trigger for CSU, but the autoimmune system may play a role.

zzz

CHRONIC (LASTING FOR AT LEAST SIX WEEKS)

SPONTANEOUSLY OCCUR

SLEEP DEPRIVATION

DEPRESSION RED HIVES (WHEALS)

DEEP TISSUE SWELLING (ANGIOEDEMA)

ITCH

PREVALENCE

1-2

61% ONLY WHEALS

33% WHEALS AND SWELLING 6% ONLY SWELLING

TREATMENT

Antihistamines are the current mainstay of treatment, but more than 50% of people with CSU on approved antihistamine doses do not achieve symptom relief.

DURATION

People with CSU who experience deep tissue swelling (angioedema) may have a greater chance of CSU lasting for >12 months or longer.

Symptoms remain uncontrolled even in many people with CSU receiving

The disease generally lasts 1–5 years but can last for decades.

Price D, et al. Prevalence and impact of night-time symptoms in COPD patients – results of a cross-sectional study in five European countries. Presented at: 4th World Asthma & COPD Forum; 2011; Paris, France 768,216.011 | May 2015

A proven track record of delivering measureable and meaningful results for brands in the area of dermatology, weight loss, oral healthcare, colds and flu, VMS and naturals, analgesics and pain relief, gastro-enterology, smoking cessation, eye care, nutrition and allergy

Evidence of successful consumer and stakeholder recruitment for health related campaigns and services

1. Primary Care Dermatology Society website. Available at http://www.pcds.org.uk/clinical-guidance/urticaria-spontaneous-syn.-chronic-ordinary-urticaria *[Last accessed August 2013] 2. Maurer M et al. Allergy. 2011;66:317–330. 3. Zuberbier T et al. Allergy. 2009;64:1417–1426. 4. Maurer M et al. Br J Dermatol. 2013 Feb;168(2):455-456. 5. Zuberbier T et al. Clinical and Experimental Dermatology. 2010;35:869-873.

PSORIASIS

up to four times the approved antihistamine dose.

Approximately 1/5 of people with psoriasis have moderate to severe psoriasis

however, recent estimates suggest that the mean age of those with COPD is less than 65 years old and around 44% of patients are women

LESS THAN

65 YEARS OLD

44% WOMEN

Rennard, S. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799–805 768,216.011 | May 2015

A thorough, inside track on what makes news and media coverage in broadcast, digital, social, national, regional, specialist and trade titles

A full suite of design, digital, video production and medical education skills on site

Creative brains and skilled practitioners which enable Red Door to marry Brilliant Basics with Intelligent Innovation on behalf of our clients

Please contact Julia Harries on +44 (0) 20 8392 8044 or email: jharries@rdcomms.com

PROJECT

WORK TYPE

Infographic design and development

Print and digital media

MOST COMMON SYMPTOMS 18

ITCHING PAIN

PEOPLE IN THE UK MAY HAVE PSORIASIS5

A wealth of examples of effective collaborations and joint work including celebrity and ambassador recruitment

1-4

PSORIASIS CAN BE MILD, MODERATE OR SEVERE6

AN ESTIMATED

Red Door is the most rated agency by UK health journalists and an Executive Committee Member of the Medical Journalists’ Association

XOL13-C082 September 2013

A COMMON, CHRONIC AND INFLAMMATORY AUTOIMMUNE DISEASE

1.8 M LL ON COPD has historically been seen as a disease that affects old men;

EMOTIONAL UPSET

At any given time, 0.5-1% of the global population is affected by CSU. Women are more likely than men to be diagnosed.

ANXIETY

SOCIAL ISOLATION

*Typical symptom presentation

Nearly 8 in 10 patients suffer from night-time disturbances as a result of COPD5

LACK OF ENERGY

MILD Less that 3% of the body has psoriasis

MODERATE

SEVERE

3%-10% of the body has psoriasis

More than 10% of the body has psoriasis

1% = Surface area of the hand

THICK, RED SKIN SCALING

EFFECTS ON QUALITY OF LIFE

6-10

The effect of psoriasis on patients’ quality of life is similar to diseases such as cancer, heart attack, arthritis, type 2 diabetes and depression. People with more severe forms of psoriasis have a significantly reduced life span.

75%

FEEL UNATTRACTIVE7

77%

54%

FEEL DEPRESSED7

31%

HAVE FINANCIAL DISTRESS7

SAY IT LEADS TO SEXUAL DIFFICULTIES10

PSORIATIC ARTHRITIS17

There is no cure for psoriasis and up to 78%7 of patients express low to moderate satisfaction with their treatment. This indicates the remaining unmet need for therapies that act faster and longer to relieve the symptoms of psoriasis.

1. The National Psoriasis Foundation website. Accessed 13 June 2013

SAY IT AFFECTS WHAT THEY WEAR10

27%

PATIENTS WITH PSORIASIS SAY THAT IT IS A PROBLEM OR A SIGNIFICANT PROBLEM, IN THEIR EVERYDAY LIVES10

TREATMENT FAILURE10-13,16

56%

7. Krueger G, Arch Dermatol 2001;137:280-284

30%

of patients are affected

8. Rapp SR et al. JAAD1999;41 (3 Pt 1):401-7

16. Sterry W et al. Br J Dermatol. 2004 Aug;151 Suppl 69:3-17

9. Guenther L et al. J Cutan Med Surg. 2009

17. Bowcock AM, Hum. Mol. Genet. 2004;13 (suppl 1): R43-R55 18. Lebwohl M et al. Int J of Dermatol. 2013 Apr; doi: 10.1111/j.1365-4632.2012.05798.x.

4. Herrier R, Am J Health-Syst Pharm 2011; 68:795-806

10. Dubertret L et al. Br J Dermatol 2006;155:729-736

5. The Psoriasis Association. ‘What is Psoraisis?’ 2013

11. Stern R S et al. J Investig Dermatol Symp. 2004

6. National Psoriasis Foundation, Psoriasis Severity. Available at http://www.psoriasis.org/about-psoriasis/treatments/severity [Accessed August 2013]

12. Christophers E et al. J Eur Acad Dermatol Venereol. 2006;20:921-925

19. Abuabara K et al. Br J Dermatol. 2010 Sep;163(3):586-92

13. Mason AR et al. Cochrane Database Syst Rev. 2009;15;(2):CD005028

20. Gelfand JM et al. Arch Dermatol. 2007 Dec;143(12):1493-9

17,19,20

PSORIATIC ARTHRITIS DEPRESSION DIABETES HEART DISEASE

15. Ljosaa TM et al. J Eur Acad Dermatol Venereol. 2012;26:29–35

2. Nestle FO et al. N Engl J Med 2009; 361(5):496-509 3. Brezinski EA et al. PLoS ONE; 7(4):e33486

14. Langley R G B et al. Ann Rheum Dis. 2005; 64(Suppl II):ii18–ii23

CO-MORBIDITIES

PSO13-C033 October 2013

CLIENT

Infographics YOUR

ADVANCED PROSTATE CANCER

How do the chances of surviving a heart attack differ across London?

HEART

MEET BOB Bob is a London cabbie whose been told by his doctor that he is at risk of a heart attack. What Bob doesn’t know is that depending on where he lives – or works - in London, he is more likely to survive from a heart attack. See how his risk varies in a typical day.

CHISWICK

HIGH ROAD

DRAFT IN THE CAPITAL? LONDON BOROUGHS

Percentage of hospital patients who die in the 30 days following a heart attack

BOB’S HOME

RUISLIP

Bob’s starts out from his home in Ruislip where his chances of survival are relatively poor in comparison with other boroughs - 20.6% of patients who go into hospital following a heart attack (STEMI) die within 30 days.

Deaths above national average

No % available - less than 5 deaths in 2011/2012

Hillingdon

17 Southwark

Harrow

18 Newham

Watham Forest

19 Bexley

Merton

20 Ealing

Hackney

21 Barking and Dagenham

Barnet

22 Camden

Westminister

23 Greenwich

Havering

24 Hammersmith and Fulham

Tower Hamlets

25 Hounslow

27 Kingston upon Thames 28 Lambeth

29 Lewisham

30 Richmond 31 Sutton

16 Enfield

32 Wandsworth

OFF TIME IN

26 Kensington and Chelsea

15 Croydon

ALGATE STATION BACK

TO UXBRIDGE

On his way home, Bob sees some angry commuters outside Aldgate station – the Metropolitan line is down. Bob takes them home, which is at the other end of the line, in Uxbridge. On the journey, the death rate following 30 days after hospital admission for heart attack doubles from 10.3% to 20.6%.

LEWISHAM

Bob picks up an MP leaving the House of Commons to go home to Lewisham for the evening, if Bob has a heart attack here his chances of survival dramatically improve as fewer than 5 people die within 30 days of hospital admission following a heart attack.

What is prostate cancer?

CAMDEN

MARKET

Bob then picks up a group of friends who want to visit Camden market. Once in Camden, Bob’s chances of survival improve again – with less than 5 people dying within 30 days of hospital admission following a heart attack in Camden.

11 Haringey

14 Islington

10 Bromley

13 Redbridge

Deaths on or below national average

12 Brent

Bob spots a golfer leaving Rusilip golf course who is meeting his son for lunch on Chiswick High Road. If Bob has a heart attack in this borough, his chances of survival improve significantly – just 6.1% of those admitted to hospital following a heart attack die within 30 days.

The prostate gland is part of the male reproductive system. About the size of a walnut, its role is to secrete ﬂuid that nourishes and protects sperm.

SLOANE

STREET

Bob drives south and picks up a couple on Oxford Street shopping for engagement rings. He takes them to Sloane Street where they can have their pick of jewellery shops. On Sloane Street, Bob’s chances of survival are again good – with less than 5 people dying within 30 days of admission following a heart attack in the Borough of Kensington and Chelsea.

In some men, prostate cancer cells may also spread beyond the prostate and move to other parts of the body, most commonly the

bones or lymph nodes

(small, bean-shaped glands throughout the body).

This is referred to as advanced or metastatic prostate cancer.

Prostate cancer refers to the growth of cancerous cells within this gland. Prostate cancer occurs when abnormal cells, supported by male hormones such as testosterone, begin to grow uncontrollably to form tumours.

CITY OF

WESTMINISTER

Prevalence

Bob sees a lawyer in Sloane Square needing a lift to the City for a business meeting. In the City of Westminster, Bob’s chances of survival start to drop, with 10.9% of hospital admissions following a heart attack resulting in death within 30 days.

Prostate cancer has emerged as the most common non-skin cancer in men in Europe, accounting for over of all cancer diagnoses in men1

20%

About

10-20%

of patients present with advanced stage disease2

PARKINSON’S

PREVALENCE OF PARKINSON’S

Parkinson’s is caused by a lack of a chemical called

DOPAMINE in affected people’s brains Around

127,000

Parkinson's is often

people in the UK have Parkinson’s1

HOUR someone in the UK is told

associated with

Every

older people

and most people who are diagnosed with Parkinson’s are over the age of 501

they have Parkinson's1

SYMPTOMS

1 in 20 people newly diagnosed is under the age 1 of

Did you know... Michael J Fox was diagnosed with Parkinson’s when he was just 29 years old (MJFox foundation)2

TREATMENT Symptoms are different for everyone,

Some treatments for Parkinson’s are

chemical BUILDING BLOCKS that the

but common symptoms include tremor, stiffness, problems with movement

and walking, pain, depression, fatigue3 and gastrointestinal problems4

body can convert into dopamine1

Other treatments called dopamine agonists act like dopamine to stimulate the nerve cells. Some dopamine agonists can be used to treat or reduce off time1

WHAT IS OFF TIME?

OFF TIME is when treatment that

helps the brain to produce more dopamine starts to ‘wear off’ before the next dose5

OFF PERIODS CAN BE

When the treatment

‘WEARS OFF’ the symptoms of Parkinson’s RETURN5

6,13

Patients can experience ‘dose failures’ where they receive no clinical benefit from treatment. This is thought to be due to problems with the medicine being absorbed in the gastrointestinal tract and also with the medicine entering the brain from the bloodstream once absorbed8 Date of Preparation: February 2014 APO1-0214-0429

A part of Health Unlimited

A six year old, specialist healthcare communications company, with a clear position in the market place as a boutique agency,

YEARS offering a personal and responsive service to our clients, which also happens to be Communiqué Small Consultancy of the Year!

Here is a quick overview of the key things you might like to know about us. Our success comes down to three critical ingredients our ethos, our clients and our team members 1 Our ethos can be defined by our core values: • Relationship focused • Positive challenge • Refreshing • Nimble

We have really great client relationships; everybody will tell you that – but there are ways of measuring it! • Scores from an independent client satisfaction survey, repeated every year (RAM Feb 2014) � 8.9 for ‘chemistry and working relationship’ � 8.4 for ‘how likely would you be to recommend the agency to a friend or colleague’ � 8.2 for ‘quality of people, resource and skills’ • The average RAM score based on 30,000 client interviews is 7.0 (1 lowest, 10 highest) We have two long standing client relationships of 5 years (and counting) The average length of client relationship is 3.2 years

staff turnover for the last three years 3 0% resulting in consistency for clients, effective teamwork and excellent team morale

AWARDS 2 wins (PMEA Award for Launch Excellence and did we mention we won Communiqué Small Consultancy of the Year?)

2014

in numbers

Access to over

Average client satisfaction rating of

8.2 8.2 (RAM)

decade (IMS data)

1/3

Secured a guinness world record for Hep C with

26,204

across 16 countries within Chemia, our Health Unlimited global network

participants

is a great place to work (Your Voice)

The launch of the

first cannabis –based treatment

A NICE HTA methodology change

PROJECT

WORK TYPE

Infographic design and development

Print and digital media

Most successful NGO video on YouTube

Helped three of our clients to trend globally on twitter! With over

90,000 Tweets alone for #worldcancerday

£18m

Drove

1,146,255

Youtube video views for one client campaign Drove

49%

Industry awards for one consumer health campaign Secured

of uk population by driving them into pharmacy when suffering cold and flu rather than wasting valuable GP time

WON 5

100% of staff thinks Liberation Unlimited

OUR TEAM HAS BEEN RESPONSIBLE FOR:

The most successful pharmaceutical launch in the last

Changed behaviour of

3 days

20 agency members

140 healthcare marcomms consultants in London to support

programmes via Health Unlimited

3 finalist rankings

Helped Boots sell out of OTC product following expertiential campaign in

Worth of funding secured ahead of health technology appraisal decision

Sales increase of health testing device during 3 month campaign period

CLIENT

Invites & Events

HERE ARE OUR 10 REASONS WHY EVERY COMPANY SHOULD EMBARK ON THE 1010 CHALLENGE:

IT’S A LOT HARDER THAN IT LOOKS

As a PR consultancy we pride ourselves on our strategic thinking and commercial acumen. When we were set the challenge, the fighting talk was rife with lots of big and bold ideas. However, when it came to the crunch, making money from £10 is much harder than it seems, which was all part of the fun of the challenge. In this time of shrinking budgets what better way to encourage people to be doing more with less.

IT’S GOOD TO CREATE SOME HEALTHY COMPETITION

MORALE HAS NEVER BEEN HIGHER

You can run the challenge as individuals but we decided to organise people into teams so they had the chance to pool their cash for greater spending power! A word of warning though, an ultracompetitive bunch can mean the competition gets fierce!

For the month when we ran the challenge the office was abuzz with bake offs, socials and general merriment. If your company has undergone recent change, you have new joiners or you’ve just finished a particularly busy period it could be a great time to do the 1010 and give everyone a real morale boost.

A MONTH MAY NOT BE ENOUGH

THERE ARE SOME SECRET ENTREPRENEURS AMONGST US

Entrepreneurship often doesn’t shine through unless you’re given the right opportunity. The 1010 challenge unlocked some really ingenious ideas, and marked out the Richard Branson’s amongst us.

We ran the challenge over a month, but in hindsight, a little longer may have been optimal to make sure all teams had a chance to run their events, sell their wares and take on their challenges to avoid charity fatigue setting in.

Health Unlimited: Clear Desk Policy Please ensure you follow the guidelines:

THE 1010 CHALLENGE IS INFECTIOUS

Everyone we told about the challenge loved the concept and wanted to get on board. One team decided to run a social media auction and asked local businesses to give prizes. The generosity was unbelievable and prizes were donated by restaurants, gyms, spas, the list goes on. Of course this was partly down to our charm ;-), but part of the success was also down to people really buying into the intriguing concept of multiplying a humble tenner. Everyone was keen to help out.

IT SHOWCASED ALL OUR SKILLS

Who knew we had a qualified beautician, singer, artist, cook, mountain climber and long distance cyclist in our midst? The challenge was a great way to get to know each other and showcase all our skills.

IT IS A FORM OF TRAINING

We often sit in boardrooms for long theory based sessions and spend a lot of cash on training budgets in the process. Our Senior Management were surprised at what great hands on training the challenge was, and how many company objectives it covered off: encouraging creativity, team work, entrepreneurship, leadership and CSR. The challenge makes business sense as well as being a great thing to do for charity.

IT HAS A REAL MESSAGE AND LINK TO THE END CAUSE

Did you know that the seed capital HOPEHIV provides the young people it serves to start up their own business is often just £10? It seems much more meaningful to support a fundraising activity that has such a strong link with the cause you’re working towards. To be able to see potential in a modest amount is exactly the message of the 1010. We multiplied our tenner by ten to give the opportunity for someone to start a business that could be life sustaining.

BUT MOST OF ALL £4000

IT HAS A SUSTAINABLE IMPACT ON THE LIVES OF OTHERS

We managed to raise £4,000 through our challenge. When we’d finished, HOPEHIV were able to let us know how that cash could be potentially spent and the lives it will impact. We found out that if 30 people took part, each would have raised enough to have transformed 7 lives through a great project called AFREDA. The project based in Tanzania works with elderly grannies and female guardians who provide for AIDS orphans to offer training in entrepreneurship, credit management and group leadership. There are few fundraising challenges through which you can measure the direct impact, which is truly hopeful.

£10

IF PEOPLE TOOK PART, EACH WOULD HAVE RAISED ENOUGH TO HAVE TRANSFORMED LIVES

PROJECT

WORK TYPE

Invites & events design and development

Print and digital media

FIRST THING:

WHEN AWAY FROM YOUR DESK:

THROUGHOUT THE DAY:

AFTER MEETINGS:

END OF DAY:

Place documents needed for immediate work on your desk only. Other documents can be locked away.

All sensitive information must be removed from the desk surface and filed or locked up.

Place sensitive documents in t he confidential waste in the bins provided.

Ensure that any information is removed from white boards, walls, desks etc.

Lock laptops in your pedestal or take it home with you.

PLAN AND ORGANISE YOUR DAY:

LOCK YOUR COMPUTER.

CONFIDENTIAL WASTE.

REMOVE INFORMATION

THERE WILL BE CONSEQUENCES FOR POLICY NON-COMPLIANCE!

ALWAYS LEAVE A CLEAN, CLEAR DESK.

CLIENT

Invites & Events DAYAW L PAYPU B CR 28th AU GUST 20 1 4

THE

TION DONA In aid of Creston’s

GOLDEN TICKET

LOCATION: CENTRAL NEAREST STATION WATERLOO/ BLACKFRIARS/ SOUTHWARK

Charity Partner

AS CHOSEN BY

JOIN US FOR A FUN FILLED EVENING AT YOUR FAVOURITE LOCALS

If you have any questions or would like to buy tickets, please contact Emily Blakemore @ eblakemore@rdcomms.com

At each of the stops you’ll also be in with the chance to win a special pub-related prize.

Your ticket automatically enters you into a prize draw to win one of dozens of prizes including tickets to Kew Gardens, a tour of Fuller’s brewery, a cut & blow at a Headmasters salon nationwide, a Benefit make-up set, cupcakes from Beas of Bloomsbury and many more!

TUESDAY

TH DECEMBER

17:30-24:00

Raffle tickets will be available for £2 each if you can’t make the pub crawl

SCHEDULE: 17:30 18:30 - 19:15 19:15 21:30 - 23:30 24:00

it Adm One

Depart from office Drinks reception Sit down for dinner DJ Finish

Dress code: formal & fabulous (no jeans or trainers) The White Horse

The Duke

Worple Way, Richmond Surrey, TW10 6DF

2 Duke Street, Richmond Surrey, TW9 1HP

TABLE NO:

Tommy’s

Tickets £5 in advance

YOU!

presents

The Slug and Lettuce Riverside House, Water Lane Richmond, Surrey, TW9 1TJ

Pitcher & Piano 11 Bridge Street, Richmond, Surrey, TW9 1TQ

www.tommys.org

To be in with a chance of winning make a donation to Tommy's - the premature and stillbirth baby charity and guess my finish time for cycling the 100 miles

WIN

WIN WIN

100 moriles

Name

CLOSEST

t Second Third Firs Prize Prize Prize

GUESS WINS... £25 £15 Contact

Finish Time

Donation

£5 Paid

COME SUPPORT US

Andrew and King will be cycling 100 miles as part of the Ride London challenge to raise money for

Tommy's - the premature and stillbirth baby charity.

Currently, 1 in 4 women lose a baby during pregnancy and labour - we want to see this change. Please help us by making a donation to support Tommy's research, and we'll take on the 100 miles of leg-testing climbs through London and into the Surrey countryside. Thanks for all your support!

Ross Wilson

Andrew and King

uk.virginmoneygiving.com/team/CrestonHealth-RideLondon 100 mForiles

www.tommys.org

Training Holiday Entitlement

Health and Lifestyle

We offer better than average annual leave, including a loyalty scheme .

Your health matters to us Company pension, healthcare benefits that extend to include your children, and other great perks.

The Little Book of Big Benefits

Healthshield Instant cashback to help cover the cost of everyday healthcare needs including £110 cashback p/a on dental & optical & £290 on physio. Access to a 24/7 counselling and support helpline.

3% contributory Company pension On successful completion of your probation period, we offer a matching contributory pension of 3% of your salary.

Group Life Assurance plan through ‘MetLife’ Our life insurance scheme pays out a lump sum of 4 x your annual salary.

There are lots of lovely ways to make more of your time at Health Unlimited.

25 days

Additional days

This is 25 days each year, which runs from 1st January to 31st December, plus all UK bank holidays. This gets prorated to your start date in your first year and is adjusted according to your working pattern if you work part time. We also give you:

More annual leave for your loyalty, starting with an extra 1.5 days after 3 years’ service, with an additional half day for every completed year of employment up to a total allowance of 30 days thereafter.

Take a look.

Giving back Wherever possible, we try to encourage support of local and international charities

Tastecard Discounted annual tastecard (corporate rate) will give you great discount deals at over 6,500 restaurants nationwide including PizzaExpress, STRADA, La Tasca, Prezzo and Zizzi.

Carnaby Privilege Card Carnaby Privilege Card Anyone who lives or works within Carnaby or Soho is eligible for a Neighbourhood Card. Offering you a 10% discount at participating shops, cafés, restaurants, bars and clubs in and around Carnaby Street, including Liberty, Office, Benefit, Flat Iron, Pizza Pilgrims and many more. In addition, you can enjoy exclusive promotions and invites to launches and events.

PROJECT

WORK TYPE

Invites & events design and development

Print and digital media

Annual Charity Day To enable you to support the charity of your choice with your own time

S Ku

CLIENT

Abbott NOW APPROVED FOR AGES 4-17*

FREE TO

DREAM WITHOUT LANCETS

†

NEW! Introducing the FREE LibreLink App1 Taking breakthrough technology a step further

Patients can now scan their FreeStyle Libre sensor using the free LibreLink app on their Android smartphone2,3

Welcome to flash glucose monitoring.

The LibreLink app makes it easier for your patients to check their glucose anytime, anywhere.

With the FreeStyle Libre system, you and your child can check glucose without routine finger pricks.‡

Why prick, when you can scan?4

Why prick, when you can scan?‡

FREE app download:

Find out more at www.FreeStyleLibre.com *A caregiver at least 18 years old is responsible for supervising, managing, and assisting the child in using the FreeStyle Libre system and interpreting its readings. Scanning the sensor does not require lancets. ‡ A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the System or when symptoms do not match the System readings. †

Information contained herein for distribution outside of the US ONLY. Local legal and regulatory approval is required to publish any content. FreeStyle and related brand marks are trademarks of Abbott Diabetes Care, Inc. in various jurisdictions. © 2015 Abbott DOC37018_Rev-B

1 The LibreLink app includes a mobile application, provided by AirStrip, and data management services, provided by NewYu, Inc. Registration with NewYu, Inc. is required during app setup. Abbott, provider of the FreeStyle Libre readers and sensors, is not the provider of the LibreLink app. 2The LibreLink app is compatible with NFC-enabled smartphones running Android OS 4.0 or higher. | 3When a FreeStyle Libre sensor is started with the LibreLink app, it is linked exclusively to the app and that smartphone. Once linked, a FreeStyle Libre reader or other LibreLink account cannot be used to scan that sensor. | 4A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the LibreLink app or when symptoms do not match the LibreLink app readings. | Airstrip Technologies develops and maintains the LibreLink app. | NewYu, Inc. is the exclusive provider of data management services for the LibreLink app. | FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. Other trademarks are the property of their respective owners. | DOC35729 Rev. C 09/15

11/15

Finger pricking is a big source of stress for children with diabetes

Children undergo finger-prick testing on average six times a day and dislike it for many reasons including hassle and pain*

Times/Day

FREE TO

PLAY

WITHOUT LANCETS*

Parents believe diabetes restricts their child’s life

51% suffer sleep disruption due to diabetes management*

FLASH GLUCOSE MONITORING SYSTEM

44% say measuring glucose levels is the biggest source of interruption for their child*

* Survey of 600 parents of children aged 4 – 14 years with type 1 diabetes. Conducted by Opinion Health January 2016

Upload Data

View Reports

Create a Practice

Manage Your Patients

Follow on-screen instructions to upload your patients’ reports

One easy view for consistent reports in one place

You can… • Customise report settings for individual patients OR all patients in your practice TIP

If your patients use the LibreLink app, their diabetes information will sync to LibreView without the need for cables

• Customise the report criteria and the types of report that are generated each time

Invite patients to share glucose data from home and invite colleagues to view the same patient data you see

• Open the menu in • Enter your practice LibreView and click information and “Create a LibreView click “Create Practice” Practice”

Front

The ‘My Patients’ dashboard

Quick Start Guide for Healthcare Professionals

Use the dashboard to identify patients and access saved reports

Flag patients to keep track of the ones that may need more attention

• Compare glucose history for each patient

CLIENT

PROJECT

WORK TYPE

Abbott

FreeStyle Libre marketing material

• Editorial Layouts • Social Media Content • Gifs • E-Marketing Designs

63% report their child having had at least one episode of severe hypoglycaemia during sleep*

• PowerPoint Presentations • Website Design • Infographics

All your patients’ glucose data in one secure, cloud-based location

CLIENT

Abbott Wednesday 18th February

CLINICAL UTILISATION OF THE FREESTYLE LIBRE SYSTEM

2015

TECHNICAL AND CLINICAL ADVANCES IN FLASH GLUCOSE MONITORING

Monday 1st October

2018

Abbott Diabetes Care Industry Symposium

16:45 — 18:15hrs

The first 14-day, no calibration sensor-based flash glucose monitoring system

CNIT

2 Place de la Défense 92053 La Défense France

FreeStyle Libre System Accuracy Study Timothy S. Bailey, MD

14:30 – 17:00

Please register with EASD in advance for this symposium.

Rapoport Hall

Industry symposium supported by Abbott on the occasion of the 54th Annual Meeting of the European Association for the Study of Diabetes.

Messedamm 22 14055 Berlin Germany

Improving Patient Outcomes with Constructive and Meaningful Dialogue using Ambulatory Glucose Profile Iain Cranston, MD Using the FreeStyle Libre System and Ambulatory Glucose Profile to Uncover Glucose Information in Patients with Type 1 Diabetes Jean-Pierre Riveline, MD Panel Discussion Professor Cliff Bailey and all Presenters

FreeStyle and related brand marks are trademarks of Abbott Diabetes Care, Inc. in various jurisdictions. ADC-EM2018FSL008

TECHNICAL AND CLINICAL ADVANCES IN FLASH GLUCOSE MONITORING

XXXXDAY XXTH AUGUST

2019 14:30 – 17:00

ABBOTT DIABETES CARE INDUSTRY SYMPOSIUM

VENUE BARCELONA

Industry symposium supported by Abbott on the occasion of the 55th Annual Meeting of the European Association for the Study of Diabetes. FreeStyle and related brand marks are trademarks of Abbott Diabetes Care, Inc. in various jurisdictions. ADC-XX2019FSL000

NE W !

CLINICAL UTILISATION OF THE FREESTYLE LIBRE SYSTEM

FLASH GLUCOSE MONITORING

The first 14-day, no calibration sensor-based flash glucose monitoring system

Clinical Use from Childhood through Adulthood Industry symposium supported by Abbott on the occasion of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2016

Wednesday 18th February 2015, 16:45—18:15hrs PROGRAMME EVALUATION FORM Your feedback on this symposium is very important to us; please take the time to answer the following questions, and leave your completed form on your seat or hand to a member of the symposium staff.

Session Evaluation Please rate each of today’s presentations where 1=poor and 5=excellent

FreeStyle Libre System Accuracy Study Timothy S. Bailey, MD Improving Patient Outcomes with Constructive and Meaningful Dialogue using Ambulatory Glucose Profile Iain Cranston, MD Using FreeStyle Libre System and Ambulatory Glucose Profile to Uncover Glucose Information in Patients with Type 1 Diabetes Jean-Pierre Riveline, MD

Welcome to Flash Glucose Monitoring.

Panel Discussion Professor Cliff Bailey and all Presenters

The days of routine glucose testing with lancets, test strips and blood are over.†

Overall Evaluation

WHY PRICK, WHEN YOU CAN SCAN?†

Will the information you have heard here change your practice in the future?

Yes

Maybe

Yes Maybe

Would you like to hear more about AGP?

To find out more, visit us at Stand #3 during the ATTD AbbottNextFrontier.com

If yes, how:

Yes

Maybe

Wednesday 3 February, 14:30 – 16:00 Hall C - Blue Hall Chair of the Symposium: Professor Emanuele Bosi, M.D. Vita-Salute San Raffaele University, Milan, Italy XX:XX – XX:XX

First Clinical Experience with FreeStyle Libre in Young Adults and Children with Type 1 Diabetes Fiona M Campbell, M.D. Leeds Teaching Hospitals Trust, UK

XX:XX – XX:XX

Clinical Use of FreeStyle Libre in Adults with Type 1 Diabetes Professor Emanuele Bosi, M.D. Vita-Salute San Raffaele University, Milan, Italy

XX:XX – XX:XX

Use of FreeStyle Libre in Intensively Managed Adults with Type 2 Diabetes Gerry Rayman, M.D. Head of Service, Diabetes Care, Ipswich Hospital NHS Trust, UK

XX:XX – XX:XX

Panel Discussion Professor Emanuele Bosi, M.D. and all presenters

Would you like to hear more about Flash Glucose Monitoring?

What topics related to sensor technology would you find interesting at future satellite symposia?

* Scanning the sensor does not require lancets. †

A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the System or when symptoms do not match the System readings. FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. Simulated data for illustrative purposes only; not real patient or data. Date of preparation: August 2014. ADCMDP140136r

‡

FreeStyle Libre is currently only available via purchase from Abbott Diabetes Care

To find out more about FreeStyle Libre go to www.AbbottNextFrontier.com FreeStyle and related brand marks are trademarks of Abbott Diabetes Care, Inc. in various jurisdictions.© 2015 Abbott ADC/ATTD2015/013

CLIENT

PROJECT

WORK TYPE

Abbott

FreeStyle Libre marketing material

• Editorial Layouts • Social Media Content • Gifs • E-Marketing Designs

• PowerPoint Presentations • Website Design • Infographics

FreeStyle and related brand marks are trademarks of Abbott Diabetes Care, Inc. in various jurisdictions. ADC/ATTD2016/008

CLIENT

Amgen YOUR E V I G ENTS’ PATI E HEALTH BON T TER A BE NCE CHA Are your patients at risk of fragility fractures?

YOUR GIVEES A BONNING WIN NCE CHA Healthy bones help you stay active and do the things you love. TALK TO YOUR DOCTOR ABOUT YOUR OSTEOPOROSIS RISK CHECK RESULTS



Book your doctor’s appointment Date

WHAT IS OSTEOPOROSIS?

Time

Osteoporosis reduces the density of your bones. This can make your bones more fragile which can lead to fractures. Bone loss occurs without you knowing, and often without symptoms until a fracture happens. You can discuss your risk and treatment options with your doctor.

QUESTIONS TO ASK YOUR DOCTOR 1. Am I at risk of osteoporosis? 2. Do I need a bone density scan?

Osteoporosis makes your bones more fragile as you age which can lead to fractures. Keep your bones healthy and do the things you love for longer.

WHAT IS A BONE DENSITY SCAN?

3. What can I do to improve my bone health?

A bone density scan, often referred to as a DEXA scan, measures your bone strength and helps your doctor make a diagnosis. It only takes 10 to 20 minutes, depending on which part of your body is being scanned. It is completely painless. You can ask your doctor to describe the procedure to you.

4. Other questions

RAISING AWARENESS OF RISK FACTORS FOR OSTEOPOROSIS

GIVER YOU ES BON NNING A W IN C E CHA

CHECKLIST

 

Print and bring my Osteoporosis Risk Check results Note any medication or supplements

Take the 1 minute test and talk to your doctor.

ILE FRAG S .EU E N O B

In collaboration with insert local P.A.G logo here

This initiative is supported by

ST? BONE TE

THE WHAT ISOROSIS OSTEOP HECK? C K IS R

THE GAME OF NCE CHA

YOUR GIVE NTS’ BONE PATIE H A BETTER HEALT CE CHAN

In collaboration with insert local P.A.G logo here

Developed by the International Osteoporosis Foundation (IOF), this eight-question risk check for older women identifies key risk factors for osteoporosis.

Q1 Q2 Q3

The Spanish Foundation for Osteoporosis and Metabolic Bone Diseases (FHOEMO) is launching a communications campaign on [date] to help women 65 years and over in Spain become more aware of their risk of fragility fractures.

Q4 Q5 Q6 The Game of Chance campaign encourages older women to take The Osteoporosis Risk Check to raise their awareness of osteoporosis risk factors. If results of the risk check are positive, women are encouraged to discuss their risk of osteoporosis with their doctor.

Q7 Q8

Are you aged 60 or older? Have you broken a bone after the age of 50? Are you underweight?

Are they at risk of fragility fractures?

Body Mass Index

After the age of 40, have you lost more than 4cm in height (ca. 1.5in)? Have either of your parents had a hip fracture? Do you have any of the following disorders? Rheumatoid arthritis ∞ Digestive tract diseases ∞ Prostate or breast cancer ∞ Diabetes ∞ Chronic kidney disease ∞ Thyroid gland disorders ∞ Lung disorder ∞ Low testosterone ∞ Early menopause, periods stopped, or ovaries removed ∞ Immobility ∞ HIV

Have you been treated with any of the following medications? Glucocorticoids ∞ Aromatase inhibitors ∞ Androgen deprivation therapy ∞ Thiazolidinediones ∞ Proton pump inhibitors ∞ Thyroid hormone treatment ∞ Immunosuppressants ∞ Antidepressants ∞ Steroid hormones ∞ Antipsychotics ∞ Anticonvulsant

Do you drink excessive amounts of alcohol (more than 3 units a day) and/or currently smoke?

The IOF Osteoporosis Risk Check (#IOFRiskCheck) is intended as a tool to raise awareness of factors which are known to increase the risk of osteoporosis and fractures. This awareness tool has been reviewed and approved by IOF’s Committee of Scientific Advisors. The IOF Osteoporosis Risk Check is not a diagnostic tool: only a doctor can diagnose osteoporosis. An interactive version of the risk check is available on the International Osteoporosis Foundation website http://riskcheck.iofbonehealth.org

In collaboration with insert local P.A.G logo here

This initiative is supported by AMGEN Europe GmbH Suurstoffi 22, P.O. Box 94, CH-6343 Rotkreuz, Switzerland

ILIT Y FRAGTURES FRAC E T V HA IMPAC A BIGIVES ON L

ILIT Y FRAGTURES FRACMORE AN E AR MON TH COMMIGHT YOU K THIN ?

+28.

≥ 330,000

Fragility fractures affect more women than stroke, breast cancer and cardiovascular disease combined.

One year after a hip fracture 63% of patients have limitations on daily tasks such as driving, shopping, walking unaided, using the toilet and taking a shower.

US HELPSE THE CLO NOSIS G DIA GAP

Women over 65 years with a previous fragility fracture are recommended for treatment. Recognising clinical risk factors to assess probability of fractures can direct management decisions to prevent fractures.

3 in 4 patients at risk of fragility fractures were not receiving osteoporosis medication.

420,000

+ 3

1 in 2 patients over 75 years visiting their primary care physician were at increased risk of fragility fractures.

This initiative is supported by

2017

2030

NTS PATIEE THEIR E VALUPENDENC INDE TIVE LIFE & ACVE ALL ABO

Prior fragility fracture

Advanced age (65 years +)

Parental history of hip fracture

20% 80%

In a survey of women 75 years and under, 80% would rather be dead than have to enter a nursing home due to loss of independence after a hip fracture.

History of falls

Glucocorticoid treatment

Incidence of fragility fractures in Spain is increasing every year.

CLIENT

PROJECT

WORK TYPE

Amgen

‘Give your Bones a Winning Chance’

• Editorial Layouts • Social Media Content • Gifs

The 1 Minute Test is not designed to assess absolute risk. Please use FRAX®,DXA or other validated clinical diagnostic tools to further assess at-risk patients.

• New Business Visualisations • E-Marketing Designs • Infographics

CLIENT

Almirall Do you know the ABC of IBS? About IBS People with IBS experience bouts of:1

IBS is a chronic,

relapsing and often lifelong disorder, characterised by abdominal pain and/or discomfort, bloating and changes in bowel habit1

IBS is common in

Scotland with a

prevalence in adults of 7.7% for those who seek medical help2

Only half

of those with IBS symptoms present to their primary care physician1

Almirall IBS Timeline

Do you know your Irritable Bowel Syndrome sub-types? IBS-C

IBS-D

Lots of stomach pain, bloating and change in

7.7%

Irritable Bowel Syndrome with CONSTIPATION - IBS-C

Abdominal pain

B Bloating

IBS

has a significant impact on both patients 3 QoL and the healthcare resource use4

Almost twice as common in women than men2

IBS

IBS-M

half

Almost of IBS patients in Scotland are treated with prescription medication2

One-third of patients with IBS are thought to have IBS-C2 which means they suffer chronically from both abdominal pain and constipation.

bowel habits – give it a week or so before thinking it’s not just a stomach bug…

– there’s some scary stuff out there! Could it be cancer? There’s lots of information but I’m still not sure what it could be.

GP tells me it’s nothing, I just need to watch what I eat. I feel like I’ve wasted her time

Irritable Bowel Syndrome with DIARRHOEA - IBS-D One-third of patients with IBS are thought to have IBS-D2 which means they suffer chronically from both abdominal pain and diarrhoea.

Change in bowel habits

Do some online research

Have been Googling. I could have something

called IBS – my symptoms do seem to match those being described. It’s a relief that it’s not cancer but I still don’t feel well and it’s now been months since my symptoms first appeared. Want to go back to my GP but not sure she can help as she didn’t last time.

Irritable Bowel Syndrome MIXED - IBS-M One-third of patients with IBS are thought to have IBS-M2 which means they suffer chronically from abdominal pain and both constipation and diarrhoea.

Additional information For further information, or to discuss your case study needs, please contact Abigail Thomson or Caroline Howley using the contact details:

Up to 50%

of referrals to gastro for IBS are perceived to be wasteful of specialist resources5

IBS cannot be cured1 and treatment focuses on symptom control.

multiple treatment

Often

approaches may be required.1 Abigail Thomson athomson@rdcomms.com 020 8392 8049

Caroline Howley chowley@rdcomms.com 020 8392 6938

50%

less than 25% of patients report complete relief of any one of their IBS-C symptoms6

Feel isolated as I don’t really

References: 1. NICE. Clinical Practice Guideline: IBS in adults. 2008 2. Information Services Division. An investigation into the prevalence, management and healthcare burden of irritable bowel syndrome in Scotland.2012 3. Spiller R, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management Gut 2007;56:1770-98 4. Cash B, Sullivan S, Barghout V. Am J Manag Care. 2005; 11(1 Suppl): S7-16

1 2

With existing treatments,

British Society of Gastroenterology. IBS functional symptoms - BSG commissioning report. Available at http://www.bsg.org.uk/images/Commissioning_report/BSG_ IBS_and_Functional_symptons.pdf [Accessed March 2013]

Hungin APS et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643–650

want to talk to my friends and family about my bowel habits and how the change in them, and the other symptoms like pain and bloating, are affecting me – have tried some over the counter things but nothing seems to work. I also feel that I’m constantly moaning about not feeling well and have even had to take a few days off work.

I found a useful resource on a patient website – it’s a

simple three question questionnaire that indicates whether or not I have IBS – seems like I do. Going to take the results to my GP and see if a diagnosis can be made…

Date of preparation: April 2013 Job number: UKLIN1826b

CLIENT

PROJECT

WORK TYPE

Almirall

Various marketing material

• • •

Editorial Layouts Social Media Content Website Design

• Infographics • Exhibition

Bite the bullet and visit my GP again as feel so rotten – feel more informed and

confident though since taking the online questionnaire. I ask to see a different GP to last time and really run through my symptoms. Much more positive experience! I now have a diagnosis and feel so relieved that I definitely know what’s wrong and that it is manageable.

Hooray! After being careful with my diet and really knowing what triggers my symptoms, I feel so much more in control of my body and my life. I’m able to socialise more without worrying about an IBS attack and my friends at work have noticed a difference too – I can’t stress enough how important it is for people to keep researching and seeking help from their GP. My life is now mine again. My IBS, my life.

CLIENT

Takeda - Alunbrig

Explore two real-life ALUNBRIG patient experiences alongside relevant efficacy and safety data Read Tom’s case

Read Susan’s case

A 60-year-old chef who has ALK+ aNSCLC that has progressed with CNS involvement after front-line therapy and is experiencing neurological symptoms.

A 73-year-old retired journalist with osteoarthritis, osteoporosis and hypothyroidism and chronic musculoskeletal pain.

Explore Tom’s experience of ALUNBRIG and the relevant supporting clinical data.

Explore Susan’s experience of ALUNBRIG after progressing with front-line therapy for ALK+ aNSCLC.

ALUNBRIG® (brigatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) previously treated with crizotinib.1

References 1. ALUNBRIG Summary of Product Characteristics.

January 2019 UK/BRIG/1810/0029k

Not for further copying or distribution

EFFICACY | TOLERABILITY | DOSING | SUMMARY | GLOSSARY

Click tabs to explore key ALUNBRIG data at any point. Use the arrows to work through the case study.

Tom’s treatment history

Crizotinib initiated

Grade 2 fatigue Grade 2 nausea

Intracranial protection extending out to one and a half yearsa,1-4

Developed CNS symptoms: unsteadiness dysarthria, vertigo and nausea Following progression on crizotinib, Tom commenced ALUNBRIG at 90 mg/day

OCT 2015

DEC 2015

Pemetrexed + cisplatin

Chemotherapy discontinued (after cycle 3)

JAN 2016

APR 2017 Discontinued crizotinib after 15 cycles

MRI: New, extensive CNS involvement (subtle leptomeningeal disease)

IRC-assessed intracranial PFSb in patients with any brain metastases at baseline1

Reviewed at 7 days, no worsening of neurological symptoms, no toxicities of treatment, so dose was escalated to 180 mg/day

Treatment goal • Palliative, aiming for improved quality of life

Adapted from Huber MH, et al. 20181

Intracranial mDOR (IRC assessed) of 16.6 months (95% CI 3.7-NR) in patients with measurable brain metastases at baseline.2-4 a

Why ALUNBRIG?

In patients with brain metastases at baseline. bIntracranial PFS does not include systemic (non-cranial) disease progression events. 180 mg once daily with 7-day lead-in at 90 mg once daily.

• PFS data from the ALTA study • As Tom works in food preparation, GI toxicity was an important consideration References 1. Huber RM, et al. Poster presentation at ASCO Annual Meeting 2018, Poster 384; 2. Camidge DR, et al. J Clin Oncol 2018;36:2693-2701; 3. Ahn M-J, et al. Oral presentation at IASLC 18th World Conference on Lung Cancer, 2017; 4. Ou S-HI, et al. Oral presentation at ESMO 2017, poster 1345P.

Not for further copying or distribution

ALTA: evaluating the eﬃcacy and safety of ALUNBRIG

Raising expectations in

ALK in Lung Cancer Trial of AP26113 (ALTA): a phase 2, global, randomised, open-label, multicentre trial. Objective: to assess the eﬃcacy and safety of two ALUNBRIG dosing regimens.

ALK+ aNSCLC post crizotinib Exceeds 1 year median PFSa in ALK+ aNSCLC patients post crizotinib1

LICENSED INDICATION

ALTA was not a controlled trial and not designed for statistical comparisons between dosing regimens.

Primary endpoint was conﬁrmed ORR according to Response Evaluation Criteria In Solid Tumors (RECIST v1.1) as evaluated by investigator. a

a IRC and investigator assessed. UK/BRI/1807/0001 Date of preparation: January 2019

CLIENT

PROJECT

WORK TYPE

Alunbrig

Isell detail aid

• E-Marketing Designs

Patients in the 90 mg arm were allowed to escalate to 180 mg after RECIST progression.

ye drop nctivitis Dosage p to be at least nsitivity ons and ystalline Contains known eported nded or istance. eriences devoid nancy if infants effects: of the ing and various ensation ts at the ritation, vision. mation) o fusidic o cause stitute a 7.57 per arketing Co), 1st Date of

ority.

orted

.com.

ary 2016

CLIENT

AMCo

Efficacy

Key facts about

Tolerability

Fucithalmic® has a proven comparable efficacy profile, as efficacious as tobramycin, chloramphenicol and norfloxacin1-3

A guide for healthcare professionals

Fucithalmic® is a well tolerated treatment with mild and transient adverse events7 Fucithalmic® is a preferred treatment option for pregnant women where benefit outweighs risk (NICE, UK health guidance body)8

Fucithalmic® has a sustained targeted action against the most common pathogens causing bacterial eye infections, namely streptococcus pneumoniae, staphylococcus aureus and haemophilus influenzae4,5

This leaflet tells you all you need to know about Fucithalmic® eye drops, an effective treatment option for the most common bacterial eye infections

Fucithalmic® offers low discontinuation rates9

Formulation

Convenience

Fucithalmic® is administered as a viscous eye drop easing application for patients of all ages and causes less blurring compared to an ointment1

Fucithalmic® is an effective and convenient twice daily treatment option2 Unique carbomer gel formulation prolongs contact time with the eye for up to 12 hours6

References 1. Normann EK, et al. Acta Ophthalmol Scand. 2002;80:183–87. 2. Jackson WB, et al. Can J Ophthalmol. 2002;37:228–237. 3. Wall AR, et al. J Clin Res. 1998;1:316–325. 4. Arrata M. Acta XXV Concilium Ophthalmologicum. 1987;1038-1042. 5. Morrow GL, et al. Am Fam Physician. 1998 Feb 15;57:4:735-46. 6. van Bijsterveld OP, Andriesse H, Nielsen BH. Eur J Drug Metab Pharmacokinet. 1987 Jul-Sep;12:3:215-8. 7. Hvidberg Jesper. Acta Ophthalmol. 1987;65:43-47. 8. NICE. Clinical Knowledge Summaries. Conjunctivitis – infective. 2015. Available from: cks.nice.org.uk/conjunctivitis-infective (accessed December 2015). 9. Sinclair NM. Curr Ther Res. 1988;44:468-73.

Fucithalmic® is a patient friendly treatment, with 91% of patients fully compliant3

Prescribing information is included at the end of this guide Initiated, funded and reviewed by AMCo/FUT/1215/0029a

Date of preparation: February 2016

BACTERIAL CONJUNCTIVITIS CONSULTATIONS

Initiated, funded and reviewed by AMCo

BACTERIAL CONJUNCTIVITIS CONSULTATIONS

Initiated, funded and reviewed by AMCo

Talking about bacterial conjunctivitis

Bacterial conjunctivitis and your patients

Conversation starters – getting the most out of your patients

If antibiotic treatment is required, encourage patient to elaborate on the below to prescribe a suitable topical eye ointment or eye drops

BACTERIAL CONJUNCTIVITIS CONSULTATIONS

Initiated, funded and reviewed by AMCo

Bacterial Conjunctivitis What is it and why do I have it? Bacterial conjunctivitis (or ‘red eye’) is a condition that causes redness and swelling of the thin layer of tissue that covers the inside of the eyelids and front of the eye – the conjunctiva. It can be easily spread by direct or indirect contact with others who are infected.

The low down on bacterial conjunctivitis

Estimated to comprise 1% of all consultations in primary care1

Leading cause of absenteeism from nursery, school and work2

Represents approximately 40% of ocular diagnoses in children3

Tips to get your patients talking about bacterial conjunctivitis

PAGE 1

Symptoms

Aetiology

Ask patient / care giver to describe symptoms and prompt to articulate duration and severity of the condition

Infectious or non-infectious? Probe to determine the most likely cause of the symptoms and identify any known risk factors

Self-treatment to date

Impact

Impact on attendance at school or work? Question to uncover the full impact of the condition on the patient’s / care giver’s day-today life

Proper care and treatment adherence are essential for speedy recovery. Some tips are provided in the accompanying take-away patient guide to reinforce any advice given during the consultation

Job Code: GL/FUC/RDP/997A/2015 | Date of preparation: November 2015

Nature of condition and how treatment may support quicker resolution of symptoms

Explore patient understanding of contagious nature of condition and provide information on how antibiotics may help to avoid spread of infection4

Lifestyle of patient or care giver

Treatment application

Confirm self-care measures to date and what has / hasn’t helped to relieve symptoms

Beyond the consultation: patient education

Here are some suggestions to support your consultations and patient dialogue

Probe to understand importance of treatment convenience for the patient / care giver, to support faster recovery and better compliance with fewer applications

Determine patient / care giver preferences regarding treatment application. Depending on the patient's agreement, prescribe a suitable treatment

Patient education is very important to stop the spread of infection and speed up the resolution of symptoms

Why not share the accompanying patient advice sheet at the end of your consultation? It contains some useful care advice to support patient compliance in the treatment of bacterial conjunctivitis

References 1. Høvding G. Acta Ophthalmol 2008;86:5–17. 2. Rose PW, Ziebland S, Harnden A, et al. Fam Pract 2006;23:226–32. 3. Gold RS. Pediatric Annals 2011;40:95–105. 4. Smith AF, Waycaster C. BMC Ophthalmology 2009;9:13.

PAGE 2

Job Code: GL/FUC/RDP/997A/2015 | Date of preparation: November 2015

CLIENT

PROJECT

WORK TYPE

AMCo

Various marketing material

• Editorial Layouts • New Business Visualisations • Infographics

Not only is bacterial conjunctivitis highly infectious, it can also be very uncomfortable.

Here are some pointers to help ease any discomfort and to prevent spreading the condition to others. Care tips

Prevent the spread of bacterial conjunctivitis

Always use medication as directed – just speak to your HCP if you have any questions

Keep face flannel, towel and pillow separate from those of the rest of the family

Clean away any discharge from eyelids and lashes using cotton wool soaked in cooled boiled water

Wash your hands thoroughly and regularly, particularly after touching your eyes

Do not wear contact lenses until the conjunctivitis has cleared up

Use tissues if you need to wipe your eyes and dispose of them immediately afterwards

Under no circumstances allow anyone else to use your eye ointment or drops. Throw them away when your treatment is finished. Never keep used bottles

Don’t go swimming at public swimming pools until your infection is completely treated

PAGE 1

Job Code: GL/FUC/RDP/997A/2015 | Date of preparation: November 2015

CLIENT

Astellas Spotlight In the

Integrity

Action

Spotlight In the

Rochelle and Daniel

Take responsibility . Act ethically . Lead by exampl e.

NAME OF PERSON

What are the outputs?

In the first of our new In The Spotlight series, we heard from Rochelle Chopamba and Daniel Schulze. They introduced us to the world of HR and legal and shared with us how they interact on a day-to-day basis. Part of their cross-functional role involves sitting on the Case Review Committee, which they tell us about in their video.

Integrity

Action

Take responsibility. Act ethically. Lead by example.

Jan 2017

For those interested in understanding more about the Case Review Committee (CRC) and what happens when you speakup, outlined below is the CRC Charter.

• Agreement on identity of investigation lead and investigation support

If you have any questions about speaking-up or this Charter, please feel free to speak to Rochelle, Daniel or their colleagues in HR/legal.

• Agreement on next steps and corrective actions if required following completion of investigation and review of the subsequent report

Welcome to the In the Spotlight newsletter. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus finibus massa erat, sed condimentum justo tincidunt in. Curabitur non odio nec urna fringilla luctus. Proin vitae dui ut nisi vehicula mattis non ac felis. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Pellentesque convallis euismod risus, sit amet interdum risus varius vel. Vestibulum id ligula faucibus, dictum purus in, condimentum dui. Donec iaculis varius erat, ac fermentum libero. Aliquam hendrerit sit amet nisi in aliquet. Maecenas faucibus lacinia massa id rutrum. Donec pharetra nisl id tincidunt pellentesque. Nullam ut vehicula dolor, ut ornare nulla.

• Agreement on lessons learned and appropriate training to EMT/HLT/affiliates when deemed necessaryappropriate

What is the purpose of the CRC? The Case Review Committee (CRC) review all reports received on a case by case basis to ensure that it is triaged to the appropriate leadership and function for investigation and resolution.

Purpose

The CRC consider whether any case received warrants disclosure to an external regulator.

The Case Review Committee (CRC) to review all reports received on a case by case basis to ensure that it is triaged to the appropriate leadership and function for Investigation and resolution.

The CRC review the outcome of the investigation and challenge/ review the steps taken and make appropriate recommendations.

The CRC to consider whether any case received warrants disclosure to an external regulator. The CRC to review the outcome of the investigation and challenge/review the steps taken and make appropriate recommendations.

Why is the CRC important? Senior leadership must demonstrate that all reports received are treated with utmost seriousness and are assigned to the appropriate function to ensure that allegations are fully investigated and outcomes are appropriately reviewed and challenged.

Importance

Two of the following are required to confirm the CRC is quorate and 1 of Head of Ethics and Compliance or General Counsel EMEA:

What input goes into the CRC? • Initial case report details

Senior leadership must demonstrate that all reports received are treated with utmost seriousness and are assigned to appropriate function to ensure that allegations are fully investigated and outcomes are appropriately reviewed and challenged.

• Head of Ethics and Compliance EMEA (Chair)

• Any expert insight as appropriate

Inputs

• President of EMEA Operations, EMEA or delegate

• Investigation report and proposed next steps/corrective actions

• Initial case report details • Any expert insight as appropriate

• General Counsel EMEA

What process do the CRC follow?

• Investigation report and proposed next steps / corrective actions

• VP, HR or delegate

• Head of Ethics & Compliance EMEA to introduce the case and chair the discussion on how to proceed

N.B. Should one of the above attendees be identified in the case report, they will be excluded from any decision related to that case

• All to advise of any legal, HR or business implications • All to consider if a disclosure to an external regulator is required

Process • Head of Ethics & Compliance EMEA to introduce the case and chair the discussion on how to proceed

• Review of output of the investigation to ensure proposed next steps and corrective actions are appropriate

• All to advise of any legal, HR or business implications • All to consider if a disclosure to an external regulator is required • Review of output of the investigation to ensure proposed next steps and corrective actions are appropriate

Outputs • Agreement on identity of investigation lead and investigation support • Agreement on next steps and corrective actions if required following completion of investigation and review of the subsequent report • Agreement on lessons learned and appropriate training to EMT/HLT / Affiliates when deemed necessary

Astellas Communications Network Map

2 of the following is required to confirm the CRC is quorate and 1 of Map Astellas Communications Network Head of Ethics and Compliance or General Counsel EMEA: EMEA TEAM:

AFFILIATES:

• Head of Ethics and Compliance EMEA (Chair) Christina Chale (EMEA)

Stefan Bevers

• President of EMEA Operations, (The Netherlands)EMEA or delegate

Interim Corporate Communications Director

AFFILIATES: Vadim Kurenkov (Russia & CIS) Head of Recruitment, Personnel Development & HR Communications

• General Counsel EMEA

Jan Milton-Edwards (EMEA)

• VP, HR or delegate

Corporate Communications Director

Louise Carmén (Nordic & Baltic Operations) Communication & Commercial

Antonella Di Lorenzo (Italy) Communications, Institutional Relations & Congress Manager

Excellence Director N.B. Should one of the above attendees be identified in the case report, they will be excluded from any decision related to that caseNeumann Anne-Katrin

Czech Republic

Belgium

Spain

Poland

Southeast Europe

Ireland

Turkey

Netherlands

Sarah Dodd (UK)

Associate Director, Employee Communications

PA to General Manager

Format fulfil its Bily Kuo (EMEA) The committee willLene Freij (Nordic & Baltic Operations) Communications Manager, responsibilities via email

EMEA

Switzerland

Carol Hammond (EMEA)

Greece

Russia & CIS

Nordic & Baltic Operations

France

Italy

Portugal

MENA/SSA

Germany

Corporate Communications

Project Manager, Communication & Commercial Excellence

Alex Orton (EMEA)

Kathrin Garcia (Switzerland)

Communications Officer

Field Market Access Manager

Jo Taylor (EMEA)

Beatrice Huber (Germany)

Senior Director, Corporate Communications

PA to Director Marketing

Emma White (EMEA)

Giota Korovesi (Greece)

Communications Manager

Executive Assistant & Communications Coordinator

Margot Kubosch (Spain) Corporate Affairs & Communications Manager

CLIENT

PROJECT

WORK TYPE

Astellas

Print and digital marketing material

• New Business Visualisations • E-Marketing Designs • Website Design • Infographics

(Switzerland)

Senior Manager Market Access

Frequency Karinaby Oppitz (Germany) On a case case basis Manager Communications

Catarina Silva (E6 - Portugal) HR Manager

Eliska Strosova (Czech Republic) HR Associate

Simona Sutaviciute (MENA/SSA) Regional Communications, PR and Events Manager

Tatiana Vanderstraeten (Belguim) PA to General Manager

Azra Pisek (South East Europe)

Yda Visser (The Netherlands)

Office Manager & PA

Management & Communication Coordinator

Barbara te Riele (The Netherlands)

Karen Welby (Ireland)

Manager Communications

Lee Roberts (E6 - Hub) HR Director

Executive Assistant

Elzbieta Wrzesinska (Poland) PA to GM / Assistant in E&C Dept.

Justine Foucault Serre (France) Business Intelligence & Services Team Manager, Marketing Corporate Communication Manager, General Management

Esra Yazici (Turkey)

CLIENT

Astellas OVERACTIVE BLADDER (OAB)

AFFECTS AROUND

Living with Prostate Cancer

OVERACTIVE

ADULTS IN THE UK

The Every Voice Matters survey provides an in-depth analysis and personal insight into the lives of 141 UK men with prostate cancer.1 The UK survey results have been taken

AFFECTS AROUND

7 MILLION 1

ONE THREE

OVER

50%

URGENCY a sudden, compelling desire to pass urine

OAB

which is difficult to defer1. This symptom is also regarded as a driver for other symptoms:

URINARY INCONTINENCE OR ‘WET’ OAB – any involuntary leakage of urine

FREQUENCY– the need to empty the bladder more

than eight times in a day5

NOCTURIA

– awakening at night one or more times to empty the bladder5

When asked what matters most since being diagnosed with prostate cancer...

THE EMBARASSING SITUATIONS LEAGUE TABLE6

83% WETTING YOURSELF IN PUBLIC

red wine on someone else’s white carpet

TESTING?

the wrong person

ONE THREE

Nearly in women don’t feel comfortable talking about it with their GP2

IS MORE COMMON

than arthritis3, angina4 and diabetes2

SYMPTOMS OF

SPILLING

7 MILLION

WHAT MATTERS MOST

OAB

of people diagnosed with OAB don’t feel comfortable talking about their waterworks with friends or family2

BLADDER (OAB) ADULTS IN THE UK1

The survey was commissioned by Astellas.

Nearly in don’t feel comfortable talking about it with their GP2

50%

from a pan-European survey of 668 men diagnosed with prostate cancer, designed to determine unmet needs in the current care and management of patients.1

FALLING over in public

Being

OVERHEARD

having a private conversation

TELLING

a joke no one laughs at

19%

10%

men highlighted the importance of living well2

spending time with family and friends2

OAB

of women diagnosed with OAB don’t feel comfortable talking about their waterworks with friends or family2

IS MORE COMMON

than arthritis3, angina4 and diabetes5

URGENCY a sudden, compelling desire to pass urine

SYMPTOMS OF

OAB

12%

17% enjoying life2

of men said that being cured is what matters most2

which is difficult to defer6,7. This symptom is also regarded as a driver for other symptoms:

URINARY INCONTINENCE OR ‘WET’ OAB6 – any involuntary leakage of urine FREQUENCY6– the need to empty the bladder

more than eight times in a day

NOCTURIA8– awakening at night more than twice

QUALITY OF LIFE MATTERS Quality of life is very important to men diagnosed with prostate cancer

to empty the bladder

THE EMBARASSING SITUATIONS LEAGUE TABLE9

1 in 5 (20%) men feel quality of life is more important than living longer3

Being

3 in 4 (74%) men feel a good quality of life is as important as being able to live longer with treatment3

compared to only 1 in 17 (6%) who feel living longer is more important3

CONTRIBUTING TO SOCIETY IS IMPORTANT

50% 40% 30% 20%

MEN

Having to get up to

A partner snoring

Noise from other

A partner fidgeting

MEN

Needing to get a

red wine on someone else’s white carpet

FALLING

over in public

TELLING

a joke no one laughs at

TEXTING

BEING OVERHEARD

the wrong person

having a private conversation

BEING STOOD UP on a date

WOMEN10

WHAT ANNOYS US MOST AT NIGHT TIME

continue to contribute to society

yourself in public

It is important for men to remain well enough to

10%

SPILLING

VS ALL CHARTS ARE REF 6

WETTING

6% 4%

STOOD UP on a Date

80%

WOMEN

50% 40% 30%

30% 20% 10% 0%

20% 10%

Wetting yourself in a

Being shown up at

Dating mishaps

Parents Grandparents showing bad

The majority of patients (87%) said they want to fight their cancer, and 2 in 5 (41%) want to continue working as much as possible4,5

UK men are working for longer – there are currently

A partner snoring

Having to get up to use the toilet

>600,000 men in the UK

Needing to get a drink of water

Noise from other rooms/flats

A partner fidgeting

over the retirement age, but still working6

N W

MEN

E S

MEN

THE ROLE OF HEALTHCARE PROFESSIONALS

66%

68%

Men feel that

65% 61%

continuity of care is important when making treatment choices

50%

Just over half of women and two fifths of men believe lifestyle advice to be the standard treatment for people with Overactive Bladder. Two fifths of men and a third of women believe that medicine is standard treatment

30% Surgery

Patients with prostate cancer also feel that they communicate

well with their doctor

10% 0%

Wetting yourself in a public place

Being shown up at school

Dating mishaps

Parents showing bad baby photos

Just over half of women and two fifths of men believe lifestyle advice to be the standard treatment for people with OAB. Two fifths of men and a third of women believe that medicine is standard treatment

Lifestyle advice (modify liquid intake/bladder/training)

agree it is important to see the same consultant over the course of their treatment7

77%

say they are well informed about their disease9

Medicine

30%

52%

42%

Grandparents/ parents

OAB TREATMENT11

40%

42%

WOMEN

20%

Surgery

Medicine

WOMEN10

30%

50%

95% Lifestyle advice (modify liquid intake/bladder)

WHAT WE FOUND MOST EMBARRASSING AS KIDS

66%

There were very slight regional variations in awareness of OAB with respondents living in the North, South West and East showing the highest levels and those in London and the South East showing the lowest levels.

40%

42%

52%

42%

10% 11%

Nothing, it’s an inevitable part of ageing

10% 11%

83%

Nothing, it’s an inevitable part of

7% 7%

agree that their nurse plays an important role in answering their questions8

62%

feel they are able to influence their treatment choice with their healthcare professional10

References: 1. Abrams P et al. Reviewing the ICS 2002 Terminology Report: The Ongoing Debate. Neurourol Urodyn 2006; 25:293-294 2. Joint Health Surveys Unit (2006) Health Survery for England 2006. Prevalence of diagnosed diabetes by sex and age. The Information Centre: Leeds 3. Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002; 41(Suppl 1):3-6 4. Joint Health Surveys Unit (2008) Health Survey for England 2006. Cardiovascular disease and risk factors. The Information Centre: Leeds 5. Abrams P et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21:167-178 6. ICM Research, Overactive Bladder Research, October 2012

7% 7% References: 1. Astellas Pharma Ltd. Data on File. STAR Number 363714 – January 2012 2. Astellas Pharma Ltd. Data on File. STAR Number 392706 – October 2012 3. Reginster JY. Rheumatology 2002; 41(Suppl 1):3-6. 4. Joint Health Surveys Unit (2008) Health Survey for England 2006. The Information Centre: Leeds. 5. Joint Health Surveys Unit (2006) Health Survery for England 2006. Prevalence of diagnosed diabetes by sex and age. The Information Centre: Leeds 6. Abrams P et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167-178. 7. Abrams P et al. Reviewing the ICS 2002 Terminology Report: The Ongoing Debate. Neurourol Urodyn 2006; 25: 293-294 8. Milsom I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU International 2001; 87(9): 760-766 9. Astellas Pharma Ltd. Data on File. STAR Number 397996 – January 2013 10. Astellas Pharma Ltd, Data on File, VES13037UKa February 2013 11. Astellas Pharma Ltd, Data on File, VES13037UK February 2013

visit bladderproblem.co.uk for further information This is part of an awareness campaign sponsored by Astellas Pharma Ltd. Date of preparation: April 2013 Job number: VES12485UKe(1)

OF THE 141 MEN SURVEYED FROM THE UK: 16%

CLIENT

PROJECT

Astellas Oncology

Print and digital marketing material

had localised prostate cancer – cancer that is only in the prostate gland and has not spread to another part of the body 11,12

WORK TYPE

10%

had metastatic castration-resistant prostate cancer (mCRPC) – cancer that may have become resistant to medical or surgical treatments 11,14

49%

had locally advanced disease – cancer that is high risk of growing or spreading within a few years 11,12

were in remission – when tests, physical exams, and scans show that all signs of your cancer are gone 11,15

had advanced/metastatic prostate cancer – cancer that has spread beyond the prostate (or metastasized) into to the lymph nodes or other parts of the body 11,13

The remaining sample did not know the stage of their disease

• New Business Visualisations 14% • E-Marketing Designs • Website Design • Infographics

14%

Some respondents provided more than one answer about their current diagnosis.

Astellas. Every Voice Matters UK survey results. Data on File - Sample size XTD15232UK 2. Astellas. Every Voice Matters UK survey results. Data on File – What matters most XTD15234UK 3. Astellas. Every Voice Matters UK survey results. Data on File – Quality of life XTD15235UK 4. Astellas. Every Voice Matters UK survey results. Data on File - Plan to fight the cancer XTD15236UK 5. Astellas. Every Voice Matters UK survey results. Data on File - Continue to work as much as possible XTD15237UK 6. Department for Work and Pensions, Older People’s Day: 1 million in work over 65: 3 years since end of default retirement age. Available at: https://www.gov.uk/government/news/older-peoples-day-1-million-in-work-over65-3-years-sinceend-of-default-retirement-age. [Last accessed January 2016] 7. Astellas. Every Voice Matters UK survey results. Data on File - Continuity of care XTD15238UK 8. Astellas. Every Voice Matters UK survey results. Data on File - Importance of nurse XTD15239UK

Date of preparation: February 2016 Job number: XTD15199UK

9. Astellas. Every Voice Matters UK survey results. Data on file - Well informed about the disease XTD15240UK 10. Astellas. Every Voice Matters UK survey results. Data on File - Influence on treatment choice XTD15241UK 11. Astellas. Every Voice Matters UK survey results. Data on File – Stage of PCa XTD15233UK 12. Cancer Research UK, Risk factors in localised prostate cancer. Available at: http://www.cancerresearchuk.org/about-cancer/type/prostate-cancer/treatment/ types/risk-factors-in-localised-prostate-cancer. [Last accessed January 2016] 13. WebMD, Prostate Cancer Health Center. Available at:http://www.webmd.com/ prostate-cancer/tc/prostate-cancer-advanced-ormetastatic-topic-overview. [Last accessed January 2016] 14. Cancer.Net, Treatment of Metastatic Castration-Resistant Prostate Cancer. Available at: http://www.cancer.net/research-and-advocacy/asco-careandtreatment-recommendations-patients/treatment-metastatic-castrationresistantprostate-cancer. [Last accessed January 2016] 15. WebMD, Remission: What does it mean? Available at: http://www.webmd.com/ cancer/remission-what-does-it-mean. [Last accessed January 2016]

eed any sk your

CLIENT

AstraZeneca Continue to use your Duaklir® Genuair® in just a few simple steps:

The colour of your Duaklir® Genuair® inhaler has changed from a white and turquoise cap and dosage button to white with an orange cap and dosage button.

INFORMATION FOR PATIENTS

Your inhaler has changed colour

Remove cap before use

Hold with the orange button facing straight up. DO NOT TILT

PRESS the orange button all the way down

ATTENTION: DO NOT HOLD THE ORANGE BUTTON DOWN WHILE YOU ARE INHALING

GREEN

RELEASE the orange button

The medicine that is taken from the inhaler has not been changed and you should continue to use the inhaler as shown previously by your doctor, nurse or pharmacist.

Ready to use

CORRECT

RED

INCORRECT

Inhaled correctly

Replace cap after use

ADVERTISEMENT FEATURE

Joint Working Project Objective

Step 4: Working with secondary care

• Reduce unwarranted variation and deliver consistent standards of care across the entire pathway for patients with asthma from the CCG’s 18 practices

• Data sharing between the hospital trust and practices was established to allow proactive case management by practices following A&E attendance

Joint Working Project Strategy

• Standardisation of hospital paperwork was agreed and that a discharge summary would be sent by the hospital to a patient’s practice to allow primary care follow up within 7 days

IWork together with NHS Improvement, practices, patients, PCT pharmacists, the Local Prescribing Committee (LPC) and secondary care specialists to create centralised guidance, education and resources that allow practices to autonomously manage their asthma patients in the most effective and efficient manner.

Working Together in Practice Step 1: Consistent patient cohorting

AstraZeneca Joint Working Case Study Improving Asthma Care in Partnership with NHS East Surrey CCG

• AstraZeneca provided a data interrogation tool which defined specific cohorts to help practices group and manage their patients — Four cohorts were identified and profiled - with the largest being patients who were receiving asthma medications but had not received a formal diagnosis – which went on to inform the types of other resources required • Risk stratification was a key outcome, and through three “Plan Do Study Act” cycles, four key cohorts were identified through risk stratification for intervention Step 2: Creating central resources

Executive Summary Following a successful Joint Working project focusing on COPD, NHS East Surrey CCG approached NHS Improvement to participate as an asthma test site for the Lung Improvement Programme. This gave the CCG an opportunity to improve asthma patient care, and reduce unnecessary spending by optimising and standardising the approach taken to the condition’s management across their 18 practices. Through a second Joint Working project with AstraZeneca, and in collaboration with local stakeholders, the CCG was able to develop a fully integrated pathway that focused on every aspect from case finding and accurate diagnosis, chronic disease management, through to acute care. This allowed practices to: • a 21% reduction in COPD hospital bed days • reduce emergency asthma hospital admissions by 21%i, and • increase patient recognition of having a formal self-management plan up to 73%i The success of the project was recognised across the NHS when it was nominated as a finalist at the 2012 National Association of Primary Care (NAPC) Vision Awards.

• From the cohort profiling, the team developed standardised read codes and two types of formal self-management plans – one pictorial and one text-based – for use by practices with patients • Local asthma diagnostic guidelines and a treatment pathway were developed in line with the BTS/SIGN Guideline, in a collaboration between the medicines management team, PCT pharmacists, LPC representatives and patients from each practice Step 3: Engaging and upskilling practices • An asthma education day was held with guest speaker, Professor Martyn Partridge, which was attended by 60 GPs and nurses • Practice specific cohort breakdowns were presented individually to practices alongside the management resources to enable and empower them to put in plan appropriate plans of action • AstraZeneca nurses helped mentor practice nurses on optimal management for different cohorts • PCT pharmacists visited practices to carry out medication reviews and went into care homes to do patient medication reviews • A monthly newsletter was developed by the project team to keep all practices up to date on project progress

AstraZeneca and Joint Working

Situation

Improving patient lives is at the heart of AstraZeneca’s business. In the UK the primary customer for our medicines, and consequent partner in helping us achieving that goal, is the NHS.

Following a highly successful COPD focused Joint Working project that NHS East Surrey CCG and AstraZeneca worked on together, the partnership embraced the opportunity to take on a new challenge to tackle the variation in asthma care across the CCG’s 18 practices.

The ambitions of the NHS are broad and wide ranging, and it faces many challenges in achieving all it wants for people across the UK. As a result, NHS organisations are increasingly calling on external expertise to help them to meet these challenges. This ‘Joint Working’ approach is one that is actively promoted by key industry bodies including the Department of Health and the ABPI (Association of the British Pharmaceutical Industry). AstraZeneca is committed to Joint Working as a means of supporting the NHS to achieve more for patients, and welcomes the opportunity to pool skills, experience and/or resources for the joint development and implementation of patient centred projects and share a commitment to successful delivery.

Key Outcomes Primary successes: • Willing and engaged practices across the CCG, allowing the new tools and guidelines to become the natural way of consulting, and standardised optimal care becoming the norm • BTS step recording went from 4% to 20%

AstraZeneca Joint Working Pulling together for patient care – highlighting the success of Joint Working initiatives

• Compliance recording increased by 7%iv • Recording of inhaler technique increased by 813 patients iv • 454 extra patients had a self-management planiv • Within the identified high risk group, improvement from 24.6% to 73.1% who were aware of having a self-management plani • 58 additional patients were referred for smoking cessationiv ‘Some increase in prescribing costs did occur, but as a consequence of the prevalence of people with asthma increasing through correct diagnosis and treatment, as well as some initial medication wastage due to therapy adjustments.’ Lizzette Howers, Primary Care Pharmacist, NHS Surrey ‘The project has been a real success for the 18 practices across the CCG and has clearly demonstrated that case finding, standardised management and medicines optimisation improves asthma care for patients, joins up the efforts of healthcare professionals working with asthma patients across the healthcare spectrum and has the potential to result in important cost savings for the NHS.’ Dr Elango Vijaykumar Respiratory Lead, East Surrey CCG ‘We have now worked on a number of successful Joint Working projects with AstraZeneca and the outcomes have been extremely valuable to the CCG. More importantly however they have had a real impact for patients and healthcare professionals in the East Surrey community. The amount that we can achieve when we pull together, pooling resources and expertise, is really impressive and proves we can do things better together.’ Dr Joe McGilligan, Chair of East Surrey CCG and Co-Chair Surrey Health and Wellbeing Board

Executive Summary A recent series of Joint Working initiatives across the country has resulted in reductions in hospital admissions, significant cost savings and empowered patients. These outcomes result from a number of Joint Working partnerships between AstraZeneca and NHS organisations around the UK, focused on working together to deliver excellence in patient-centred care. In its drive to fulfil its commitment to improving patients’ lives, and in line with the Department of Health’s definition of Joint Working, AstraZeneca has partnered with the NHS to achieve more for patients by pooling skills, experiences and resources for the joint development and implementation of patient-centred projects. The following examples below highlight the significant benefits of a successful, collaborative approach to patient care.

OneHeart

STAIRS (Stockport Airways Project)

AstraZeneca and the Bristol Heart Institute (BHI) are currently working together to improve treatment adherence in patients with acute coronary syndrome (ACS), by introducing the OneHeart programme – a personalised patient support service that addresses unhelpful beliefs that can lead to a patient’s non-adherence to prescribed medical treatment through a range of tailored interventions.

Stockport CCG, formerly Stockport Managed Care, identified that there was scope for improvement in their area’s management of Chronic Obstructive Pulmonary Disease (COPD). AstraZeneca and Stockport CCG collaborated to develop a steering group (STAIRS) which placed trained respiratory nurses within 12 practices with the highest rates of COPD-related hospital admissions to assess and improve patient identification of those most at risk and review in line with NICE guidance. These skills were then evaluated in all Stockport CCG-based Practice Nurses, and further training was offered.

Anecdotal feedback from the team at BHI suggests that they have already seen some early success in terms of better patient understanding of their illness and proactivity in seeking further information. “Our collaboration with AstraZeneca, through the OneHeart project, has already demonstrated the positive impact of NHS and Industry partnerships for patients.” Dr Tom Johnson, Consultant at Bristol Heart Institute The OneHeart programme will continue until 2016, with the ultimate aim of reducing re-admissions to hospital.

The prevalence of asthma in England is amongst the highest in the world, estimated to affect 3 to 5.4 million people . Between 1,000 -1,200 people a year still die from asthma in England, and it is estimated that 90% of those deaths are attributed to preventable factorsii. Asthma is managed predominately in primary care with patients taking responsibility for lots of the management of their condition themselves outside of the healthcare setting. Despite emergency admission rates being low (84 in 2010/11 ) across the CCG’s patient population, it was recognised that the care patients received from the 18 practices was variable and that this variation could lead to suboptimal patient outcomes and ultimately unnecessary spending.

Caption to film

This targeted activity resulted in: • Between December 2008 – June 2010 there was a 40% reduction in highrisk COPD patients’ hospital admissions (vs. 7% reduction in the remaining Stockport CCG practices)1 • £70,500 cost savings as a result of the reduced hospital admissions, which could result in a total saving of £210,000 if applied across the group2 “I believe Joint Working with the right partner not only brings fantastic benefits to patients and potential cost savings to the NHS, but enhances the day to day working practices of our NHS teams.” Dr Jaweeda Idoo, Clinical Director of Services Transformation, Stockport CCG

To read more about the successes of the Joint Working initiatives that AstraZeneca has successfully implemented in partnership with the NHS, please visit http://www.astrazeneca.co.uk/astrazeneca-in-uk/who-dowe-work-with/working-with-the-nhs. To discuss a potential Joint Working initiative with us, please contact Jack Wood, Head of Field Medical Operations on 01582 836000, or your local AZ Regional Account Manager.

References 1. Pulse Practical Commissioning, Raising the Asthma Care Bar, Dr Vijaykumar, December 2012. 2. Department of Health, An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England, 18 July 2011. Accessed on 14.12.2012 via http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_127974 3. South East Coast Quality Observatory , EsyDoc hospital admissions with asthma as a primary diagnosis (18 + yrs), 2012 4. NHS Improvement – Lung, Improving adult asthma care: Testing the case for change, August 2012

AZ respiratory offerings and partnerships are endorsed by the NAPC

References

12 | Section or brochure name

Section or brochure name | 13

1. Stockport Airways Project Overview, 2012 2. AstraZeneca Data on File (DOF SYM\113\May2012)

Date of Preparation: September 2013 Atlas ID: 2702503

There is also a drive nationally and locally to minimise prescribing costs. The priority areas locally are respiratory and gastro. Dermatology is not a priority area, as the overall spend on dermatology prescribing is relatively low. This is conﬁrmed by the local health economy websites.

BILL

+ +

ALWAYS CONSCIOUS OF TREATMENT COSTS.

BOB I know from Dr Maria and the practice team that many patients with psoriasis are struggling to control their condition. Genalcitrol is usually the ﬁrst line for mild to moderate psoriasis.

POST-CALL ACTIONS AUTHORITY LEVEL This is a fictional scenario and fictional medications. These materials are intended for selling skills training and development purposes only. Proprietary and Confidential AZ document – For internal training use only. © 2018 AstraZeneca All local training/communication should be signed off via the applicable MC process Approval ID: Z4-8464 Date of Preparation: 08/12/2017 Expiry date: 08/12/2019

CLIENT

PROJECT

WORK TYPE

AstraZeneca

Print and digital marketing material

• • •

Editorial Layouts New Business Visualisations Website Design

After that, the patient pathway moves to topical steroids, alone or in combination with genalcitrol. Stronger steroids may be prescribed if needed.

Then patients are frequently referred to the specialists – who may well prescribe vitamin D analogues and steroids, before using systemic treatments and UV therapy. And several patients will require management for co-morbidities such as anxiety or even depression.

CLIENT

Bayer KNOWING WHERE TO GO FOR SUPPORT AND MORE INFORMATION FOR YOURSELF AND YOUR LOVED ONE There are many sources of information, especially on the internet, including chat forums and blogs etc. Additionally there are patient support telephone helplines and groups.* It’s important to make sure that the information you are accessing is reliable and accurate. Healthcare professionals are best placed to provide you with reliable advice and to direct you to reliable sources of information. Patient.info patient.info/health/prostate-cancer-leaflet

Patient Support Groups Many patients and their families and loved ones find attending a support group really helps them. People often imagine support groups to consist of sitting in a circle and one by one telling the group about themselves and their experiences. This isn’t the case. They more commonly involve talks and activities not limited to prostate cancer, besides offering information and disease-management advice from professionals and patients who have had a similar experience. Most importantly, attending a group is a chance to meet other people going through a similar experience. Don’t underestimate the positive impact this face-to-face contact can have.

The Manversation campaign has been developed in consultation with leading prostate cancer charities, Orchid — Fighting Male Cancer and Tackle Prostate Cancer. The campaign has been organised and funded by Bayer.

THINGS TO CONSIDER WHEN A LOVED ONE HAS BEEN GIVEN A DIAGNOSIS OF PROSTATE CANCER

Orchid - Fighting Male Cancer orchid-cancer.org.uk Helpline: 0808 802 0010 Tackle Prostate Cancer tackleprostate.org

The Patient.info website provides comprehensive health information, including information about the diagnosis, assessment and management of prostate cancer.

HELPING YOU HAVE A CONVERSATION ABOUT PROSTATE CANCER

To find your nearest support group, speak to your healthcare team who will be able to advise you. You can also access information via patient organisations.

Support group location finder: tackleprostate.org/find-asupport-group-near-you.php Helpline: 0800 035 5302 Manversation manversation.co.uk

When you find out that a loved one has prostate cancer it can be as scary for you as it is for him. You are likely to have a lot of questions and to want to try to support your loved one as best you can. Through this journey there are likely to be times when you need to have difficult conversations, from speaking to your loved one to speaking to the doctors and nurses and telling other family members and friends.

The Manversation website provides more information including a similar guide for your loved one with prostate cancer. The Manversation campaign has been developed in consultation with leading prostate cancer charities Orchid - Fighting Male Cancer and Tackle Prostate Cancer. The campaign has been organised and funded by Bayer.

* Bayer does not take responsibility for the content of materials provided from the listed organisations.

More than a third of diabetic patients will develop some level of macular oedema1

Follow our live updates on

7th March 2019 #OphthHonours

1. Macular Society. Your guide to diabetic macular oedema. Available at: https://www. macularsociety.org/sites/default/files/resource/Accessible%20MS025%20DMO%20 FEB17pdf .pdf (Last accessed: October 2020)

October 2020 | XXXXXXXXXXX

Sponsored by

Prostate Cancer In the UK, prostate cancer is the most common cancer in men and the 2nd most common cause of cancer-related death in men1

48k+

men in the UK are diagnosed with prostate cancer every year, on average.1 Despite having hormone therapy, a proportion of these patients will have disease progression to castration-resistant prostate cancer (CRPC)2

About

There are several unmet needs that need to be addressed4,5

of men with non-metastatic castration-resistant prostate cancer (nmCRPC) go on to develop metastases within two years2

Unmet Need In Prostate Cancer Prostate cancer treatments have advanced in recent years, but unmet needs persist4,5

of men upon their diagnosis of prostate cancer present with cancer that has spread from the original (primary) tumour3

Overall Survival

It is vital for patients across all stages of prostate cancer to have treatment options that may help to improve their overall survival6

Role of Side Effects Delay Progression

Ophthalmology Honours

EYLEA® (aflibercept) now available in pre-filled syringe

2018/19 The Uveitis Service Building a holistic personalised service for patients with sightthreatening inflammation University Hospitals Birmingham NHS Foundation Trust

Treatments for prostate cancer may have challenging side effects which can impact quality of life8

Progression to metastasis increases the risk of mortality and morbidity, reduces quality of life and increases healthcare costs7

Honouree Best Ophthalmology Team

Prostate Cancer References 1. Cancer Research UK. Prostate Cancer Statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer? Accessed October 2020. 2. Kirby M. et al. Characterising the castration-resistant prostate cancer population:a systematic review. Int J Clin Pract. 2011;65(11):1180-1192. doi:10.1111/j.1742-1241.2011.02799. 3. Terris M. Metastatic and Advanced Prostate Cancer: Overview, Epidemiology of Advanced Prostate Cancer, Presentation of Advanced Prostate Cancer. Medscape. https://emedicine.medscape.com/article/454114-overview. Published 2018. Accessed October 2020. 4. Hussain, M., Fizazi, K., Saad, F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–2474. 5. Smith, M.R., Saad, F., Chowdhury, S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–1418. 6. Fizazi K, Shore N, Tammela T, et al. Darolutamide In Nonmetastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(7). 7. Hong J, Kim IY et al. Nonmetastatic Castration-Resistant Prostate Cancer. Korean J Urol. 2014;55(3):153. doi:10.4111/kju.2014.55.3.153. 8. Tannock et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004;351:1502-12. doi:10.1056/NEJMoa040720. © 2020 Bayer plc. All rights reserved. BAYER and the Bayer Cross are registered trademarks of Bayer.

Ophthalmology Honours is an educational initiative fully funded by Bayer. The judging process is carried out by a panel of independent judges and is wholly independent of Bayer.

The recently launched EYLEA® (aflibercept) pre-filled syringe (PFS) is now available in the UK across all NHS Trusts, providing an alternative method of intravitrial injection for physicians.

Bayer is working closely with centres to provide support where possible, including investigating innovative solutions such as the community-based macular service established in Manchester.3

The EYLEA PFS requires fewer steps to prepare than the standard glass vial, giving physicians a choice of option that works best for them, their patients and the efficiency of their clinic.

Over 1.5 million people in the UK have macular disease, over a third of these have wet AMD with nearly 40,000 new cases arising every year.4,5

ABOUT EYLEA Tight binding affinity EYLEA has a higher binding affinity for VEGF-A than native receptors, ranibizumab or bevacizumab, in vitro6†

EYLEA is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).1

DURABLE

Multi-target MOA EYLEA is the only anti-angiogenic agent licensed for intraocular use that binds to VEGF-B, PiGF and galectin-1,‡ in addition to all known VEGF-A isoforms1,6,8-11

PATIENT CARE DURING THE COVID-19 CRISIS The Royal College of Ophthalmologists’ guidance of 30 March provides a pragmatic approach to care during the COVID-19 pandemic. The guidance outlines maintenance of care for those who need it, while deferring care for those patients who can wait.2

EYLEA has an established safety profile,1 with over 30 million doses administered worldwide since launch12

Deferral of existing patient clinical review for 4 months (with exceptions) has been advised for patients with DMO, branch RVO or central RVO.2

GLOSSARY: Fc: Fragment crystallisable IgG1: Immunoglobulin G1 MOA: Mode of action PiGF: Placental growth factor VEGF-A: Vascular endothelial growth factor A VEGF-B: Vascular endothelial growth factor B

All patients already under hospital review for wet AMD should maintain an 8-weekly dosing regimen of anti-VEGF therapy with no clinical review unless they mention a significant drop in vision at their injection visit.2 EYLEA offers the option to treat wet AMD patients proactively with either a fixed 8-weekly dosing regimen, or a treat-and-extend regimen with up to 16-week intervals.1

PP-EYL-GB-0596 | May 2020

Durable EYLEA includes the Fc portion of a human IgG1 antibody, which provides stability and durable anti-VEGF activity7-9

Prescribing information can be found on the next page † Bevacizumab is not licensed for intraocular use6 Data obtained in vitro6

‡

Eylea® 40 mg/ml solution for injection in a vial & Eylea® 40 mg/ml solution for injection in pre-filled syringe (aflibercept) Prescribing Information (Refer to full Summary of Product Characteristics (SmPC) before prescribing) Presentation: 1 ml solution for injection contains 40 mg aflibercept. Vial: Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. Pre-filled syringe (PFS): Each PFS contains 90 microlitres, equivalent to 3.6 mg aflibercept. Indication(s): Treatment of neovascular (wet) age- related macular degeneration (wAMD), macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) in adults and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Posology & method of administration: For intravitreal injection only. Must be administered according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. Each vial or PFS should only be used for the treatment of a single eye. Extraction of multiple doses from a single vial or PFS may increase the risk of contamination and subsequent infection. The vial or PFS contains more than the recommended dose of 2 mg. The extractable volume of the vial (100 microlitres) or PFS (90 microlitres) is not to be used in total. The excess volume should be expelled before injecting. Refer to SmPC for full details. Adults: The recommended dose is 2 mg aflibercept, equivalent to 50 microlitres. For wAMD treatment is initiated with 1 injection per month for 3 consecutive doses. The treatment interval is then extended to 2 months. Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at 2 months or further extended using a treat-andextend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly to a minimum of 2 months during the first 12 months of treatment. There is no requirement for monitoring between injections. Based on the physician’s judgement the schedule of monitoring visits may be more frequent than the injection visits. Treatment intervals greater than 4 months between injections have not been studied. For RVO (branch RVO or central RVO), after the initial injection, treatment is given monthly at intervals not shorter than 1 month. Discontinue if visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment. Treat monthly until maximum visual acuity and/or no signs of disease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-andextend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes, however there are insufficient data to conclude on the length of these intervals. Shorten treatment intervals if visual and/or anatomic outcomes deteriorate. The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response. For DMO, initiate treatment with 1 injection/month for 5 consecutive doses, followed by 1 injection every 2 months. No requirement for monitoring between injections. After the first 12 months of treatment, and based on visual and/or anatomic outcomes, the treatment interval may be extended such as with a treat-and-extend dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however there are insufficient data to conclude on the length of these intervals. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The schedule for monitoring should therefore be determined by the treating physician and may be more frequent than the schedule of injections. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, treatment should be discontinued. For myopic CNV, a single injection is to be administered. Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. The schedule for monitoring should be determined by the treating physician. The interval between 2 doses should not be shorter than 1 month. Hepatic and/or renal impairment: No specific studies have been conducted. Available data do not suggest a need for a dose adjustment. Elderly population: No special considerations are needed. Limited experience in those with DMO over 75 years old. Paediatric population: No data available. Contraindications: Hypersensitivity to active substance or any excipient; active or suspected ocular or periocular infection; active severe intraocular inflammation. Warnings & precautions: As with other intravitreal therapies endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract have been reported. Aseptic injection technique is essential. Patients should be monitored during the week following the injection to permit early treatment if an infection occurs. Patients must report any symptoms of endophthalmitis or any of the above mentioned events without delay. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection; special precaution is needed in patients with poorly controlled glaucoma (do not inject while the intraocular pressure is ≥30 mmHg). Immediately after injection, monitor intraocular pressure and perfusion of optic nerve head and manage appropriately. There is a potential for immunogenicity as with other therapeutic proteins; patients should report any signs or symptoms of intraocular inflammation e.g pain, photophobia or redness, which may be a clinical sign of hypersensitivity. Systemic adverse

PP-EYL-GB-0596 | May 2020

PP-PF-OPHT-GB-0009-1 | January 2019

PROJECT

WORK TYPE

Bayer

Manversation - BOH marketing materials

• Editorial Layouts • Social Media Content • Gifs • E-Marketing Designs

Eylea® is a trademark of the Bayer Group Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel.: 0118 2063500, Fax.: 0118 2063703, Email: pvuk@bayer.com © Bayer plc. ® Registered trademark of BAYER AG, Germany.

1. Bayer 2019. Eylea 40mg/ml solution for injection SmPC. Available at https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf. Accessed May 2020 2. RCOphth 2020. Medical Retinal Management Plans during COVID-19. Available at https://www.rcophth.ac.uk/wp-content/uploads/2020/03/Medical-Retinal-Management-Plan-during-COVID-19-UPDATED-300320-1-3. pdf. Accessed May 2020 3. Bayer 2018. New services launched in Manchester bring vital eye care to the high street. Available at https://www.bayer.co.uk/en/media/latest-news/new-services-launched-inmanchester-bring-vital-eye-care-to-the-high-street.php. Accessed May 2020 4. Macular Society 2018. Nearly 1.5m people in the UK are affected by macular disease. Available at https://www.macularsociety. org/news/nearly-15m-people-uk-are-affected-macular-disease. Accessed May 2020 5. NICE 2018. Age-related macular degeneration. Available from https://www.nice.org.uk/guidance/ng82/chapter/ Context. Accessed May 2020 6. Papadopoulos N, et al Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-185 7. Regeneron Pharmaceuticals Inc Traps. Available at https://www.regeneron.com/technology. Accessed May 2020 8. EMA. EYLEA EPAR assessment report 2012. Available at https:// www.ema.europa.eu/en/documents/assessment-report/eylea-epar-public-assessment-report_en.pdf. Accessed May 2020 9. Rudge JS, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007;104:18363-18370 10. Kanda A, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep 2015;5:17946 11. Amadio M, et al. Targeting VEGF in eye neovascularization: What’s new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res 2016;103:253-269 12. Data on file 2019. Ref EYLO010_30 million vials of EYLEA sold worldwide

PP-UN-ONC-GB-0043 | October 2020

CLIENT

events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. Safety and efficacy of concurrent use in both eyes have not been systemically studied. No data is available on concomitant use of Eylea with other anti-VEGF medicinal products (systemic or ocular). Caution in patients with risk factors for development of retinal pigment epithelial tears including large and/or high pigment epithelial retinal detachment. Withhold treatment in patients with: rhegmatogenous retinal detachment or stage 3 or 4 macular holes; with retinal break and do not resume treatment until the break is adequately repaired. Withhold treatment and do not resume before next scheduled treatment if there is: decrease in best-corrected visual acuity of ≥30 letters compared with the last assessment; central foveal subretinal haemorrhage, or haemorrhage ≥50%, of total lesion area. Do not treat in the 28 days prior to or following performed or planned intraocular surgery. Eylea should not be used in pregnancy unless the potential benefit outweighs the potential risk to the foetus. Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection. In patients presenting with clinical signs of irreversible ischaemic visual function loss, aflibercept treatment is not recommended. Populations with limited data: There is limited experience in DMO due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy. Eylea has not been studied in patients with active systemic infections, concurrent eye conditions such as retinal detachment or macular hole, or in diabetic patients with uncontrolled hypertension. This lack of information should be considered when treating such patients. In myopic CNV there is no experience with Eylea in the treatment of non-Asian patients, patients who have previously undergone treatment for myopic CNV, and patients with extrafoveal lesions. Interactions: No available data. Fertility, pregnancy & lactation: Not recommended during pregnancy unless potential benefit outweighs potential risk to the foetus. No data available in pregnant women. Studies in animals have shown embryo- foetal toxicity. Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last injection. Not recommended during breastfeeding. Excretion in human milk: unknown. Male and female fertility impairment seen in animal studies with high systemic exposure not expected after ocular administration with very low systemic exposure. Effects on ability to drive and use machines: Possible temporary visual disturbances. Patients should not drive or use machines if vision inadequate. Undesirable effects: Very common: Visual acuity reduced, conjunctival haemorrhage (wAMD phase III studies: increased incidence in patients receiving anti-thrombotic agents), eye pain. Common: retinal pigment epithelial tear (known to be associated with wAMD; observed in wAMD studies only), detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract (nuclear or subcapsular), corneal abrasion or erosion, increased intraocular pressure, blurred vision, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, increased lacrimation, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival or ocular hyperaemia. Serious: cf. CI/W&P - in addition: blindness, culture positive and culture negative endophthalmitis, cataract traumatic, transient increased intraocular pressure, vitreous detachment, retinal detachment or tear, hypersensitivity (during the post-marketing period, reports of hypersensitivity included rash, pruritus, urticaria, and isolated cases of severe anaphylactic/anaphylactoid reactions), vitreous haemorrhage, cortical cataract, lenticular opacities, corneal epithelium defect/erosion, vitritis, uveitis, iritis, iridocyclitis, anterior chamber flare, arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. As with all therapeutic proteins, there is a potential for immunogenicity. Consult the SmPC in relation to other side effects. Overdose: Monitor intraocular pressure and treat if required. Incompatibilities: Do not mix with other medicinal products. Special Precautions for Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Unopened vials and unopened syringe blisters may be stored at room temperature (below 25°C) for up to 24 hours before use. Legal Category: POM. Package Quantities & Basic NHS Costs: Single vial or PFS pack: £816.00 MA Number(s): EU/1/12/797/001-002. Further information available from: Bayer plc, 400 South Oak Way, Reading RG2 6AD, United Kingdom. Telephone: 0118 206 3000. Date of preparation: April 2020.

• PowerPoint Presentations • Website Design • Infographics

CHOLESTEROL AWARENESS 29% of over 45s

Almost 45% of over 45s have no idea what their cholesterol level is

CLIENT

Benecol

have never had a cholesterol test,

25%

8% said they weren’t currently doing anything about their cholesterol level

WHO IS YOUR PLUS-ONE

DID YOU KNOW…? A daily intake of 1.5 –2.4g plant stanols is proven to lower LDL cholesterol by 7 – 10% in 2 to 3 weeks

19%

34% of women

said they were more worried about their partner’s cholesterol than their own

Cholesterol affects 3 out of 5 adults in the UK1

72%

In contrast,

of men

only 19%

said they were more worried about their partner’s cholesterol than their own

FOODS AND ACTIVITIES THAT HELP TO REDUCE CHOLESTEROL

But in fact,

raised cholesterol affects

men and women over 45 equally2

One in four of those aged 45 and over already take between 3 and 6 prescription meds every day

Eating cholesterol lowering functional foods that contain plant stanols or plant sterols is clinically proven to lower LDL cholesterol

HEALTH AND WELLBEING

2nd

of people over 45 years old say maintaining their heart health is “extremely important” to them

39% 39

Heart disease ranks second among this groups health concerns

Eating more fruits and vegetables 72% say they would prefer to lower their cholesterol through diet and exercise alone

72%

are worried about cholesterol which is a major risk factor in the development of heart disease

But 25% of people are unaware that (functional) foods and drinks containing Plant Stanols are proven to lower cholesterol

Reducing dairy products Reducing red meats Eating more wholegrains & oats

25%

Eating more ﬁsh Eating more soya

CHOLESTEROL AWARENESS Almost 45% of over 45s have no idea what their cholesterol level is

Exercise

29% of over 45s

have never had a cholesterol test,

* Based on research undertaken by Redshift Research on behalf of Benecol amongst

DID YOU KNOW…?

2000 people over 45 in the UK

A daily intake of 1.5 –2.4g plant stanols is proven to lower LDL cholesterol by 7 – 10% in 2 to 3 weeks

rising to 40% in the 45 to 54 year old population

But 25% of people are unaware that (functional) foods and drinks containing Plant Stanols are proven to lower cholesterol

rising to 40% in the 45 to 54 year old population

45%

Cholesterol By Numbers*

72% say they would prefer to lower their cholesterol through diet and exercise alone

May 2014

8% said they weren’t currently doing anything about their cholesterol level

AIM YOUR PLUS-ONE WHO IS Collect 5 different fruit foam

% 34 5 A DAY

FOODS AND ACTIVITIES THAT HELP TO REDUCE CHOLESTEROL

Eating cholesterol lowering functional foods that contain plant stanols or plant sterols is clinically proven to lower LDL cholesterol

pieces along the assault course. Once all 5 pieces are collected they get to throw them into a giant cup with the message ‘one % of your 5 a day’. Each piece of fruit will have a fact about it.

of women said they

In contrast,

of men

were more worried about their partner’s cholesterol than their own

only 19%

said they were more worried about their partner’s cholesterol than their own

ORANGES Oranges contain vitamin C and folate. I'll look after your immune system and help reduce tiredness

Eating more fruits and vegetables But in fact,

Reducing dairy products

raised cholesterol affects

men and women over 45 equally2

Reducing red meats

BANANAS I'm a good source of potassium for normal blood pressure, muscle function and the nervous system One in four of those aged 45 and over

Eating more wholegrains & oats

already take between 3 and 6 prescription meds every day

Eating more ﬁsh Eating more soya

72% say they would prefer to lower their cholesterol through diet and exercise alone

72%

But 25% of people are unaware that (functional) foods and drinks containing Plant Stanols are proven to lower cholesterol PINEAPPLE I'm a good source of vitamin C, which helps % immune system your

RASPBERRY

Exercise I'm a source of

manganese which helps keep bones APPLE Based on research undertaken healthyby Redshift Research on behalf of Benecol amongst I'm a *good source 2000 people over 45 in the UK of vitamin C to A DAY support your immune system References:

1. Heart UK, ‘Cholesterol – The Silent Killer http://heartuk.org.uk/files/uploads/documents/HUK_memberapplicationform.pdf (Accessed 25th February 2014) 2. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M, Leal J, Luengo-Fernandez R, Rayner M (2012). Coronary heart disease statistics 2012 edition. British Heart Foundation: London.

May 2014

CLIENT Benecol

DID YOU KNOW…? PROJECT A daily intake ofMarketing 1.5 –2.4gmaterial plant stanols is proven to lower LDL cholesterol by 7 – 10% in 2 to 3 weeks

FOODS AND ACTIVITIES THAT HELP TO REDUCE CHOLESTEROL

WORK TYPE

• Editorial Layouts • Social Media Content • New Business Visualisations • Infographics

SHOOT THE FRUIT Once all the fruit pieces are collected the participants can then throw into the fruit bin.

CLIENT

Gilead Everyone with hepatitis C is entitled to receiving care. Hep C is treatable and curable in the majority of patients.

Ambassador Newsletter ISSUE 1 | OCTOBER 2017

Hep C affects thousands of people in the UK. You might be among those living with the day-to-day reality of being infected with a virus that can cause permanent damage to the liver, and potential health problems in other parts of the body.

It is important to remember that hep C is a virus; it is not something that defines you as a person. You’re worth the best care and treatment. The longer you have lived with hep C, the more likely it is that your liver may be damaged and your health in the long-term could be affected. If you have hep C, don’t ignore it; speak to your doctor to find out what treatment and care options are right for you.

• Presentations by I’m Worth… ambassadors Louise and Brian at meetings in Wales and to support World Hepatitis Day in July • The addition of new ambassadors to support the campaign and further its reach across the UK • A survey in Drink and Drug News to identify community needs through those working in addiction services

Visit

Information for people living with hep C

World Hepatitis Day 2017 Thank you for your continued support to the I’m Worth… campaign! It’s been an exciting few months for the campaign; some highlights include:

www.imworth.co.uk

In this first edition of your campaign newsletter, you can read more about the recent campaign activities and find out how you can get more involved in the coming months!

for more information, useful resources and to hear about others experiences

We know a number of you were able to attend the Hepatitis C Trust’s patient conference in London on World Hepatitis Day (28th July) and were able to hear from advocates and community members from around the world affected by hepatitis C. We spoke to Brian, who said;

“This day is an opportunity to reduce the stigma by educating people. It’s still a relatively unknown disease to many people, even those that are most at risks from it” You can read more about Brian’s experience during World Hepatitis Day on the I’m Worth… website here: www.imworth.co.uk/ world-hepatitis-daymatters-view-imworth-ambassadorbrian

Did you or your community do anything to mark World Hepatitis Day? If so, we’d love to hear about your experience and what World Hepatitis Day means to you.

Stock imagery, posed by models July 2017 | HCV/UK/16-04/CI/1422b

July 2017 | HCV/UK/16-04/CI/1422b

By 2030 Approximately 3 in 4 people with HIV in Europe will be over 501 HIV

THE

LONG VIEW

Developed and funded by

References: 1. Vance DE et al. Predictions of geriatric HIV in 2030. Lancet Infect Dis. 2015;15(7):753–754 2. Guaraldi G et al. Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles. PLoS One. 2015;10(4):e0118531 UNBC4086 | December 2016

CLIENT

PROJECT

WORK TYPE

Gilead

‘I’m Worth’ marketing material

• Editorial Layouts • Social Media Content • Gifs • E-Marketing Designs

• PowerPoint Presentations • Website Design • Infographics

October 2017 | HCV/UK/17-04/NM/1558j

CLIENT

ViiV Healthcare Kivexa®: Confidence from the start

Kivexa: Confidence from the start A trusted foundation: Well-known tolerability and efficacy profile

A trusted foundation: Well-known tolerability and efficacy profile

Simplicity: A single HLA-B*5701 test and low additional product-specific monitoring

Simplicity and flexibility: · A single HLA-B*5701 test

Flexibility: Once-a-day dosing, with or without food, and few drug-drug interactions

· Low additional productspecific monitoring · Once-a-day dosing with or without food · Few drug interactions · Suitable for use with a variety of 3rd agents

In treatment-naïve patients

RAPID RESPONSE AND STATISTICALLY SUPERIOR EFFICACY VS DRV/r UP TO 96 WEEKS1,2*

EFFECTIVE REGARDLESS OF BASELINE VIRAL LOAD1,2

FLAMINGO—Proportion of treatment-naïve patients with HIV-1 RNA <50 copies/mL up to 96 weeks (N=484)1,2

FLAMINGO—Proportion of treatment-naïve patients with HIV-1 RNA <50 copies/mL at 48 and 96 weeks in high viral load subgroup (n=122)1,2

Proportion (%) of patients HIV-1 RNA <50 copies/mL

New 96-week data from the

FLAMINGO Study

TIVICAY IS SUPERIOR TO DRV/r UP TO 96 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HIV1,2

83%

70 60

68%

50 40 30 20

P =0.025

Presented at the HIV Drug Therapy Glasgow Meeting 2-6 November 2014

80%

Week

12 16

P =0.002 60

Darunavir/r 800 mg/100 mg QD + 2 NRTIs (n=242)

on therapy.

Adapted from Clotet et al, 2014.1,2

Statistically superior virological response at 48 and 96 weeks

1,2

More rapid virological response with TIVICAY vs DRV/r—87% vs 31%, respectively, at Week 82 Virological response was higher for TIVICAY vs DRV/r, regardless of NRTI backbone1

Group of Companies nc code: UK/DLG/0055/13(4)

A HIGH BARRIER TO RESISTANCE UP TO 96 WEEKS1,2

ng forms and information and, adverse events should vigilance Section, Health n 2, Tel: +353 1 676 4971, ported to GlaxoSmithKline 5 in Ireland.

0% treatment-emergent resistance in either arm

93%

82%

70%

80 70

52%

60 50 40 30 20 10 57/61

Weeks 48 and 96 snapshot analyses.

TIVICAY 50 mg QD + 2 NRTIs (n=242)

100

Proportion (%) of patients HIV-1 RNA <50 copies/mL

90%

100

43/61

50/61

Week 482 Baseline viral load

32/61

Week 961 >100,000 copies/mL

TIVICAY 50 mg QD + 2 NRTIs

Darunavir/r 800 mg/100 mg QD + 2 NRTIs Adapted from Clotet et al, 2014.1,2

In patients with baseline viral load >100,000 copies/mL, greater virological response at Weeks 48 and 96 with TIVICAY vs DRV/r1,2

GENERALLY WELL TOLERATED UP TO 96 WEEKS1,2 Diarrhoea was more common in patients receiving DRV/r (24% vs 10%) Significantly fewer patients receiving TIVICAY had ≥Grade 2 fasting LDL values vs DRV/r (3% vs 10%; P<0.001)

*From an open-label, multicentre study comparing TIVICAY 50 mg once daily plus abacavir/lamivudine or tenofovir/emtricitabine or DRV/r 800 mg/100 mg once daily plus abacavir/lamivudine or tenofovir/emtricitabine.2

HIV Drug Therapy Glasgow et al. Lancet. 2014;383:2222cteristics.

er 2014. VIIV/DLG/0116/14a

f ficacy

Prescribing Information can be found on the back cover.

Beyond Ef ficacy

Prescribing Information can be found on the back cover.

CLIENT

PROJECT

WORK TYPE

Kivexa Tivicay

Isell detail aid and marketing materials

• • •

Editorial Layouts New Business Visualisations PowerPoint Presentations

Beyond Ef ficacy

CLIENT

ViiV Healthcare 17.10.2013

17.10.2013

Square Brussels | Gold Hall | Thursday 17th October 2013 | 18.15-19.45

Square Brussels | Gold Hall | Thursday 17th October 2013 | 18.15-19.45 Take part in a different kind of symposium chaired by Professor Brian Gazzard Join experts in HIV and patient centred care to investigate the development of an HIV decision-aid in real time.

Just another

HIV

THINK

AGAIN

symposium?

AGENDA Prof. Brian Gazzard , UK

Beyond the evidence base My HIV. My Life. A personal perspective

Video

The importance of being involved

Sandra Van den Eynde, Belgium

Are we prepared to manage HIV as a chronic condition?

Prof. Andrew Miles, UK

Collaborative care in action: creating a decision aid in real time

Panel discussion facilitated by Prof. Andrew Miles

Meeting summary and close

Prof. Brian Gazzard, UK

Panel members: Prof. Brian Gazzard, UK Sandra Van den Eynde, Belgium Prof. Jürgen Rockstroh, Germany Prof. Gilles Pialoux, France

THINK AGAIN

Just another HIV symposium?

Take part in a different kind of symposium chaired by Professor Brian Gazzard Join experts in HIV and patient centred care to investigate the development of an HIV decision-aid in real time.

Speakers and panelists: Professor Brian Gazzard, Sandra Van den Eynde, Professor Andrew Miles Professor Gilles Pialoux Professor Jürgen Rockstroh

AGENDA

Just another HIV symposium?

Beyond the evidence base

Prof. Brian Gazzard , UK

My HIV. My Life. A personal perspective

Video

The importance of being involved

Sandra Van den Eynde, Belgium

Are we prepared to manage HIV as a chronic condition?

Prof. Andrew Miles, UK

Collaborative care in action: creating a decision aid in real time

Panel discussion facilitated by Prof. Andrew Miles

Meeting summary and close

Prof. Brian Gazzard, UK

Panel members: Prof. Brian Gazzard, UK Sandra Van den Eynde, Belgium Prof. Jürgen Rockstroh, Germany Prof. Gilles Pialoux, France

THINK AGAIN A Satellite Symposium organised and funded by ViiV Healthcare ©2013 ViiV Healthcare group of companies All rights reserved. Date of preparation: September 2013. Job Code: BE/HIV/0025/13 Not for distribution

Lectern Panel

17.10.2013

703mm

Lectern Panel with Screen

450mm

Square Brussels | Gold Hall | Thursday 17th October 2013 | 18.15-19.45

1920 pixels

Just another HIV symposium?

THINK AGAIN Take part in a different kind of symposium chaired by Professor Brian Gazzard Join experts in HIV and patient centred care to investigate the development of an HIV decision-aid in real time.

Just another HIV symposium?

THINK AGAIN

1163mm

1080 pixels

1100mm

Speakers and panelists: Professor Brian Gazzard, Sandra Van den Eynde, Professor Andrew Miles Professor Gilles Pialoux Professor Jürgen Rockstroh

FRONT VIEW

Not for distribution

SIDE VIEW

FRONT VIEW

Not for distribution

Just another HIV symposium?

Not for distribution

CLIENT

PROJECT

WORK TYPE

ViiV Healthcare

HIV Symposium

• Conference Materials • Editorial Layouts • PowerPoint Presentations

CLIENT

ViiV Healthcare

AGENDA

M E N U

Wednesday 24th October AUDIENCE All All

Crossfunctional group split Crossgroup split

LIGHTHOUSE MEETING:

DOLUTEGRAVIR LOC ACTIVATION MEETING DATES:

Monday 22nd (Evening), 2012 Tuesday 23rd, 2012 Wednesday 24th October, 2012

VENUE:

Millbank Tower, 21-24 Millbank Westminster, London, SWIP 4QP

All

TIME

SESSION OUTLINE

PRESENTER(S)/ FACILITATOR LEAD(S)

AUDIENCE

08.30 – 08.45

Opening speech – Day Two

Michael Grant Gregory Reinaud

All

08.45 – 09.15

Tactical Launch Plan Plenary

Tom Williams Jon Greggs Nathalie Dang

All

09.15 – 12.15

Tactical Launch Plans Interactive Workshop Session

Katie Lipscombe & team CrossCross-functional facilitators functional group split

12.15 – 12.45

Working Lunch Break

12.45 – 13.30 functional

Lighthouse Identity

13.30 – 14.00

Building a Local DTG Launch Plan – Launch Excellence Framework and Key Deliverables Plenary

Saskia Fontein

Observation Deck 3 Workshop

Crossgroup split

Ulrike Mucha Jason Coull Sara LeClerc Dustin Haines

STARTER Beetroot-marinated and grilled Claire Island organic salmon hand-picked white crab, crunchy shaved fennel, white anchovies and dill salad

LIGHTHOUSE MEETING:

DOLUTEGRAVIR LOC ACTIVATION MEETING

Question for the team?

MAIN

Dry-aged fillet of Cumbrian beef with wild mushroom crust, roasted winter vegetables and fondant potato

DATES:

All VENUE:

Monday 22nd (Evening), 2012 Tuesday 23rd, 2012 DESSERT Wednesday 24th October, 2012 Trio of vanilla seed creme brulee Millbank Tower, 21-24 Millbank single origin chocolate and Westminster, London, SWIP 4QP

To:

Question:

zesty lemon curd tart

Vegetarian option available on request

AGENDA

Monday 22nd October

TIME

SESSION OUTLINE

PRESENTER(S)/ FACILITATOR LEAD(S)

AUDIENCE

TIME

SESSION OUTLINE

PRESENTER(S)/ FACILITATOR LEAD(S)

AUDIENCE

19.00 – 21.30

Welcome Reception Welcome Speech with hot buffet at Millbank Tower

Tom Laughery Jonathan Anderson

All

19.00 – 21.30

Welcome Reception Welcome Speech with hot buffet at Millbank Tower

Tom Laughery Jonathan Anderson

All

LIGHTHOUSE MEETING :

DOLUTEGRAVIR LOC ACTIVATION

DIRECTIONS

Millbank Tower 21 - 24 Millbank London, SW1P 4QP

Double Tree Hotel

22 - 24 October 2012 | Millbank Tower | London

From:

Maurizio Amato ITALY

From Double Tree Hotel Double Tree Hilton Hotel Westminster, London, SW1P 4DD Approximately 4 minutes by foot Directions on Foot Turn right on John Islip St towards Page St Turn right onto Page Street Turn right onto Thorney Street Turn right onto Millbank Slight right to stay on Millbank Destination on the right Millbank Tower

CLIENT

PROJECT

WORK TYPE

ViiV Healthcare

Dolutegravir Symposium

• Conference Materials • PowerPoint Presentations

CLIENT

LEO Pharma LEO Pharma UK/IE presents

LEO Pharma UK/IE presents

D E R M ATA L K

DERM CONNEXT 27th November 2020

Inaugural Virtual Event.

INAUGURAL VIRTUAL EVENT

VIEW DETAILS

27th November 2020 Agenda and Speakers

— we help people achieve healthy skin

DERM CONNEXT

NEWS

OCTOBER 2020 | SUBJECT: MOSAIC NEWS

Session Agenda

Dear all, We wanted to take this opportunity to thank you for attending the 2020 MOSAIC virtual launch event. The 2-day meeting was a milestone for the MOSAIC project, which we hope you found both enjoyable and enlightening.

We are keen to collate as many thoughts and feedback on MOSAIC as possible so we can use this to shape the program moving forward. If you haven’t done so already, please click on the below link to complete the evaluation form. Thank you in advance for your honest response:

people to look under the skin of psoriasis to see the seriousness treatment options and improved access to care for the 125 million people who are living with the condition today.

treatment options and improved access to care for the 125 million people who are living with the condition today.

Often regarded as ‘just a skin condition’; psoriasis is in fact a serious, lifelong disease that carries with it a number of potentially life-limiting comorbidities. ‘I’m more than my skin’ aims to increase understanding of psoriatic disease and its comorbidities.

a serious, lifelong disease that carries with it a number of

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

potentially life-limiting comorbidities. ‘I’m more than my skin’ aims to increase understanding of psoriatic disease and its comorbidities.

Copy 3

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Evaluation form

‘I’m More Than My Skin’, an awareness campaign. By asking of the disease, the campaign aims to advocate for better

Often regarded as ‘just a skin condition’; psoriasis is in fact

Copy 2

World Psoriasis Day 2018 sees the launch of LEO Pharma’s

‘I’m More Than My Skin’, an awareness campaign. By asking of the disease, the campaign aims to advocate for better

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

I’m more than my skin

World Psoriasis Day 2018 sees the launch of LEO Pharma’s people to look under the skin of psoriasis to see the seriousness

Copy 1

Feedback

I’m more than my skin

For more information about the campaign, visit

www.immorethanmyskin.com

For more information about the campaign, visit

www.immorethanmyskin.com

Copy 4

https://mosaic2020.com/attendee/#ss--MGNaYbe00KgXdmp5acy

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Meeting summary From tackling the clinical challenges associated with psoriasis to getting your first real look at the MOSAIC app we hope you found the virtual launch training valuable and thought-provoking.

Models are for illustrative purposes only.

Thank you for engaging in such fruitful, constructive and open exchanges throughout the presentations and workshops. Special thanks to the steering committee presenters Professor Peter van de Kerkhof, Dr Anna López-Ferrer and Dr Athanasios Tsianakas for their role in delivering high quality educational content and invaluable insights into the value of MOSAIC.

Let’s keep in touch — MOSAIC teams channel We have taken the opportunity to create a MOSAIC teams channel to keep in touch and share thoughts as we lead up to the official MOSAIC app rollout in 2021. Please do join the group to keep the conversation going; you will have received a link from Kasper Vadstrup. We encourage you to reach out with any feedback or questions in relation to MOSAIC. We hope the virtual MOSAIC launch event has left you feeling energized and excited for introducing MOSAIC into your HCP engagements and benefiting from more insightful interactions.

What’s coming next? From now until the launch we will be providing you with lots of different resources to help utilize MOSAIC once available, including: • Virtual Coffee and Connect sessions • e-learning modules • Case study and MOSAIC handbooks

More information will follow but do keep a lookout in our newsletters to keep up to date.

As always, if you have any questions feel free to get in touch. Kasper Vadstrup Senior Global Scientific Advisor Global BioDermatology +45 3137 5114 VPDDK@leo-pharma.com

Majid Sheikh Medical Science Liaison LEO Pharma UK/IE +447825919184 mshuk@leo-pharma.com

CLIENT

PROJECT

WORK TYPE

Leo Pharma

Various marketing materials

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

• E-Marketing Designs • PowerPoint Presentations • Infographics

CLIENT

LEO Pharma

Psoriasis is a common and complex disease

Brodalumab

tions Communica it Launch Toolk

Social stigma places a heavy burden and can negatively impact mental health1

14 million in Europe

Affects

125million

have experienced 77% stigmatisation

people worldwide2

BEGIN

Two to three-fold risk of anxiety and depression 2

Many types Job Code: XXXXX | Date of Preparation: October 2017

97%

Plaque psoriasis

of patients1

is most common affecting up to

COMMUNICATIONS TOOLKIT

In a study

INTRODUCTION

Severity DEAR COLLEAGUE

~25

How to use the Kyntheum® Communications Launch Toolkit

Welcome to the Kyntheum® Communications Launch Toolkit. The launch of Kyntheum® represents a significant milestone for LEO Pharma. For the first time ever, we will be able to offer people living with psoriasis a biologic treatment. This will enable us to help more people overcome their skin disease and live positive lives.

Patient Advocacy Group (PAG) Engagement Plan

The guidance within this Toolkit has been developed to support markets to prepare for and engage with the media and other important stakeholders to support the launch of Kyntheum®. The aim is to support you in delivering an effective and engaging launch which is suited for your market.

Sourcing case studies/ambassadors

Prior to any use, please ensure that all activities are compliant with local regulations before implementation. All the materials will require local adaptation and approval. The Global Communications Team would love to assist you and see the results of your good work. Please do share your questions, learnings and successes with us so that we can learn from your experiences and pass them on to other colleagues.

Cost

Social media

Feelings of

anger

helplessness

44%

for patients and healthcare systems

Marie Schleimann Nordlund Senior Global Patient Communication Manager Bio Dermatology, Global Commercial Strategy marie.nordlund@leo-pharma.com

often or always depressed because

among psoriasis patients also translate into higher rates of suicidal ideation compared to other patients1

Significant costs

On behalf of the Bio Dermatology team, good luck with your media launch!

of people

of psoriasis3

will have moderate-tosevere psoriasis4

Sourcing spokespeople

Media outreach

46%

with moderate-to-severe psoriasis reported being

References 1. World Health Organization (WHO). Global Report on Psoriasis. 2016; 2. The International Federation of Psoriasis Associations. Home page; 3.Ortonne J 2004; 4. Mantovani L et al. Dermatol Ther. 2016 Jun; 6(2):151-167

increased risk

of suicidal ideation and behaviour compared to the general population4

References 1. World Health Organization (WHO). Global Report on Psoriasis. 2016; 2. Dalgard F, et al. JID. 2015;135(4), 984-991; 3. Weiss SC, et al. J Am Acad Dermatol. 2002;47:512-18; 4. Kurd et al, Arch Dermatol 2010;146(8):891-895

People with moderate-tosevere psoriasis have a two to three-fold risk of anxiety and depression 4

SYMPTOMS

• Brodalumab delivered almost clear skin (PASI 90) or completely clear skin (PASI 100) in more than three-quarters (76.8%, n= 779) and more than half (56.2%, n=779) of patients after 120 weeks of treatment, respectively

This meeting will provide an interactive forum in which we will discuss and seek input on our planned patient activities and campaigns.

• The proportions of patients achieving high levels of skin clearance were comparable at year one (week 52) and year two (with 78% and 53% of patients achieving PASI 90 and PASI 100, in year one respectively)

Ahead of the advisory board meeting we will share pre-read materials and an agenda to help you prepare for the meeting.

If you haven’t done so already, please contact me at morgane.cuisenier@leo-pharma.com in regards to flight and accommodation booking. We very much look forward to welcoming you to Copenhagen. Best wishes,

Static Physician Global Assessment (sPGA)

Psoriasis Area and Severity Index (PASI)

• Clinical assessment tool that ranges from mild to very severe and is a physician’s overall impression of the severity of the psoriasis at a single point [BAD, psoriasis worksheet]

• Used in clinical trials to indicate a % change in disease; i.e. PASI 75 = 75% reduction in disease severity. PASI 90 or 100 indicates almost clear or completely clear skinand personal relationships compared with placebo

Morgane Cuisenier Global Public Affairs Associate LEO Pharma A/S

People with psoriasis have a

44 % increased risk of suicidal ideation and behaviour compared to the general population 5

DIAGNOSIS

• At week 120, brodalumab continued to be well-tolerated with a comparable safety profile as observed in the 52-week studies

We will also contact you to enter into a written agreement about your participation in the advisory board.

Most frequently reported symptoms are scaling and thickening of the skin, itching and erythema (reddening of the skin) 3

IMPACTS

There are several types of psoriasis, of which plaque psoriasis is the most common affecting up to

RESULTS • 1604 patients entered the long term extension (140 mg Q2W, n=158; 210 mg Q2W, n=1392; 140 mg Q4W, n=40; 140 mg Q8W, n=14); total exposure was 3228.5 years

The efficacy and safety of Kyntheum® was evaluated in three clinical trials: AMAGINE-1 comparing Kyntheum® to placebo and AMAGINE-2 and -3 comparing Kyntheum® to placebo and ustekinumab 5

In a study

Psoriasis can vary from moderate to severe and the systemic (entire body) nature often remains unrecognised*

46 % of people with moderate-to-severe psoriasis reported being often

or always depressed because of psoriasis 6

* Other comorbid diseases, such as metabolic syndrome, chronic obstructive pulmonary disease, asthma, peptic ulcer disease, liver disease, renal failure, and rheumatoid arthritis, have also been associated with a diagnosis of psoriasis7 1 2 3

4 5 6 7

April 2017

THREE STUDIES

As a global patient centric company with the vision of becoming the preferred dermatology care partner, LEO Pharma very much welcomes the input of our key stakeholders to help us develop and shape our advocacy activities and ensure that they benefit patients, first and foremost. The advisory board meeting is being held to gather valuable insights and opinions from a number of patient organisations across different countries. We would very much appreciate your input based upon your professional experience and expertise in the area of psoriasis, specifically, supporting people with the condition.

Kyntheum® (brodalumab) is a self-injectable IL-17 biologic for the treatment of moderateto-severe psoriasis5 that can give a high level of skin clearance 6 and sustained response for patients who are candidates for systemic treatment3

with psoriasis say that they have experienced stigmatisation 1

97 % of patients3

Date: 8 June 12.00 to 9 June 13.00 (CET) Location: Norstat Frederiksborggade 1, 1360, Denmark th

Achieving rapid 1,2 and sustained 3 complete skin clearance4 (or PASI 100, where PASI refers to the Psoriasis Area Severity Index, and 100 denotes free from visible disease) is a desirable treatment outcome

A NEW TREATMENT

Assessment (sPGA) score of 0 (clear) and/or 1 (almost clear); PASI 75/90/100; exposure-adjusted incidence of adverse events switched to brodalumab 210mg Q2W. At week 52 ustekinumab patients switched to brodalumab 210mg Q2W.

Thank you for your interest and confirming your attendance at the LEO Pharma Global Patient Organisations Advisory Board Meeting – details below:

Psoriasis is associated with social stigma, which can negatively impact mental health 3

77 % of people TYPES

Key endpoints evaluated at week 120: static Physician Global

Dear invitee,

About Kyntheum®

(brodalumab)

Psoriasis is a common, chronic, immune-mediated inflammatory disease that primarily involves the skin

Trial design: patients were randomized 2:2:1:1 to brodalumab 140 or 210mg every 2 weeks (Q2W), ustekinumab or placebo, respectively. At week 12, brodalumab patients were re-randomized (2:2:2:1) to 140 or 210mg Q2W, 140mg Q4W or 140mg Q8W; placebo patients switched to brodalumab 210mg Q2W.

Factsheet for journalists

The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed July 2017) Ortonne J, et al. Eur J Dermatol. 2004;14:41–45 World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstr am/10665/204417/1/9789241565189_eng.pdf (Accessed July 2017) Dalgard F, et al. JID. 2015;135(4), 984-991 Kurd et al, Arch Dermatol 2010;146(8):891-895 Weiss SC, et al. J Am Acad Dermatol. 2002;47:512-18 Yeung H, et al. JAMA Dermatol. 2013;149(10):1173-1179

Job Code: XXXXX | Date of Preparation: August 2017

CLIENT

PROJECT

WORK TYPE

Leo Pharma

Various marketing materials

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

• E-Marketing Designs • PowerPoint Presentations • Infographics

The trials in total 5 included 4,373 patients with moderate-to-severe psoriasis, the largest study population in the development program of any new biologic treatment in psoriasis to date6,7,8,9,10,11

At week 2 1 in 4 patients reached PASI 75 after two weeks of treatment in clinical trials 12

FINDINGS

About Psoriasis

Dr Mark Lebwohl et al. P1790

8-9th June, Copenhagen

worldwide live with psoriasis1

14,000,000 in Europe2

UNMET NEED

Brodalumab provides robust and sustained levels of efficacy in moderate-to-severe psoriasis: 120 weeks of treatment in the AMAGINE 2 study.

LEO Pharma Global Patient Organisations Advisory Board Meeting

125 million people

Approximately twice as many patients on Kyntheum® achieved complete clearance (PASI 100) compared to patients treated with ustekinumab in the AMAGINE-2 (44 % versus 22 %) and AMAGINE-3 (37 % versus 19 %) studies 4

7 in 10 patients reported psoriasis no longer impaired their health-related quality of life compared with placebo 3

At week 52 More than half of patients (53-56%) maintained complete clearance of their psoriasis (PASI 100) and three quarters (75%) achieved almost clear skin (PASI 90) 3

When almost clear or completely clear of psoriasis symptoms (PASI 90 / 100), people experience greater improvements in their health-related quality of life than patients with a lower treatment response13 With current available treatments, many patients achieve only incomplete clearance, and treatment discontinuation rates are high.14 Kyntheum® offers patients the opportunity to achieve high levels of skin clearance3 and improved health-related quality of life15

Data from the three large randomised, controlled AMAGINE clinical trials, found Kyntheum® to be well tolerated, with an acceptable safety profile.16,17 The most common adverse events were arthralgia (joint pain), nasopharyngitis (inflammation of the nose and pharynx), headache, and upper respiratory tract infection 4 1. Russell CB, et al. J Immunol. 2014; 192: 3828-36 2. Papp K, et al. The American Academy of Dermatology annual meeting 2017. Poster 4978 3. Supplement to: Lebwohl M, et al. N Engl J Med 2015;373:1318-28 4. Lebwohl M, et al. N Engl J Med 2015;373:1318-28 5. Kyntheum® Summary of Product Characteristics 2017. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/003959/WC500232913.pdf 6. European Medicines Agency. EPAR summary for the public: Cosentyx. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003729/WC500183132. pdf (Accessed July 2017) 7. Taltz®. Summary of Product Characteristics 2016. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf (Accessed July 2017) 8. Stelara®. Summary of Product Characteristics 2009. Available from: https://www.medicines.org.uk/emc/medicine/32569 (Accessed July 2017) 9. Enbrel®. Summary of Product Characteristics 2000. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000262/WC500027361.pdf (Accessed May 2017) 10. Humira®. Summary of Product Charateristics 2003. Available from: https:// www.medicines.org.uk/emc/medicine/31860 (Accessed July 2017) 11. Remicade®. Summary of Product Characteristics 1999. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf (Accessed July 2017) 12. Blauvelt A, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phased-3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017; in press 13. Strober B, et al. J Am Acad Dermatol. 2016; 75:77–81 14. Khalid JM, et al. J Dermatolog Treat. 2014;25:67-72 15. Gordon KB, et al. Br J Dermatol. 2014;170:705–15 16. Attia A, et al. Clin Drug Investig.2017; DOI: 10.1007/s40261-017-0500-9 17. Papp K, et al. Br J Dermatol. 2016;175:273–286

RESULTS

Disease factsheet for journalists

CLIENT

Novartis COPD Life is Calling Roadmap

Still Fighting for Breath

About Chronic Obstructive Pulmonary Disease (COPD)

2014 Jul

Asthma Patient Survey

Asthma is a global health problem, 1 affecting 300 million people worldwide. 2 A new large-scale survey of almost 1,333 patients from around the world* revealed uncontrolled asthma is extremely common and restricting lives.3

MILLION PEOPLE

worldwide are living with COPD and the prevalence is rising 2

COPD

is the world’s fourth leading cause of death3

affects both men and women equally4

88%

Oct

Nov

Dec

2015 Q1

42%

Phase III Phase III is the pinnacle of the programme. An event that will bring together key stakeholders to seek creative solutions to improve the lives of people with COPD.

Ensure the creation and launch of a successful programme.

Inspire and empowerpatients to speak to their HCP.

Position Novartis as a thought leaders in: COPD, the pharmaceutical industry and business.

Interviews kick-off

self-estimated themselves as controlled, compared to 6% deemed controlled according to clinical guidelines

Phase II Phase II is the campaign kick-off which will inspire and enable patients to share their personal challenges with the community and their HCP to obtain better care.

Milestones

COPD is a progressive, potentially life-threatening condition that makes it hard to breathe1

reported their condition impacted their daily lives

Sep

Objectives

Headline findings: 3

COPD today

Description

Aug

Phase I Phase I will identify key stakeholders to engage throughout the programme. Insights gathered will inform and shape the remainder of the programme.

Website launch

Twitter launch

Facebook page launch

CrOwdshaPeD event

Key online influencers engagement Patients/PAGs/carers/family, HCPs, media, citizen journalists

Tactical Execution

• Novartis values your opinion and would love your input and support (online/offline) in a global patient programme COPD interviews + report Stakeholders (patients/ PAGs/carers/family, HCPs, media, citizen journalists) • Novartis would like you to help inform and shape an exciting global patient programme to change the face of COPD

Website Patients and HCPs • Set your own personal goal and speak to your HCP about how to achieve it • Share your challenge with the global online community to inspire others to join you

• Novartis is facilitating a game-changing event in healthcare • Provide your input and show your support online • Become part of the solution by getting involved on Facebook and Twitter

Facebook page Patients

84% Symptoms

Diagnosis

Most common symptoms are shortness of breath, phlegm, a chronic cough, wheezing and tightness of the chest5

COPD is diagnosed with spirometry10

• Join the global online COPD community to share your experiences, take part in the campaign, support others and improve your QoL

said physical activities were affected by their asthma

34%

Global and local outreach

61%

mild-to-moderate COPD remain undiagnosed

reported they need >24 hours to recover after an asthma attack

50%

Common treatments

Patients/PAGs, HCPs, media, Novartis, stakeholders from other industries • Novartis is a thought leader committed to improving the lives of people with COPD and is investing in discovering innovative solutions to meet patient needs

have reported being diagnosed with a psychological condition because of their asthma

Twitter handle Patients/PAGs, HCPs, media, general public • Novartis is facilitating a game-changing event in healthcare • Provide your input and show your support online • Become part of the solution

Bronchodilators are central to treatment . They work by relaxing and opening air passages in the lungs

Two Kinds (resuce medication) – help to decrease shortness of breath

Long-acting13 used regularly to open the airways and keep them open

• Novartis is a thought leader committed to improving the lives of people with COPD and is investing in discovering innovative solutions to meet patient needs Event

60-85% of people with

Short-acting13

• Novartis is facilitating a game-changing event in healthcare • Provide your input and show your support online • Become part of the solution

Media outreach

• Novartis is encouraging people with COPD to inspire one another by setting themselves personal challenges and sharing them with a global online community • By working with their HCP to achieve these challenges, people with COPD can improve their QoL

Most are not diagnosed until disease is advanced ,

COPD exacerbations worsen disease progression , and increase risk of hospitalization and death8,9

have taken time off work due to their condition

Inhaled corticosteroids recommended for those at high risk of exacerbations, but there

I have to live within my limitations, avoid situations

My asthma completely incapacitates

where my asthma is triggered. I’m not as fit and active as I would like to be anymore.

me. It turns me into a different person.

are health risks with long-term steroid use , , ,

Inhalers may contain either a single or a combination

Inputs

of medication

* Data collected from: References 1. COPD Foundation. What is COPD. https://www.copdfoundation.org/What-is-COPD/Understanding-COPD/What-is-COPD.aspx. Last accessed March 2018. 2. World Health Organization. Chronic Obstructive Pulmonary Disease Fact Sheet. November 2017. http://www.who.int/mediacentre/factsheets/fs315/en/ . Last accessed March 2018. 3. World Health Organization: The top 10 causes of death fact sheet No 310. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ [Accessed December 2017]. 4. Jenkins CR, Chapman KR, James FD et al.Improving the Management of COPD in Women. Chest 2017; 151(3):686-696 5. COPD Foundation. Signs and Symptoms of COPD. https://www.copdfoundation.org/What-is-COPD/Understanding-COPD/What-is-COPD.aspx. Last accessed March 2018. 6. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370(9589): 786-96. 7. Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention. A Guide for Health Care Professionals. 2018 Report. http://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf. 8. Seemungal T et al. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009; 4: 203–223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699821/# 9. Torabipour A et al. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: a state-level cross-sectional study. Tanaffos 2016; 15(2): 75-82 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127618. 10. Global Initiative for Chronic Obstructive Lung Disease. Diagnosis. Pocket guide to COPD diagnosis, management and prevention. A Guide for Health Care Professionals. 2018 Report. http://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf. Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. Int J Gen Med. 2011; 4: 729-739. Kaplan W. Background Paper 6.13: Chronic Obstructive Pulmonary Disease (COPD).http://www.who.int/medicines/areas/priority_medicines/BP6_13COPD.pdf. Last accessed April 2018. Pharmacologic therapy for stable COPD. Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention. A Guide for Health Care Professionals. 2018 Report. http://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf. Kew KM, A S. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 10. Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 2017; 50. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.

The study enrolled 1,333 adult patients (≥18 years) and children (6-17 years old) suffering from severe persistent asthma. Interviews were conducted between 12th July and 31st October 2016. All data labeled as from adolescent patients were captured through interviews with their caregivers, due to legal restrictions.

Outputs

References: 1. Global Strategy for Asthma Management and Prevention (2017). Available at: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/ [Accessed April 2017]. 2. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007. http://www.who.int/gard/publications/GARD%20Book%202007.pdf. [Accessed August 2017] 3. Katsaounou P, Conde L G, Kroegel C et al. The challenges of living with severe asthma in Europe, 2017.

• Insights and content inform the digital strategy • New relationships augment reach and secure success • Report results will shape media outreach • Successful identification of key stakeholders • Quality insights • New relationships with potential for growth

KPIs

Activity

Stakeholders

• Insights and content from Phase I and II define CrOwdshaPeD • User submitted challenges infrom CrOwdshaPeD and media outreach • Online/offline noise builds excitement for CrOwdshaPeD

• Patient submitted challenges • Dwell time/interactions on the patient support web page • Quality of social media interactions • Global media coverage • Participation from key global stakeholders • CPO programme uptake

• 4+ creative solutions to real life COPD patient needs • Potential to help bring the idea to market

• Quality of participants • Quality of solutions • Social media participation • Augmented Novartis SoV (online/offline) • Quality of online and offline coverage

Messaging

Date of Prep: August 2017 Job code: GLRESP/SoM/0003

VivindaTV Experience congress education virtually

Virtually attend sessions and speaker presentations from a laptop, tablet or phone

VivindaTV

VivindaTV is free-to-use service and registration is simple

Scientific content provided by Medical Societies

Step 1

Step 2

Step 3

Create your account

Virtual access to congresses

• Go to www.vivindatv.com registration page from any device

• Navigate and discover the available congresses

• Click the ‘Event Page’ during the designated period to view content

• Click ‘Register’ during the designated period for each congress you would like to attend

• View congress dates and summaries for availability of congress content

• Click ‘Sign Up’ to create a unique account for all congresses • If you already have an account, click to ‘Log in’

VivindaTV enables virtual access to the latest scientific data from around the world

• We can notify you via email each time new congress data is available

• Specific speakers or video pages can be selected, allowing virtual access to the sessions of your choice

Experience congress education virtually at:

www.vivindatv.com

Jobcode: xxx | Date of preparation: September 2017

“I have to live with my

limitations, avoid situations where my asthma is triggered. I’m not as fit and active as I would like to be anymore”

The number of new COPD diagnoses is

growing nearly 3X FASTER in women than in men

No. 1 Top tip to prevent attacks:

Relax and take it easy. Stress can cause asthma attacks

88%

Did you know? Your left lung is smaller than your right lung to make room for your heart

http://www.nhlbi.nih.gov/health/health-topics/topics/hlw/system

CLIENT

PROJECT

WORK TYPE

Novartis

Various marketing materials

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

• E-Marketing Designs • PowerPoint Presentations • Infographics

of people reported their condition impacted their daily lives

CLIENT

Novartis womentalkcopd.com

Women Talk COPD WOMEN TALK

COPD Crowdshaped

Avoiding Isolation

A new approach to thinking about COPD

How can I stay active?

How do I talk to my doctor about my breathlessness?

Everyone’s lungs weaken over time, but it happens faster in people who have COPD. As COPD worsens, everyday actions like getting dressed can cause breathlessness.

If at any point you discover a new symptom or if your symptoms get worse, you should call your doctor.

This may make you feel uncomfortable, but you should not be less active because of it. Regular exercise can actually make you feel less breathless over time.

6 Go to physical therapy if recommended by your doctor

Walk around the house

Stay mobile and participate in activities like going for a walk

See how far you can walk in 6 minutes and try to go further next time

• Set a clear goal for your next visit • Monitor how you feel and take your notes to your next visit • Write down any questions and topics you want to discuss with your doctor

During your appointment: • Be assertive and open • Be clear on the problem • Ask for a solution and work with your doctor

After your appointment: • Take time to reflect

Job Number: XXX/XXX/XXXXXX Date of preparation: March 2015

Eating a healthy diet is important for everyone, especially if you have COPD. The muscles you use for breathing may need 10 times more calories than those of a person without COPD. Here are some things you could do to get the right nutrients while maintaining a healthy weight:

Before your appointment:

Consult your doctor for advice on what you can do to manage your breathlessness

Consult your doctor for advice on what you can do to stay active.

Tips on eating and energy

CLIENT

PROJECT

WORK TYPE

Novartis

Various marketing materials

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

Eat high-fiber foods like vegetables and whole grains

Drink non-caffeinated or non-alcoholic drinks

Consult your doctor for advice on healthy eating. Job Number: GLRESP/COPD/0014c Date of preparation: March 2015

• E-Marketing Designs • PowerPoint Presentations • Infographics

Use herbs instead of salt

Stay away from foods that cause bloating (soda or fried foods)

CLIENT

Novartis

COPD & DIAGNOSIS CLINICAL ENDPOINTS

COPD CLINICAL ENDPOINTS CHRONIC OBSTRUCTIVE

PULMONARY DISEASE

Chronic Obstructive Pulmonary Disease (COPD)

(COPD)

is a progressive, life threatening condition characterized by

Common symptoms include:

210 million

Approximately people have COPD

of people with COPD are

Burden of this disease impacts individuals and society:

remains a serious global health problem

There are signiﬁcant associated direct and indirect healthcare costs

• Chronic sputum/phlegm production

There is an unmet need to optimize the management of

• Chronic cough

COPD

AFFECTS UP TO

Shortness of breath This is the most common symptom of COPD and is persistent3. It is caused by lung inﬂammation and airﬂow limitation and worsens over time, particularly with exercise4

• Shortness of breath

less than 65 years old2

COPD

Chronic Obstructive Pulmonary Disease

Symptoms and exacerbations

Who’s affected?

50%

LANTERN STUDY

is a condition characterized by airﬂow obstruction1

AIRFLOW OBSTRUCTION1

Estimates suggest that

COPD

• Wheeze2

Projected to be the

LAMA

symptoms worsen beyond the day-to-day norm5

COPD treatments aim to reduce symptoms and the future risk of exacerbations, and to improve the quality of life and well-being for the patient5

COMMON SYMPTOMS INCLUDE:

Shortness of breath • Chronic sputum/phlegm production Chronic cough • Wheeze3 The morning is reported as the worst time of the day for shortness of breath making routine activities e.g. showering and getting dressed difﬁcult to complete5

Shortness of breath This is the most common symptom of COPD and is persistent4. It is caused by lung inﬂammation and

airflow limitation

What are the risk factors for

COPD?

Tobacco smoking is one of the major risk factors of COPD1

Other risk factors include smoke from home cooking and heating fuels, occupational dusts, environmental pollution and chemicals or a family history of COPD1

Transition Dyspnea Index (TDI) TDI gives the change in breathlessness severity from a baseline assessment established by the BDI. Ranging from - 9 to + 9, the lower the score, the more deterioration in severity of breathlessness8

If an individual over 40 years old displays any of the symptoms or risk factors associated with COPD, the physician will do a breathing test to measure airﬂow limitation1

COPD diagnosed in the clinic?

How is

Spirometry

This is a test to measure how WELL a person can blow air out of their lungs (volume) It also measures how FAST a person can blow air out (f low)

A spirometry test is measured by a device called a spirometer and helps diagnose COPD and calculate the severity of the disease:

1 2 3 4 5 6

What are

–

FVC (Forced Vital Capacity) The amount of air that can be forced out after taking a deep breath

FEV1/FVC The ratio of FEV1 to FVC expressed as a percentage and is decreased in patients with COPD6

Trough FEV1 The mean value of FEV1 measured at 24h after the morning doses

Spirometry

Exacerbations contribute to an increased shortness of breath, at times acute and life-threatening, and increases the rate of disease progression for the patient7. It could also result in an unexpected death

COPD treatments aim to reduce symptoms and the future risk of exacerbations, and to improve the quality of life and well-being for the patient7

What clinical endpoints

are measured in

WEEK STUDY

THIS STUDY WAS CONDUCTED IN

Rescue medication use As the use of rescue medication reﬂects effects on symptoms it can be considered a clinical endpoint. Studies may record the number of times that it is required during the day and at night and the number of puffs per occasion

COPD?

Baseline Dyspnea Index (BDI) BDI evaluates the severity of breathlessness (dyspnea) at a single point in time. Ranging from 0 to 12, the lower the score, the worse the severity of breathlessness8

A spirometry test is measured by a device called a spirometer and helps diagnose COPD and calculate the severity of the disease:

1 2 3

St. George's Respiratory Questionnaire (SGRQ) This is designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease9. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health Rescue medication use As the use of rescue medication reﬂects effects on symptoms it can be considered a clinical endpoint. Studies may record the number of times that it is required during the day and at night and the number of puffs per occasion

5 6

Exercise endurance Methods for evaluating exercise capacity include 6-min walking test, progressive exercise testing and endurance tests, using a cycle ergometer or treadmill10

FVC (Forced Vital Capacity) The amount of air that can be forced out after taking a deep breath

FEV1 (Forced Expiratory Volume in 1 Second) The amount of air that can be forced out in ONE SECOND after taking a deep breath

FEV1/FVC The ratio of FEV1 to FVC expressed as a percentage and is decreased in patients with COPD6

FEV1 AUCo-4h The change in FEV1 0-4 hours after the morning dose, known as the Area Under The Curve (AUC)9

Trough FEV1 The mean value of FEV1 measured at 24h after the morning doses Peak FEV1 The maximum FEV1 observed

744

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html [Accessed 17 July 2014]

Fletcher MJ et al. COPD Uncovered: An International Survey on the Impact of Chronic Obstructive Pulmonary Disease (COPD) on a Working Age Population. BMC Public Health 2011;11:612

Partridge MR et al. Patient Insight into the Impact of Chronic Obstructive Pulmonary Disease in the Morning: an internet survey. Curr Med Res Opin 2009;25(8):2043-2048

Pitta F, Troosters T, Spruit MA, et al. Characteristics of Physical Activities in Daily Life. Am J Respir Crit Care 2005;171:972–977. Available at: http://www.atsjournals.org/doi/pdf/10.1164/rccm.200407-855OC [Accessed 17 July 2014]

Joshi M et al. Symptom Burden in Chronic Obstructive Pulmonary Disease and Cancer. Curr Opin in Pulm Med 2012;18(2):97–103

Spirometry in Practice. Available at: https://www.brit-thoracic.org.uk/document-library/delivery-of-respiratory-care/spirometry/spirometry-in-practice/ [Accessed 17 July 2014]

Vestibo J et al. (2012). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD executive summary [published online ahead of print August 9, 2012]. Am J Respir Crit Care Med. doi: 10.1164/rccm.201204-0596PP. [Accessed 17 July 2014]

American Thoracic Society. Available at: http://www.thoracic.org/assemblies/srn/questionaires/bdi-tdi.php [Accessed 17 July 2014]

American Thoracic Society. Available at: http://www.thoracic.org/assemblies/srn/questionaires/sgrq.php [Accessed 17 July 2014]

ACROSS

Lantern met both primary and key secondary endpoints

Ultibro Breezhaler demonstrated non-inferiority vs Seretide Accuhaler in terms of trough FEV1 at Week 267 Results showed

superiority of Ultibro Breezhaler in improving lung function

(as measured by trough FEV1) compared to the Seretide Accuhaler at week 267

Ultibro Breezhaler signiﬁcantly reduced the rate of moderate-to-severe exacerbations by

Partridge MR et al. Patient Insight into the Impact of Chronic Obstructive Pulmonary Disease in the Morning: an internet survey. Curr Med Res Opin 2009;25(8):2043-2048

Joshi M et al. Symptom Burden in Chronic Obstructive Pulmonary Disease and Cancer. Curr Opin in Pulm Med 2012;18(2):97–103

American Thoracic Society. Available at: http://www.thoracic.org/assemblies/srn/questionaires/bdi-tdi.php [Accessed 17 July 2014]

American Thoracic Society. Available at: http://www.thoracic.org/assemblies/srn/questionaires/sgrq.php [Accessed 17 July 2014]

Oga T et al. Exercise responses during endurance testing at different intensities in patients with COPD. Respiratory Medicine 2004; 98:515–521

Spirometry in Practice. Available at: https://www.brit-thoracic.org.uk/document-library/delivery-of-respiratory-care/spirometry/spirometry-in-practice/ [Accessed 17 July 2014]

PROJECT

WORK TYPE

Novartis

Various marketing materials

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

31% **

Exacerbations are categorised by severity according to need for additional treatment. * The LANTERN study used Seretide (salmeterol/ﬂuticasone) 50/500 mcg, which is indicated in the UK for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (prebronchodilator) and a history of repeated exacerbations, who have signiﬁcant symptoms despite regular bronchodilator therapy8. The patient population in the LANTERN study were moderate-to-severe COPD patients with or without (≤1) exacerbation in the previous year7. Seretide is also known as Advair® and Accuhaler is also known as Diskus®. Seretide, Advair, Diskus and Accuhaler are registered trademarks of the GlaxoSmithKline group of companies.

References:

CLIENT

56 sites

** RR [95% CI]: 0.69 [0.48, 1.00]; p=0.048)

10 Oga T et al. Exercise responses during endurance testing at different intensities in patients with COPD. Respiratory Medicine 2004; 98:515–521 11 EMA. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). 21 June 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf [Accessed 17 July 2014]

Argentina, Chile, China and Taiwan6

Global Alliance Against Chronic Respiratory Disease (GARD). Global Surveillance, Prevention and Control of Chronic Respiratory Disease: a Comprehensive Approach. Available at: http://www.who.int/entity/gard/publications/GARD%20Book%202007.pdf?ua=1 [Accessed 17 July 2014]

Global initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2014. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf [Accessed 17 July 2014]

EMA. 2012. Ultibro Breezhaler EU Summary of Product Characteristics. [Online] 3 October 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdf [Accessed 17 July 2014].

References: 1

assessing the efficacy and safety of Ultibro Breezhaler vs Seretide® Accuhaler®* in patients with moderate-to-severe COPD, with or without a history of moderate-to-severe exacerbations (worsening symptoms) in the previous year6

This is a test to measure how well a person can blow air out of their lungs (volume) It also measures how fast a person can blow air out (ﬂow)

Patients with exacerbations are at an increased risk of hospitalization and often require a change in medication1

is a once-daily maintenance bronchodilator treatment approved in the EU to relieve symptoms in adult patients with COPD3

was a

Diagnosis

COPD exacerbations?

Ultibro® Breezhaler®

Breezhaler®inhalation device allows patients and see hear , feel

was a

Peak FEV1 The maximum FEV1 observed

Exacerbations are when a patient’s respiratory symptoms worsen beyond the

Questionnaires and other measures are often used to assess the overall impact of COPD on the patient’s quality of life, for example:

LABA indacaterol

LANTERN LANTERN

Exercise endurance Methods for evaluating exercise capacity include 6-min walking test, progressive exercise testing and endurance tests, using a cycle ergometer or treadmill8

FEV1 AUCo-4h The change in FEV1 0-4 hours after the morning dose, known as the Area Under The Curve (AUC)6

day-to-day norm7

–

FEV1 (Forced Expiratory Volume in 1 Second) The amount of air that can be forced out in ONE SECOND after taking a deep breath

+ +

that they have taken the full treatment correctly 4,5

Baseline Dyspnea Index (BDI) BDI evaluates the severity of breathlessness (dyspnea) at a single point in time. Ranging from 0 to 12, the lower the score, the worse the severity of breathlessness6

Questionnaires and other measures are often used to assess the overall impact of COPD on the patient’s quality of life, for example:

3rd

The

Clinical endpoints

and worsens over time, particularly with exercise5

leading cause of 2

glycopyrronium bromide

COPD symptoms?

people worldwide1

3rd DEATH by 2020

Exacerbations are when a patient’s respiratory What are

210 million

Pavkov et al. Characteristics of a Capsule Based Dry Powder Inhaler for the Delivery of Indacaterol. CMRO 2010;26;11:2527-2533

Onbrez® Breezhaler® (indacaterol) EU Summary of Product Characteristics. [Online] July 26, 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001114/WC500053732.pdf [Accessed 17 July 2014]

Clinicaltrials.gov. A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 (LANTERN). NCT01709903. Available at: http://clinicaltrials.gov/ct2/show/NCT01709903 [Accessed 17 July 2014]

Zhong N et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study. [ERS abstract 700090; Session 281; Date: September 8 2014; Time].

Seretide® Summary of Product Characteristics [Online] Available at: https://www.medicines.org.uk/emc/medicine/2317/SPC/Seretide+100,+250,+500+Accuhaler [Accessed 17 July 2014]

• E-Marketing Designs • PowerPoint Presentations • Infographics

CLIENT

Health Unlimited

Open Source

Innovation

osi = zmp?

When

Zeitgeist, MIT and Pharma Collide

Date & Time: 16:00 - 16:45, Sunday, June 19, 2016 Stage: Inspiration Stage Session Holder: Health Unlimited Title: Open Source Innovation When Zeitgeist, MIT and Pharma Collide

Chair: Yossi Vardi, Internet Investor, Entrepreneur Speaker(s): Dr Jack Kreindlier, Founder and Chairman, Sentrian, Remote Patient Intelligence Mark Lightowler, Head of Digital Solutions, Novartis Matt Lowe, Director, Health Unlimited Tal Achituv, Entrepreneur, a full-stack engineer and a seasoned CTO, MIT Media Lab

Open Source

Innovation When

Zeitgeist, MIT and Pharma Collide

CLIENT

PROJECT

WORK TYPE

Health Unlimited

OSI internal event

•

New Business Visualisations

regimen providing clinically-proven support for anyone suffering from thinning hair. Backed by world-class research and scientifically proven to deliver results, TRX2® products are discreet and easy-to-use, delivering thicker, healthier hair without compromise.

CLIENT

Oxford Biolabs

THE BUILDING BLOCKS OF HEALTHY-LOOKING HAIR TRX2® Molecular Food Supplements for Hair are based on natural ingredients and have been specifically designed for men and women suffering from the early stages of hair loss. Packed with all the nutrients needed to maintain a healthy-looking head of hair, including:

YOUR ROOT TO HEALTHIER LOOKING HAIR HAIR LOSS WILL AFFECT 50% OF PEOPLE AT SOME POINT DURING THEIR LIFETME.

Carnitine-L-tartrate

Biotin

Studies show that L-carnitine-L-tartrate promotes human hair growth by increasing the energy supply to the hair.

A deficiency in biotin intake can cause brittle hair and can lead to hair loss. A single boiled egg contains 25 µg of biotin. TRX2® has 150 µg of biotin in a serving – 3 capsules – meaning you would need to eat 6 eggs every day in order to get the same amount.

A portion of red meat provides around 162 mg of L-carnitine-L-tartrate per serving. TRX2® contains 800 mg of L-carnitineL-tartrate in a serving – 3 capsules – meaning you would need to eat meat five times a day to experience the same benefits.

x5 Male-pattern baldness is the most common type of hair loss. It affects around half of all men by 50 years of age1

Around half of women over the age of 70 experience female-pattern baldness2

HAIR GROWTH Hair is the fastest growing tissue in the human body, with most people having between 100,000 and 120,000 strands.3 Optimal growth occurs from age 15 – 30. Hair growth reduces from age 40 - 50.

Promoting new hair growth Regular scalp massages are a great way of boosting hair health, and can simultaneously improve circulation and reduce stress. Follow our guide for the ultimate massage:

Zinc

Selenium

Zinc conditions the hair and helps prevent shedding. Chickpeas, pumpkin seeds, cashews and chicken are all good sources of zinc.

Selenium is needed for a healthy scalp. Nuts, some oily fish, turkey and spinach are all good sources of selenium. A 75g serving of salmon contains 81.15 µg of selenium. TRX2® contains 75 µg of selenium in a serving – 3 capsules – meaning you would need to have salmon for dinner every day for the same effects.

TRX2® contains 15 mg of zinc in a serving – 3 capsules – the same as two cups of cashew nuts.

3-4 1

times

Hair can be wet or dry, Spread your fingers, Extend and contract but should be clean. If placing fingertips on INFORMATION the fingers three or CONSUMER your hair is wet comb your scalp – avoid using four times, then Please read the consumer information thata comes with TRX2® Hair Revitalizing Lotion (hereinafter referred to as TRX2® through first. You may your fingernails, as they move to different before you start using it. also want to add some can break theLotion) hair and spot and repeat. TRX2® HAIR If you have questions regarding application of this product, contact us at support@trx2.com or +44 800 808 5251. conditioner or hair lotion* damage the scalp. REVITALIZING LOTION For more information on TRX2® Products or to reorder visit our homepage: www.trx2.com.

Full range of products available from www.trx2.com

TRX2® Hair Revitalizing Lotion with TRX2® active ingredients is a topical, natural-based solution containing a propriWhat is TRX2® Lotion? Hair Revitalizing Lotion - £42.36 per bottle etary complex of Carnipure™ Tartrate (L-Carnitine Tartrate), Potassium, BCAA, Niacin and other essential nutrients,

produced under the highest quality control. TRX2® Lotion is used to revitalize hair follicles, and nourish thinning hair.

Who may use TRX2®

USE

TRX2® Lotion is suitable for use by men and women. This natural-based solution is specifically designed to revitalize

hair and nourish thinning hair. Lotion? TRX2®: HAIR HEALTH & follicles CONFIDENCE

Created with the expertise of Oxford Biolabs is thinning a safe,hair natural hair loss a decline in potassium channel activity. These pore formPeople whoTRX2® experience often demonstrate How does scientists, ing proteins, which reside in the cell membranes, are responsible for the correct transport of potassium ions over the TRX2® Lotion work? regimen providing clinically-proven support for anyone suffering from thinning hair. Backed thusresults, maintaining the membrane potential by world-class research and scientifically provenmembranes, to deliver TRX2® products are and a normal uptake of nutrients by the hair follicle. TRX2® Lotion is based on the same effective formula as the TRX2® Molecular Food Supplement for Hair. This means that the discreet and easy-to-use, delivering thicker,same healthier hair without compromise. active ingredients help to strengthen the hair by ensuring a sufficient nutrient supply to the hair root. This can

Original TRX2® Molecular Food Supplements for Hair

be achieved by the reactivation of dysfunctional potassium channels, thereby revitalising and strengthening the hair follicle at the molecular level. More detailed information about the science behind the TRX2® formula can be found at www.trx2.com/the-science.

£47.96

per bottle (one month’s supply)

How should I apply TRX2® Lotion?

When using TRX2® Lotion for the first time, remove the cap. Insert the dropper into the bottle. Squeeze the bulb and release it, allowing the dropper to fill with 1ml of the product. Part your dry, or towel dry, hair in the area of thinning hair. Apply TRX2® Lotion using the tip of the dropper directly onto the part of the scalp you want to treat. Squeeze the bulb slowly to achieve gradual solution release. Apply small amounts of solution to prevent it from running off the scalp. Use your fingers to massage TRX2® Lotion into the scalp. Wash your hands well afterwards. Blow dry or style your hair only after the product has been completely absorbed into your scalp. Allow enough time to dry your hair before going TRX2® Molecular Food Supplements for Hair aretobased onTRX2® natural andfor have bed. Allow Lotioningredients to stay on your scalp a few hours before washing your hair. Apply TRX2®from Lotionthe twiceearly a day, stages in the morning and in the evening. To ensure long-term results, use TRX2® Lotion conbeen specifically designed for men and women suffering of hair loss. sistently as part of your daily routine, and according to the instructions.

THE BUILDING BLOCKS OF HEALTHY-LOOKING HAIR

WITH EITHER / OR

Packed with all the nutrients needed to maintain a healthy-looking head of hair, including:

What should I do if I forgot to apply TRX2® Lotion? Precautions:

Carnitine-L-tartrate

Does TRX2® Lotion contain any harmful ingredients?

Use the usual amount of TRX2® Lotion the next morning or evening. Keep out of reach of children. Store at room temperature. In case of contact with eyes, rinse immediately with cool water.

Biotin TRX2® Lotion is dermatologically tested and doesn’t contain any harmful ingredients. It is free from synthetic fragrances and dyes. Active ingredients of TRX2® Lotion (see label) are natural-based. A small dosage of a mild preservative is used to prevent product spoilage.

Studies show that L-carnitine-L-tartrate A deficiency in biotin intake can cause brittle promotes human hair growth by increasing and can lead to Propanediol, hair loss. Phenoxyethanol, Biotin, Leucine, Isoleucine, Valine, Niacin, Potassium Chloride, Aqua, Carnitine Tartrate, Ingredients: hair Zinc Citrate, Dimethyl Sulfone. the energy supply to the hair. A single boiled egg contains 25 µg of biotin. Dermatologically tested. A portion of red meat provides around TRX2®Free hasfrom 150 µg of biotin in a serving – 3 synthetic frangrances and dyes. 162 mg of L-carnitine-L-tartrate per serving. capsules – meaning you would need to eat 6 TRX2® contains 800 mg of L-carnitineeggs everyend: daysee inbottom orderoftobottle. get the same Best before Specifications: 60 ml. L-tartrate in a serving – 3 capsules – amount. Manufactured for and distributed by: Information updated: November 2015 meaning you would need to eat meat five times a day to experience the same benefits.

NEW TRX2®

TRX2®

Hair Revitalising Foam

Hair Revitalising Lotion

£42.36

per bottle

AND FINISH WITH

Made in the European Union

NEW TRX2® Oxford Biolabs Ltd. Robert Robinson Avenue The Oxford Science Park Oxford OX4 4GA, UK

Advanced Care Thickening & Styling Cream

£17.25

Science that delivers noticeable, honest results

support@trx2.com

per jar

Full range of products available from www.trx2.com References

CLIENT

PROJECT

WORK TYPE

Oxford Biolabs

Various marketing materials Selenium

• Editorial Layouts • E-Marketing Designs

Zinc

Zinc conditions the hair and helps prevent shedding. Chickpeas, pumpkin seeds, cashews and chicken are all good sources of zinc. TRX2® contains 15 mg of zinc in a serving – 3 capsules – the same as two cups of cashew nuts.

1. http://www.nhs.uk/Conditions/Hair-loss/Pages/Introduction.aspx and Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am 2007; 36: 379–98. 2. International Journal Of Trichology [serial online]. July 2016;8(3):116-120. Available from: Academic Search Elite, Ipswich, MA. Accessed February 20, 2017.) 3. S. Bouabbache, A. Galliano, P. Littaye. M/ Leportier, F. Pouradier, E Gillot, S. Panhard, G. Loussouarn, What is a Caucasian ‘fine’ hair? Comparing instrumental measurements, self-perceptions and assessments from hair experts. Volume 38, Issue 6. December 2016, Pages 581–588

CLIENT

Sunovian

Expert Panel Report

port_14_

ellence

iatry 20

at http://

Health Care

No Mental Health Care Without Physical Health Care Executive summary In what has been described as a national scandal,1 people with schizophrenia die 10-20 years earlier on average than the general population.2,3 An estimated 60% of this is due to physical health issues,4 and preventing premature mortality in people with schizophrenia and other severe mental illness (SMI) is now a national priority.5 Numerous publications aimed at addressing this have appeared recently including a national strategy, recommendations for policy makers, evidence-based practice guidelines and NHS indicators and incentives. However, there is a limited supply of practical advice and recommendations to help practising healthcare professionals make a real difference for people with schizophrenia now. To address this gap, a Panel of national experts has developed a series of steps that can be implemented immediately at the clinical level in both secondary and primary care as appropriate. Broader considerations of how to make optimal use of other community services that can promote physical and mental wellbeing are also included, and may enable local teams to make use of innovative services and approaches that are appearing in many parts of the UK. The recommendations cover four key areas of critical need, in which real change can be driven relatively easily and cheaply by local teams working together with commissioners:

1. Adopt a patient-centred approach starting with a holistic assessment of the needs of a person with schizophrenia 2. Ensure people with schizophrenia receive regular physical health assessments and intervene when necessary 3. Develop an integrated service to promote physical health in people with schizophrenia, there is no one-size-fits-all approach 4. Continuity of care and message – consider who engages with the person in their care and makes their experience as streamlined and simple as possible Underneath these themes the Panel has developed recommendations and practical advice to help implement change, as well as providing best practice case studies and listening tools and guidance available to help local care teams. It is hoped that this report will help in some way to bridge the gap between the wider systemic changes that need to happen to ensure parity of outcomes for people with schizophrenia, and the pressing need to drive meaningful changes for people affected by physical health problems now.

On average, people with schizophrenia can expect to die 10-20 years before people without a SMI, with cardiovascular disease being the leading cause of mortality.2,3 NHS England has committed to reducing this gap, including it as an indicator in the NHS Outcomes Framework and incorporating financial incentives into its Commissioning for Quality and Innovation (CQUIN) framework for 2014-15.

No Mental Health Care Without Physical Health Care

Job Code: XXXXXXX | Date of preparation: October 2014 | 1

A 2012 audit of over 5,000 mental health patients found that fewer than 29% receive the basic annual physical health checks and ongoing monitoring support they need.9

Change is coming? NHS outcomes measures for physical health in people with SMI defined At the time of writing real change does appear to be forthcoming, with the Department of Health and NHS England taking more concrete steps to drive behaviour change. In November 2013 the new NHS Outcomes Framework, the mechanism by which the success of the NHS is judged, was published. It now includes a specific indicator for physical health in people with SMI (1.5 Reducing premature death in people with SMI) and a number of related indicators such as Reducing premature death due to cardiovascular disease and Improving quality of life for people with a SMI. This now requires health providers to demonstrate that they are delivering against these indicators and achieving measurable change.10 In February 2014, NHS England went further when it published its 2014-15 Commissioning for Quality and Innovation (CQUIN) framework. The new framework provides financial incentives for NHS trusts to take a more proactive approach to physical health care for people with SMI, and includes two relevant indicators for the 2014-25 financial year: • Indicator 1: 65 % of funding for demonstrating, through a national audit process similar to the National Audit of Schizophrenia, full implementation of appropriate processes for assessing, documenting and acting on cardio-metabolic risk factors in patients with psychoses, including schizophrenia • Indicator 2: 35 % of funding for completion of a programme of local audit of communication with patients’ GPs, focusing on patients on the Care Programme Approach (CPA), demonstrating by Quarter 4 that, for 90 % of patients, an up-to-date care plan has been shared with the GP, including the holistic components set out in the CPA guidance

And finally, in September this year, the Chief Medical Officer for England, published her annual report with focus on ‘Public Mental Health Priorities: Investing in the Evidence’, within which a number of recommendations in the mental health arena are made that are based on and reinforced by the above proposals. These include:

29% Evidence-based guidance and the first steps towards system-level changes NICE published its revised Schizophrenia Clinical Guideline (CG178) in March 2014. This made a number of evidence-based recommendations aimed at improving the physical health of people with schizophrenia. Please see box out for key recommendations. In May the BMA published a comprehensive report entitled Recognising the Importance of Physical Health in Mental Health and Intellectual Disability, which aimed to help the medical profession to drive change. Its recommendations focus on providing parity of esteem for people with mental health problems and intellectual disability, and focus on key areas such as promoting prevention strategies, delivering joined-up care and ensuring adequate training is provided for healthcare professionals.11 This report included an example pathway for an integrated physical care service for people with SMI. The pathway was developed by Rethink Mental Illness in collaboration with the Royal College of General Practitioners, Royal College of Nursing and the Royal College of Psychiatrists. The pathway is available to download here: http://www.rethink.org/about-us/health-professionals/physical-healthintegrated-physical-health-pathway

Getting to the heart of the matter – why this report is necessary Behind all the statistics and talk of systemic change, a large number of people living with schizophrenia need significant and immediate change in the clinical care they receive. This report is designed to represent a natural ‘next step’ to the performance indicators and evidence base through providing practical steps that can be taken now. While the political will to deliver change is clear and evidence-based interventions exist, there remains a lack of practical help and advice for local care teams who are committed to driving change in their area. This report builds on the work of others and the experience of experts in the field to create a set of practical recommendations that can help implement NICE guidance, achieve CQUIN targets and, most importantly of all, provide increased longevity and quality of life to people living with schizophrenia.

• All Health and Wellbeing Boards being informed by a Joint Strategic Needs Assessment (JSNA) which includes the information needed to plan services to integrate the mental and physical health needs of their populations • The Outcomes Frameworks working together to develop a metric that recognises patient experience of the integration of their care and leads to rewards for effective integration around the patient’s health and social care needs • The Mental Health Intelligence Network linking routine mental health data to longitudinal mental health survey data to better understand patterns of mental illness across the community, including those affected by the 75% treatment gap • Ensuring a period of specific mental health training in GP training

A further example care pathway can be found within the Lester UK adaptation. It outlines an intervention framework for people experiencing psychosis and schizophrenia. The resource was co-produced by NHS England, NHS Improving Quality, Public Health England and the National Audit of Schizophrenia Team, and is available for download here: http://www.rcpsych.ac.uk/quality/NAS/resources

4 | Job Code: XXXXXXX | Date of preparation: October 2014

CLIENT

PROJECT

WORK TYPE

Sunovian

Various marketing materials

• Editorial Layouts • E-Marketing Designs • Infographics

The report is available for download here: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/351629/Annual_ report_2013_1.pdf No Mental Health Care Without Physical Health Care

No Mental Health Care Without Physical Health Care

Job Code: XXXXXXX | Date of preparation: October 2014 | 5

CLIENT

Takeda

TRE

A AT E D s

Controversies and Progress in T-Cell Lymphoma Including a preview of the 2021 BSH T-cell guidelines 12th November 2020 | 8:00am – 9:30am This symposium with Dr Graham Collins, Dr Matthew Ahearne, Dr Chris Fox and Professor Tim Illidge will be taking place tomorrow on the 12th November from 8:00am – 9:30am. Please find the agenda below:

ADCETRIS

Time

Session

Speaker

8:00 – 8:05

Introduction

Dr Graham Collins

8:05 – 8:20

T-Cell Lymphoma – A Moving Target

Dr Graham Collins

8:20 – 8:35

Towards Molecularly-Guided Therapy for TNHL

Dr Matthew Ahearne

8:35 – 8:50

Guidelines Update – Controversies & Progress

Dr Chris Fox

8:50 – 9:15

Challenging Clinical Cases – Ask the Experts

Professor Tim Illidge

9:15 – 9:30

Q&A Meeting Close

All Dr Graham Collins

brentuximab vedotin

Your treatment and what to expect from it Information for people who have been prescribed ADCETRIS (brentuximab vedotin) for Hodgkin lymphoma, systemic anaplastic large cell lymphoma or cutaneous T-cell lymphoma.

We look forward to welcoming you to what we anticipate will be a thought-provoking and informative symposium. If you have any questions, please don’t hesitate to contact: Steve Meredith Takeda Oncology Key Account Manager West Midlands

Tory Griffiths Takeda Oncology Key Account Manager Manchester & Merseyside

This booklet does not replace your healthcare professional’s advice. Always ask your doctor, nurse or pharmacist any questions you might have about your treatment or disease.

Geeta Menon Takeda Oncology Key Account Manager East Midlands & Anglia

ADCETRIS in combination with CHP is indicated for adult patients with previously untreated sALCL.2 ADCETRIS has received a conditional marketing authorisation in Europe. Prescribing information can be found on the last page.

Takeda medicines will be discussed during this meeting. This sponsored symposium is organised and fully funded by Takeda UK Ltd. and is intended for healthcare professionals only as part of the BSH 2020 annual conference. Prescribing information will be available during this meeting.

Please refer to the patient information leaflet for brentuximab vedotin. In the UK it can be found at www.medicines.org.uk/emc/product/2859/pil. In Ireland it can be found at www.medicines.ie/medicines/adcetris-50-mgpowder-for-concentrate-for-solution-for-infusion-31191/patient-info.

C-APROM/UKI/ADCE/0007 | October 2020

Mepact demonstrated a predictable, manageable tolerability profile1,2

NICE sALCL background Study design Study design

When used in combination with chemotherapy, Mepact was shown to have mild to moderate side effects.2 These were largely related to immune activation and the resulting biological activity.1- 3

Population Efficacy Tolerability

Hearing loss was the only AE that occurred at a higher frequency with Mepact in combination with chemotherapy, versus chemotherapy alone.1

Dosing Summary

See ALK+ aNSCLC, Think Brain Metastases, Choose ALUNBRIG (brigatinib)

MEETINGS SUMMARY

UNDERSTANDING COMMON ENDPOINTS AND TERMINOLOGY IN LUNG CANCER CLINICAL TRIALS

HIGHLIGHTS

Trial design

Reported endpoints

For both intracranial and extracranial efficacy1 Up to 90% of ALK+ aNSCLC patients will develop brain metastases during their disease.2

Treatment decision

Patients need a treatment that delivers both intracranial and extracranial efficacy.

N=? PFS

ORR

QOL

iPFS

DOR

Cross-over Single-arm

With your help, these sessions were lively and engaging exchanges, in which we explored and interrogated the latest developments in lung cancer research from the 2018 WCLC and ESMO conferences. By linking research developments to how they might improve outcomes for lung cancer patients and impact clinical practice in the UK, we hope you found these sessions to have relevance to your current and future clinical practice.

Randomised

Please take the time to watch the key takeaways from the meetings, as summarised by our expert panel below

Inclusion/ exclusion

Phase

Interventional/ observational

Comparator arm

ALUNBRIG has a generally manageable tolerability profile

• Halved the risk of disease progression or death vs crizotinib in ITT population (BIRC-assessed mPFS of 24.0 months with ALUNBRIG vs 11.0 months with crizotinib, HR=0.49; P<0.0001)1

• In the ALTA-1L study, the most common (>25%) AEs of any grade included diarrhoea, increased blood CPK, cough, hypertension, nausea, and increased AST1

• Two thirds reduction in risk of intracranial disease progression or death in patients with any brain metastases at baseline (BIRCassessed intracranial mPFS of 24.0 months with ALUNBRIG vs 5.6 months with crizotinib, HR= 0.31; P<0.0001)1

Patients should be provided with a Patient Alert Card when prescribed ALUNBRIG.

What do these endpoints mean?

CON

OVERALL SURVIVAL (OS), PROGRESSION-FREE SURVIVAL (PFS) AND DURATION OF RESPONSE (DOR)1

GENE RA TO LLY LE M RA

BLE EA AG Y1 ANILIT B

1 D CY AN ICA IC FF M LE A

Primary endpoint

Thank you for attending one of the Takeda Oncology organised HIGHLIGHTS: WCLC and ESMO Lung Cancer Updates held last year in London and Manchester.

ALUNBRIG provided superior systemic and intracranial efficacy vs crizotinib1

LIF

Dear healthcare professional,

INTRA SYS CR TE AN I

LUNG CANCER UPDATES

Wednesday 5th December 2018 Cheltenham Suite, Manchester Airport Marriott Hotel

Clinical interpretation

WCLC & ESMO

Death

DOR We are also pleased to announce that, due to the success of these meetings, we are looking to hold similar sessions following the 2019 conferences later this year. So please make sure you keep an eye out for further correspondence, and we hope to see you at a future HIGHLIGHTS meeting.

Advantages1 OS

Yours sincerely,

PFS

Takeda Oncology Medical Department

DOR Job code: XXX | Date of preparation: March 2019

Disadvantages1

• Considered the gold standard in lung cancer trials2 • Easily and precisely measured • Completely objective

• Often affected by crossover and/or subsequent therapies • Needs long follow-up to get enough events • Includes non-cancer deaths

• Generally assessed earlier than OS • Requires a smaller number of trial participants than OS • Not influenced by crossover and subsequent therapies

• Potentially influenced by assessment bias • May be confounded by frequency of radiological or other assessments • May not correlate highly with survival

• Can reflect fast onset of treatment efficacy • Can highlight a plateau in response

• Only based on a subset of patients (responders)3 • May not be balance of baseline characteristics3

SIN

ALUNBRIG comes with a convenient dosing schedule

Until disease progression or cancer death

PFS

NICE RECOMMENDED TREATMENT OPTIONS IN ALK-POSITIVE ADVANCED NSCLC A GUIDE FOR HEALTHCARE PROFESSIONALS

Disease progression

Documentation of tumour response

Randomisation or enrolment OS

• The only licensed first-line treatment for ALK+ aNSCLC that has a single tableta,once-daily dosing regimen3–6

ALUNBRIG delivered a sustained and significantly longer duration of improvement in quality of life vs crizotinib1 • Median duration of improvement in GHS/QOL not reached with ALUNBRIG vs 12 months for crizotinib (HR=0.27; P<0.0001)1,7

INDICATIONS3 • ALUNBRIG is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.1 Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinib.1 Please refer to the Summary of Product Characteristics for full prescribing and monitoring guidance.1 For more information, please visit www.ALUNBRIG.co.uk (for UK use only)

• ALUNBRIG is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. In circumstances where dose is modified from the recommended dose, more than one tablet may need to be taken.

CLIENT

PROJECT

WORK TYPE

Takeda Oncology

Isell detail aid Marketing materials Virtual Expo

• Editorial Layouts • New Business Visualisations • E-Marketing Designs • PowerPoint Presentations • Infographics

UK/BRIG/1905/0037a(2) Date of preparation: June 2020

RECOMMENDED IN

ADCETRIS® (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended by NICE, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma (sALCL) in adults.1

CLIENT

Takeda

ADCETRIS + CHP demonstrated improvement in PFS* vs. CHOP in patients with previously untreated sALCL1,2†

sALCL is clinically aggressive and associated with poor outcomes1,2 References

NICE First-line treatment of sALCL has typically been multi-agent chemotherapy, such as CHOP or CHOP-like regimens4–6

sALCL background

ADCETRIS + CHP provided PFS benefit vs. CHOP regardless of consolidative therapy3*

Abbreviations

Percentage of Progression-Free Patients (%)

— Consolidation of the initial response by means of ASCT to prevent relapse is sometimes used5,7

Study design

• UK guidelines (2011) recommend initial treatment with CHOP for ALK– sALCL (if clinical trial is not an option) and for ALK+ sALCL4

Population

Most clinical practice guidelines recommend inclusion in clinical trial as the preferred first-line option for sALCL, highlighting the need for novel therapies4–6

Efficacy Typical treatment pathway4–6

Tolerability

Clinical trial (preferred)

If no response or relapse

Second-line therapy

Response

ASCT

Multi-agent chemotherapy

The benefit of ADCETRIS + CHP vs. CHOP was seen both with and without censoring patients in both treatment groups who received consolidative ASCT therapy3

60 50 40 30 N

20 10 0

Events Median, months

ADCETRIS + CHP 162

CHOP 154

ADCETRIS + CHP 162 CHOP 154

Summary

55.7

HR (95% CI)

P-value (nominal)

0.58 (0.40, 0.84)

0.0032

27.1

101 85

85 71

75 65

61 50

21 28

13 15

4 5

2 1

0 0

ADCETRIS + CHP reduced the risk of a PFS event by 42% compared with CHOP (censored at time of ASCT)3

Time (Months)

N at risk

Dosing

ADCETRIS + CHP CHOP

100

Abbreviations

Consolidative SCT therapy did not affect the results of the secondary endpoint of PFS in patients with sALCL3

PFS (sALCL population; censored at the time of ASCT)3 • Multi-agent chemotherapy has been the standard first-line treatment for sALCL for decades, with CHOP, or variants of it, being the most popular regimen5,7

Study design

References

47 43

37 37

*Post-hoc analysis.

NICE

Background

Study design

Efficacy

Tolerability

Dosing

Summary

NICE

Background

Study design PFS

Efficacy OS

Tolerability

Dosing

Summary

ORR/CR

Three-step approach to objection handling 1

This three-step approach to objection handling will help you provide comprehensive answers to address questions from HCPs. Although it is important that you use this approach with all HCPs, there may be instances when you do not need to use all steps (e.g. skipping the probe if the question is obvious).

Probe: ● Question the HCP to gain a more detailed understanding of the underlying driver of the objection (use only if needed)

ACKNOWLEDGE

Please note that this objection handler is intended to help you provide the best possible responses to HCPs. Your sales skills and judgment will help you to adapt this approach for specific HCPs.

ALUNBRIG

3 Acknowledge: Let the HCP know you understand their question and consider it to be important

ANSWER

OBJECTION HANDLER

UNMET NEED

ALTA-1L

EFFICACY

TOLERABILITY

ANSWER

●

Confirm: Confirm the question has been addressed to the satisfaction of the HCP

●

Transition: Resume the call dialogue at the point at which the question was raised

●

Answer: ● Provide a response to the objection following the “acknowledge and probe” interaction. If applicable, utilise approved resources (e.g. ALUNBRIG iSell, leave pieces) as part of the answer

(brigatinib)

●

CONVENIENCE

QOL

SUMMARY

See ALK+ aNSCLC, Think Brain Metastases, Choose ALUNBRIG For both intracranial and extracranial efficacy1

❍

ALUNBRIG provided superior systemic and intracranial efficacy vs crizotinib1 ❍ Halved the risk of disease progression or death vs crizotinib in ITT population

(BIRC-assessed mPFS of 24.0 months with ALUNBRIG vs 11.0 months with crizotinib, HR=0.49; P<0.0001)1

❍ Two thirds reduction in risk of intracranial disease progression or death in

patients with any brain metastases at baseline (BIRC-assessed intracranial mPFS of 24.0 months with ALUNBRIG vs 5.6 months with crizotinib, HR= 0.31; P<0.0001)1

ALUNBRIG has a generally manageable tolerability profile1

REFS

MOA

❍ In the ALTA-1L study, the most common (>25%) AEs of any grade included

diarrhoea, increased blood CPK, cough, hypertension, nausea, and increased AST1

ALUNBRIG comes with a convenient dosing schedule2 ❍ The only licensed first-line treatment for ALK+ aNSCLC that has a single tableta,

once-daily dosing regimen2–5

ALUNBRIG delivered a sustained and significantly longer duration of improvement in quality of life vs crizotinib1 ❍ Median duration of improvement in GHS/QOL not reached with ALUNBRIG

vs 12 months for crizotinib (HR=0.27; P<0.0001)1,6

When responding to objections, be sure to align with the key messaging presented in the ALUNBRIG iSell where appropriate

a In circumstances where dose is modified from the recommended dose, more than one tablet may need to be taken. Please refer to the SmPC for full dosing guidance.2

Medical Science Liaison referral: There may be occasions on which you cannot answer specific medical questions; for example, if it concerns offlabel use of ALUNBRIG, or other products in the Takeda Oncology pipeline. Such questions should be referred to Medical Information or, at the request of the HCP, can be referred directly to a Takeda Oncology Medical Science Liaison (MSL) ● There are also a number of situations in which a KAM may refer to an MSL aside from responses to specific objections. Refer to the MSL Ways of Working SOP for guidance: SOP-TUK-MI-607 V5.0 MSL Ways of Working combined ●

Aside from crizotinib, ALUNBRIG was not studied versus other ALK inhibitors.1 Because there are no head-to-head trials, we can’t compare directly to other ALK inhibitors. It is not clear if differences in outcomes are related to the study drug or differences in study design and patient populations The approval of ALUNBRIG in the first-line was based on the ALTA-1L study versus crizotinib in adult patients with ALK+ aNSCLC who had not previously received an ALK inhibitor1 At the time the trial was designed, crizotinib was the standard of care for first-line treatment2–4 ALUNBRIG provided superior systemic and intracranial efficacy vs crizotinib5 ❍ Halved the risk of disease progression or death vs crizotinib in ITT population (BIRC-assessed mPFS of 24.0 months with ALUNBRIG vs 11.0 months with crizotinib, HR=0.49; P<0.0001)5 ❍ Two thirds reduction in risk of intracranial disease progression or death in patients with any brain metastases at baseline (BIRCassessed intracranial mPFS of 24.0 months with ALUNBRIG vs 5.6 months with crizotinib, HR= 0.31; P<0.0001)5

●

Would you like to discuss the ALUNBRIG efficacy data in more detail? Now that we’ve talked a little about the efficacy of ALUNBRIG, let me provide you with additional information that may be helpful to you when making first-line treatment decisions for your patients with ALK+ aNSCLC

NB: There is a “?” tab in the iSell which can be used reactively to ensure the clinician understands alectinib trial design and headline results. This should not be used to make direct comparisons of the data set but to ensure the clinician is clear on details of the ALEX study.

References 1. ALUNBRIG Summary of Product Characteristics. 2. ClinicalTrials.gov. NCT02737501 Available at: clinicaltrials.gov/ct2/show/record/NCT02737501. Accessed November 2020. 3. Xalkori. Summary of opinion (post authorisation). Available at: www.ema.europa.eu/en/documents/ smop/chmp-post-authorisation-summary-positive-opinion-xalkori_en-0.pdf. Accessed November 2020. 4. Solomon BJ, et al. N Engl J Med 2014;371:2167–2177. 5. Camidge DR, et al. J Clin Oncol 2020;38:3592–3603.

Confidential and proprietary business information. For internal use only.

ALUNBRIG (brigatinib) | OBJECTION HANDLER | 5

Confidential and proprietary business information. For internal use only.

ALUNBRIG (brigatinib) | OBJECTION HANDLER | 15

C-ANPROM/UKI/ALUN/0006 | Date of preparation November 2020

Patient PI

EFFICACY | TOLERABILITY | DOSING | SUMMARY | GLOSSARY

What serious side effects do I need to look out for?

Nurse

Click tabs to explore key ALUNBRIG data, prescribing information and adverse event reporting Use the arrows to work through the case studies

Tell your nurse or oncologist straight away if you experience signs relating to any of the following:

Alunbrig dosing Explore two real-life ALUNBRIG® (brigatinib) patient experiences alongside relevant efficacy and safety data

If patient does not have hepatic/renal impairment:1 ● The starting dose for Alunbrig is one 90 mg tablet once daily for the first seven days (blue part of

initiation pack), and then one 180 mg tablet once daily thereafter (green part of the initiation pack)

Read Tom’s case

Read Susan’s case

A 60-year-old chef who has ALK+ aNSCLC that has progressed with CNS involvement after front-line treatment with crizotinib and is experiencing neurological symptoms.

A 73-year-old retired journalist with osteoarthritis, osteoporosis and hypothyroidism and chronic musculoskeletal pain.

Explore Tom’s experience of ALUNBRIG and the relevant supporting clinical data.

If patient has severe hepatic impairment (Child-Pugh class C):1

If patient has severe renal impairment (eGFR < 30 mL/min):1

Due to your liver condition, you will start treatment on a 60 mg dose once daily for the first seven days, and then a 120 mg dose once daily thereafter if well tolerated.

Explore Susan’s experience of ALUNBRIG after progressing on frontline crizotinib for ALK+ aNSCLC.

ALUNBRIG is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) previously treated with crizotinib.1 These are not the patients’ real names.

● Your dose will be escalated in this way so we can monitor how you respond to Alunbrig at the

Signs of muscle damage

Lung problems

Signs of inflammation of the pancreas

Signs of liver problems

Slow heartbeat

Increased blood sugar

High blood pressure

start of treatment and look out for certain side effects that occur in some patients being treated with Alunbrig1 ● Depending on how you respond to Alunbrig you may need your dose adjusted; we will make this

References 1. ALUNBRIG Summary of Product Characteristics.

decision if we need to when we monitor your progress January 2019 UK/BRIG/1810/0029k

Not for further copying or distribution

Due to your kidney condition, you will start treatment on a 60 mg dose once daily for the first seven days, and then a 90 mg dose once daily thereafter if well tolerated.

Vision problems

1. Alunbrig Summary of Product Characteristics.

CLIENT

PROJECT

WORK TYPE

Takeda Oncology

Isell detail aid

• E-Marketing Designs

CLIENT

Tenovus 1

Singing For Health Student Task Sheets Sheet One

Correlation or causation? The Task • Imagine that you work for a sunscreen company whose research team has developed a new product. Your job is to design a trial for this new sunscreen and find out if it is more effective than the existing products. It has been established that the new product is safe, but not whether it is more effective. • Explain how you could use a randomised control trial to compare the new product with the existing leading brand. • Explain why this would be a better test than simply handing out some samples of the new product to a few friends and asking them in a week’s time how it went.

Fundraising for Tenovus Cancer Care

Schools Education Programme Singing for health Secondary School Resource

Key Stage 3 and Key Stage 4 Science

tenovuscancercare.org.uk

www.tenovuscancercare.org.uk

Singing For Health Student Task Sheets Sheet Two

Teachers’ Guide Singing for Health This resource is divided into FOUR SECTIONS

Correlation or causation? The Task This story appeared in the Mail Online:

• Setting the Scene • Introducing Singing for Health and the concept of Randomised Control Trials

Introducing singing for health and the idea of randomised control trials.

Setting the scene

• Getting Better or Feeling Better • Reflecting on the Research

• Read the story and discuss what it says. Agree on the key points. • Find out what Nobel prizes are awarded for. • Did the researchers find a correlation? Suggest what evidence they had for this. • Explain why this doesn’t automatically mean that consuming milk and milk products causes more of a country’s population to be awarded Nobel prizes?

• Why might there be a link? • What would need to be done to establish whether or not there was a link?

Each section varies in length and is presented in a way that is flexible and can be used in a variety of ways, depending upon lesson length, available time and other learning activities being deployed.

Objectives: •

To understand what microscopes are used for

•

To understand what cells are and that they are affected by cancer

•

To explore the idea of ‘well-being’

Introduction: Begin by asking pupils if they know what a microscope is and what it does. This could be supported by showing images of a microscope or, even better, display one. Ask pupils to suggest what they think could be studied through a microscope. We would then recommend asking pupils to identify a range of magnified images e.g.

• In fact, the authors of the research report warned that it shouldn’t be taken as being causative. Why do you think they said this? MOTH’S EYE (SLIDE 1)

tenovuscancercare.org.uk

Singing for Health

SALT CRYSTALS (SLIDE 2)

HEAD OF A MOSQUITO (SLIDE 3)

Singing for Health

Developing the investigation

Singing for Health

Section Header Placeholder

Secondary Key Stage 3/4

Tenovus teaching materials for secondary

Supplementary powerpoint

• Three sources of evidence are being gathered Questionnaires. One of the areas of research is ﬁnding out whether people feel positive and good about themselves. Gathering their responses will be important. Breathing measurements. Although the starting point for this investigation is a sense of well-being, it seems reasonable to expect singing over a period of time to have some eﬀect on the performance of the lungs. Testing biomarkers from analysis of saliva samples. Biomarkers include indicators such as mood states, stress hormones and immune function chemicals.

•

CLIENT

PROJECT

WORK TYPE

Tenovus

Various marketing materials

• • •

Editorial Layouts New Business Visualisations PowerPoint Presentations

Think about each of these sources of evidence and why it’s being gathered.

•

Is each source testing the same thing?

•

Would you expect positive responses on one of these to mean that the researchers should get positive responses on the others?

•

What do you think they will ﬁnd out?

CLIENT

Tropicana For media use only

For media use only

The

Go dness of Juice: MEDIA INFOGRAPHIC

INTRODUCTION

Know 200 ml VITAMIN C

Only 30% of adults aged 19-64 and 10% of children aged 11-18 meet the ‘at least 5 a day’ recommendation for fruit and vegetables i

A 200ml serving of 100% pure orange

juice counts once toward your 5 a day

People who drink orange juice are

100% pure orange juice only contains sugars

that are naturally contained within the fruit from which it

DIET

providing energy to refuel the body after an overnight fast. Breakfast (breaking-the-fast) provides the brain and body with the energy it needs to function properly. Enjoying a glass of 100% pure orange juice with a wholegrain cereal such as porridge can make a great breakfast. The vitamin C in juice can help your body better absorb the iron naturally present in the oats as well as helping to maintain healthy skin and gums. In addition, oats are high in ﬁbre. A glass of 100% pure orange juice also provides: potassium, folate, a range of phytochemicals which emerging research indicates can be beneﬁcial to health, and counts towards 5 a day. What better way to start the day?

KEEPING THE IMMUNE SYSTEM

IN WORKING ORDER

which is the body’s natural defence. 100% pure orange juice is an excellent source of vitamin C which helps protect the body’s cells from damage from oxidative stress. It also contains folate which helps maintain a healthy immune system as well as being essential for cell growth and maintenance.

more likely to achieve at least 5 a dayii

an antioxidant nutrient which is important in maintaining a healthy immune system and helping the body absorb iron from plant foods

LTHY HEDA BALANCED

Breakfast is widely considered to be the most important meal of the day

Eating food and drink rich in vitamin C and folate can help maintain a healthy immune system

A 200ml serving (approximately one small glass) of orange juice is an excellent source of vitamin C –

SUGARS

is made

100%

A DAY

juicy

WITH A

BREAKFAST

Staying healthy starts with what we eat and drink and 100% pure orange juice can play an important role in a healthy, balanced diet.

Did You

KICK

START YOUR DAY

The Government’s healthy eating advice, the Eatwell Plate, demonstrates that 100% fruit juice can be part of a healthy, varied and balanced diet

100% pure orange juice is one of the most nutrient rich fruit juices iii

JUICY TIPS

Healthy FOR A

DIET

Tip

Drink a glass of juice a day with a meal

Drinking a glass of orange juice with a meal based on plant foods such as veggies, beans, lentils, whole grain nuts and seeds, can help to increase the uptake of iron from these foods which is needed for healthy blood

Tip

and porridge make 2 aJuice great breakfast

A breakfast of porridge with a glass of 100% juice ticks many key dietary recommendations: wholegrain, ﬁbre, vitamin C, 1 of your 5 a day and just enough beta glucan to help lower cholesterol

Make your own muesli

Tip For a different breakfast option, why not make your own muesli and soak it in juice to give your breakfast some zing in the morning!

4 Eat colourfully!

Tip The different colours of fruit and vegetables are derived from plant components such as carotenoids and ﬂavonoids that have been linked with health beneﬁts such as protection against cerebrovascular diseases (conditions that develop as a result of problems with the blood vessels inside the brain) iv

5 Eat a varied diet

Tip Eat a varied and balanced diet to ensure you get the full complement of vitamins and minerals your body needs

For media use only

CLIENT

PROJECT

WORK TYPE

Tropicana

Print and digital marketing materials

• Editorial Layouts • Gifs • E-Marketing Designs

THE ROLE OF FRUIT JUICE IN THE DIET How Does 100% FRUIT JUICE Fit Within a Healthy Diet? Most nutritionists and dietitians agree that 100% fruit juice can be part of a varied, healthy and balanced diet. A minimum of 150ml of 100% orange juice counts towards 5 a day. Orange juice is an excellent source of vitamin C and a good source of folate and potassium, all of which have a role in maintaining a healthy body. › Results from the National Diet and Nutrition Survey (NDNS)1 showed that adult 100% fruit juice consumers had a lower body weight, body mass index (BMI) and waist circumference than non-consumers2 › Fruit juice consumption was also associated with improved dietary quality and a lower risk of micronutrient inadequacy and it did not displace whole fruit or vegetable intake2 » Similar results were observed in the US National Health and Nutrition Examination Survey (NHANES)3 » Overall dietary quality (assessed by the Healthy Eating Index-2005) was shown to be positively associated with 100% fruit juice consumption4 › Fruit juice consumers ate more fruit and vegetable portions than non-consumers with:2

› Fruit juice consumers were also less likely to have intakes below the lower reference nutrient intake for vitamins A and C, folate, Mg, Se and Fe and superior intakes of Vitamin C, folate, thiamin, niacin, Fe, Mg, K, Zn & Se2 » Data from NHANES also revealed that consumption of orange juice was higher in those with lower BMI and consumers had higher intakes of certain vitamins and minerals5 › A higher percentage of children who consume orange juice met the estimated average requirement for vitamins A and C, folate and Mg6

» Adults: 5.1 vs. 3.7 portions a day » Children: 3.5 vs. 2.5 portions a day

EMERGING RESEARCH

Fruit ON

JUICE

Phytochemicals and fruit juice • Fruits, vegetables and 100% juices are an important source of a wide range of phytochemicals such as polyphenols • Citrus fruits and juices are a rich source of ﬂavanones, polyphenolic compounds which are members of the ﬂavonoid family

Orange juice, hesperidin and cardiovascular disease • A study has shown that orange juice, which is naturally rich in hesperidin, and an isolated form of hesperidin are both able to induce the modification of the expression of genes related to positive cardiovascular health7 • These effects were significantly greater after orange juice consumption compared to consumption of hesperidin alone, suggesting a synergy between other components within the juice7 • Hesperidin may also be responsible for the beneficial effects on vascular function which were observed following 4 weeks of orange juice consumption7

An educational resource for health professionals | November 2014

Flavonoids and health • Research suggests that flavonoids may, in part, be responsible for the health benefits of fruits and vegetables8,9 • Studies have revealed improvements in risk factors associated with cardiovascular disease and dementia following consumption of flavonoid containing foods10.11,12 Orange juice and cognitive function • Research suggests that certain flavonoid rich food and drink may influence cognitive function10.11,12 • In one study, drinking 250ml of orange juice a day for 8 weeks improved executive function and memory13

CLIENT

World Hepatitis Alliance (WHA)

ATEIFTAICSTS: HEOP W TH

Know it. Confront it.

Know the main routes of transmission of hepatitis

HEPATITIS

UNPROTECTED

BLOOD TRANSFUSIONS

SHARING

NEEDLES

This is hepatitis...

MOTHER TO

World Hepatitis Day: 28 July www.worldhepatitisday.info

USING THE

SHARING

SEX

The clock is ticking. Act now to protect a new generation.

CHILD

TOILET

Know it. Confront it.

UTENSILS

Know it. Confront it.

TOOTHBRUSHES & RAZORS

What you can do

HEPATITIS

SEE A

GET

HEPATITIS

DOCTOR VACCINATED

Hepatitis does not discriminate. 500 million people are infected.

The risk of transmission of hepatitis C during unprotected sex is considered very low, especially if you are in a long-term, stable relationship. This risk may be higher among men who have sex with men or if blood is involved.

This is hepatitis... Know it. Confront it.

This is hepatitis... World Hepatitis Day: 28 July www.worldhepatitisday.info

www.worldhepatitisalliance.org

CLIENT

PROJECT

WORK TYPE

World Hepatitis Alliance (WHA)

FreeStyle Libre marketing material

• New Business Visualisations • Infographics

The clock is ticking. Act now to protect a new generation.

This is hepatitis... World Hepatitis Day: 28 July www.worldhepatitisday.info

CLIENT

World Health Organization (WHO) THE ROLE OF INFECTION PREVENTION AND CONTROL IN PREVENTING ANTIBIOTIC RESISTANCE IN HEALTH CARE

• On average, 1 in every 10 patients is affected by health care-associated infections (HAIs) • Antibiotic-resistant HAIs can double or more, the likelihood of death • Over 50% of surgical site infections can be resistant to antibiotics

Your exclusive invitation from the

World Health Organization

Effective infection prevention and control (IPC) and water, sanitation and hygiene (WASH) stops the spread of antibiotic-resistant organisms

IPC and WASH in health care protects patients and health workers from avoidable infections

The World Health Organization (WHO) antimicrobial resistance (AMR) team are delighted to offer you the opportunity to participate in an exclusive interview with [INSERT REGIONAL / GLOBAL AMR SPOKESPERSON].

The building blocks of IPC and WASH in health care facilities are: • effective hygiene practices, including hand hygiene • core components of IPC programmes • a clean, well-functioning environment and I equipment P W

Every infection prevented is an antibiotic treatment avoided • Play your role in controlling antibiotic resistance! • Ensure IPC programmes are in place and champion IPC practices

This year’s World Antibiotic Awareness Week (WAAW) will be held from 13–19 November. This year’s key theme will focus on the importance of seeking advice from a qualified healthcare professional before taking antibiotics.

This leads to: • less spread of antibiotic-resistant organisms • a reduced need for antibiotics

IPC saves millions of lives every year EXIT

RSVP to this invitation to secure your exclusive interview with an WHO expert. Click here for more information on this year’s WAAW campaign and supporting materials

Sources: World Health Organization. Infection prevention and control. Available at: http://www.who.int/infection-prevention/en/ World Health Organization. Water sanitation and hygiene. Available at: http://www.who.int/water_sanitation_health/en/ © World Health Organization 2017. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

The role of

MISUSING AND OVERUSING

INFECTION PREVENTION CONTROL (IPC)

ANTIBIOTICS Taking antibiotics when they are not needed accelerates emergence of antibiotic resistance,

one of the biggest threats to global health

Overuse of antibiotics can cause bacteria to become resistant,

meaning current treatments will no longer work

It is the bacteria itself

– not the person or the animal – that becomes resistant to antibiotics

When bacteria become resistant to antibiotics, infections which are normally minor, such as bronchitis, sinus and ear infections, or urinary tract infections, may become

much more dangerous and require treatment with drugs that may be more expensive and more toxic Antibiotic resistant infections can longer hospital affect anyone, stays, higher of any age, in any country medical costs and more deaths Antibiotic resistant infections can lead to

You can help reduce antibiotic resistance.

Always follow the advice of a qualified health care professional when taking antibiotics

to prevent the spread of antibiotic resistance in health care The emergence of antimicrobial resistance (AMR) can be likened to a forest fire: once it takes hold, it can spread swiftly, with dire consequences.

The spread of microorganisms, including those resistant to antibiotics, can be stopped with good infection prevention and control (IPC) practices including the use of safe water, sanitation and hygiene practices (WASH) in health facilities.

WHERE WILL YOUR

NEXT MOVE

Without adequate IPC, health care facilities can become dangerous breeding grounds for bacteria and endanger the patients they aim to help – as well as staff working there.

PROJECT

WORK TYPE

World Health Organization (WHO)

Various marketing materials

• • •

Editorial Layouts Social Media Content New Business Visualisations

• Implementation of core components of successful IPC programmes • Good hygiene practices and precautions • Clean environment • Safe water • Adequate sanitation

Good IPC practices may reduce transmission of infections in health care facilities by half, saving millions of lives every year.

The emergence and spread of antimicrobial resistance (AMR) are largely due to the inappropriate use of antibiotics and poor IPC practices.

On average, 1 in every 10 patients is affected by HAIs worldwide1 and improved IPC practices can lead to more than a 30% reduction in HAI rates.

Healthcare-associated infections (HAI) can prolong hospital stays and create long-term disability – when resistant to antibiotics, can double the risk of death.

The spread of AMR is similar to that of a forest fire, with effective antibiotics representing the fire fighters needed to put out the fire – reducing AMR. However, in many cases these effective antibiotics are still at least 5 years away in their development and in the meantime, good IPC practices can be used as a ‘fire break’ to stop the spread of AMR.

Every infection prevented is an antibiotic treatment avoided – effective IPC is critical to tackling AMR. • Be a champion of IPC practices and play your role in controlling the spread of AMR. • Be a leader to ensure the core components of effective IPC programmes are in place in your facility.

CLIENT

IPC helps to control the spread of infection within health care facilities and consists of:

Effective IPC practices are critical to tackling the emergence and spread of AMR, by: • reducing the need for antibiotics by reducing the risk, transmission and spread of infections that require the use of antibiotics • reducing the spread of already circulating resistant pathogens

TAKE YOU?

Find out more about Mobility via http://intranet.who.int/sites/mobility/, or contact Human Resources at: globalmobility@who.int.

IPC is a practical, evidence-based approach preventing patients and healthcare workers from being harmed by avoidable infections.1

• PowerPoint Presentations • Infographics

CLIENT

World Health Organization INTRODUCING

GEO MOBILITY:

Country

Headqu a

rs rte

LAUNCH OF THE VOLUNTARY PHASE

Reg i

al on

VECTOR

BORNE

DISEASE

MAJOR

COPENHAGEN DENMARK

GENEVA

SWITZERLAND

OFFICES IN

Geographic (Geo) Mobility i Move for health

CAIRO

MOBILITY

EGYPT

NEW DELHI INDIA

MANILA

PHILIPPINES

BRAZZAVILLE CONGO

Geographic Mobility is an opportunity for WHO staff members to rotate to positions globally to help address the increasingly complex public health challenges of the 21st century.

A VECTOR TRANSMITS A DISEASE FROM

ONE HOST TO ANOTHER

Geo Mobility strengthens the power of ‘One WHO’ with stronger working relationships and greater knowledge sharing across the Organization. Geo Mobility will further upskill the existing, workforce to be increasingly dynamic and adaptable.

Some vector-borne diseases have been around for over

Account for around

Seeking a new challenge? Move to expand your personal and professional

Mobility i Move for Health

17%

of infectious disease cases

400 YEARS

Mobility is an opportunity for WHO staff members to rotate to positions globally to help address the increasingly complex public health challenges of the 21st century. Mobility strengthens the power of ‘One WHO’ with stronger working relationships and greater knowledge sharing across the Organization. Mobility will further upskill the existing workforce to be

horizons

Key Mobility Facts

people travelled outside their native country last yearii

and experience by working in a variety of duty stations across the Organization.

Experience different countries and cultures, learn from and transfer knowledge to other WHO colleagues and further build your career within the Organization.

Seize the opportunity: Choose your move

VECTORS

can be microscopic, but in some cases deadly

HIGH RISK AREA

THE USUAL SUSPECTS

Embrace Mobility: Move with your family

The first compendium includes a variety of technical and

Around

You are at risk if you visit or inhabit a

During the voluntary phase, the opportunity is open to WHO staff members on a fixed-term and continuing appointment, irrespective of the number of years already served in the current duty station. For more information and eligibility criteria go to (http://intranet.who.int/sites/mobility/), or contact Human Resources at: globalmobility@who.int.

increasingly dynamic and adaptable.

1 BILLION

Geo Mobility represents an exciting personal and professional development opportunity for staff to broaden their skills, knowledge

of WHO staff are eligible to take part in Mobility in the voluntary phase

management roles

geographically spread across

the three levels of the Organization

Mobility will cover

150+ country offices 5 regional offices and headquarters

3 years for voluntary phase, 3 weeks to apply once the Mobility compendium is published,

can apply for

3 positions

Where can I get more information?

This tiny mosquito…

http://intranet.who.int/sites/mobility or by email at:

Malaria

WHO is committed to supporting and ensuring a smooth transition for colleagues and their families when moving to a new post as part of the Geo Mobility programme.

May carry , which affects 275iii million people each year, killing 1.2iv million of them or even

typhus

leishmaniasis, which eats at the skin

Your next move

dengue fever

The first Mobility compendium (http://intranet.who.int/sites/mobility/) contains the list of open Eligible staff can apply for up to three positions. The deadline will be specified for three weeks after the compendium is published. If your application for Geo Mobility is successful you will be contacted by HRD by the end of March.

Bats carry the

hendra virus,

Up to 100 million cases of

and even

are reported annuallyv

posts.

globalmobility@who.int

The tiniest of fleas can transmit

rabies

Move to grow personally and professionally Mobility represents an exciting personal and professional development opportunity for staff to broaden their skills, knowledge

and experience by working in a variety of duty stations across the Organization. Experience different countries and cultures, learn from and exchange knowledge with other WHO colleagues and further build your career within the Organization. Experience at the 3 levels of the Organization will position you better for future advancement opportunities.

Key Geo facts The first compendium will include a variety of

technical and management roles geographically spread across the three levels of the Organization

Around of WHO staff are eligible to take part in Geo Mobility in the voluntary phase

Embrace Mobility: Move with your family

Geo Mobility will cover

3 years for voluntary phase, 3 weeks to apply once Mobility

compendium is published, can make up to

3 choices

157+ country offices 5 regional offices and headquarters

WHO is committed to supporting and ensuring a smooth transition for colleagues and their families when moving to a new post as part of the Mobility scheme.

Seize the opportunity: Choose your move

Geographic Mobility will be gradually rolled out across the Organization over the next three years on a voluntary basis, becoming mandatory in 2019 End of January first voluntary compendium issued

YOU CAN

The deadline will be specified for three weeks after the compendium is published End of March, applicants notified of the outcome of their application Successful colleagues will usually be asked to move to their new position within three months

REDUCE YOUR CHANCE

During the voluntary phase, the opportunity is open to WHO staff members on a fixed-term and continuing appointment, irrespective of the number of years already served in their current duty station.

OF CONTRACTING ALL OF THESE CONDITIONS

COPENHAGEN

REGIONAL

OFFICES

DENMARK

CAIRO

NEW DELHI

EGYPT

INDIA

Timeline

MANILA

PHILIPPINES

BRAZZAVILLE CONGO

Mosquito nets, insect repellents, antimalarial tablets and vaccinations

Long-sleeves can protect the skin

Take extra precaution when working near irrigated water systems

Where can I get more information? http://intranet.who.int/sites/mobility or by email at: globalmobility@who.int

Geo Mobility will be gradually rolled out across the Organization over the next three years on a voluntary basis, becoming mandatory in 2019. Geo Mobility will be evaluated annually during the voluntary phase with feedback from staff members, supervisors and staff representatives, to improve the policy and process in following years.

References i WHO ‘Exploiting the potential of vector control for disease prevention’ who.int/bulletin/volumes/83/12/942.pdf [August 2013] ii Reuters ‘International tourism to reach record 1 billion travellers in 2012’ in.reuters.com/article/2012/12/06/tourism-record-idINDEE8B50GK20121206 [August 2013] iii WHO ‘Six diseases cause 90% of infectious disease deaths’ who.int/infectious-disease-report/pages/ch2text.html [August 2013] iv WHO ‘Vector-borne disease’ who.int/heli/risks/vectors/vector/en/ [August 2013] v WHO ‘Dengue and severe dengue’ who.int/mediacentre/factsheets/fs117/en/ [August 2013]

The voluntary phase of Geo Mobility is a new opportunity for personal and professional development and one which will offer equal benefits to the Organization.

Mobility will be gradually rolled out across the Organization over the next three years on a voluntary basis, becoming mandatory in 2019

End of January 2016 first voluntary compendium issued

PROJECT

WORK TYPE

World Health Organization (WHO)

Various marketing materials

• • •

Editorial Layouts Social Media Content New Business Visualisations

End of March, applicants notified of the outcome of their application

Successful colleagues will usually be asked to move to their new position within three months

Where can I get more information?

http://intranet.who.int/sites/mobility or by email at:

globalmobility@who.int

Job number: XXXXXXXXX Date of prep: August 2013

CLIENT

The deadline to apply is three weeks after the compendium is published

• PowerPoint Presentations • Infographics

CLIENT

Avanos BRAND GUIDELINES

Released July 2018 Version 1.0

CORTRAK* NJ FEEDING

REDUCING RISK REDUCING COST

CORTRAK*: PROVIDING SOLUTIONS TO CHALLENGES

CORTRAK* is FDA cleared and studies have shown that CORTRAK* can confirm feeding tube placement at bedside without x-ray1–3

REDUCING RISK, REDUCING COST FOR NJ FEEDING IN ADULTS

2-4%

66%

EARLY ENTERAL NUTRITION IS ESSENTIAL TO AVOID THE CONSEQUENCES OF MALNUTRITION

Greater likelihood of DYING5

15.5 MINS

Greater likelihood of DEVELOPING SURGICAL SITE INFECTIONS4,6,7

An estimated 1/3 of patients enter hospital malnourished4

1.5x

Greater risk of REMISSION within 15 DAYS8

Greater likelihood of DEVELOPING PRESSURE ULCERS4,6,7

NJ, nasojejunal.

WITH CORTRAK*, EVEN PATIENTS WITH DGE CAN RECEIVE MORE EFFECTIVE NUTRITION COMPARED TO USING PROKINETICS ALONE5 † Based on a systemic literature review of nine studies.

6. Barker LA, et al. Int J Environ Res Public Health 2011;8(2):514–27

1. Gray R, et al. Nutrition Clin Pract 2007;22(4):436–44

7. Guenter P, et al. J Qual Patient Safety 2015;41(10):469–73

2. Smithard D, et al. Dysphagia 2015;30:275–285

8. Lim SL, et al. Clin Nutrit 2012;31(3):345–50

3. Taylor SJ, et al. Br J Intensive Care 2010;(summer):38–44 4. Nguyen N, et al. Crit Care 2007;11(1):R16 5. Taylor J, et al. J Parenter Enteral Nutr 2010;34:289–294 6. Koopmann MC, et al. Ann Surg 2011;253(2):297–302 7. Taylor SJ, et al. Intensive Crit Care Nurs 2019;55:10276629

aspHirate pH INDICATOR STRIPS INNOVATING THE STANDARD – HOW TO USE GUIDE

4.0

4.5

5.0

5.5 3 4.5

6.0

6.5

7.0 5 min

pH• Indicator strips for the colour change to complete Wait for 30 seconds

For •professional use only The strip can be read

IVD

≥ 7.5

15°C

Implementation of an electromagnetic imaging system to facilitate nasogastric and post-pyloric feeding tube placement in patients with and without critical illness

for up to 5 minutes, discard after use

150.1 1500001 04-2022

patients included in analysis

referrals for post-pyloric feeding

had tubes successfully fit

referrals for nasogastric feeding

had tubes successfully fit

22%

£111

£120

request for X-ray confirmation on post-pyloric placements

Mean cost per tube insertion

CORTRAK* confers clinical and cost advantages in the real-world setting

Authorised Representative

Distributor

Johnson Test Papers Ltd Hainge Park, Hainge Road Oldbury, B69 2NU United Kingdom

Avanos Medical Belgium BVBA Leonardo Da Vincilaan 1 1930 Zaventem Belgium

Tel: +44 (0)121 557 3883 Email: cs@jtp.uk.com

Tel: +00 000 000 0000 Email: avanos@avanos.com

INTRODUCTION

METHODS

Blind placement of feeding tubes at the bedside can be problematic and may require x-ray confirmation if pH testing of tube position is inconclusive. Endoscopic guidance may be used but presents challenges in terms of staffing and costs. Alternately, parenteral nutrition may be considered, however this method has numerous potential clinical considerations and is generally more costly.

A retrospective analysis of the CORTRAK* system database and medical, dietetic and nursing records was undertaken across 14 months (October 2007 to December 2008) at Pinderfields General Hospital (hospital A) and Dewsbury and District Hospital (hospital B) within Mid Yorkshire Hospitals NHS Trust. Data were collected on:

Electromagnetic sensing devices (ESD) can be used to facilitate bedside placement of nasogastric and post-pyloric feeding tubes. This study aimed to audit referral trends, practice and effectiveness of placement of nasogastric and post-pyloric feeding tubes after implementation of an ESD tube placement system (CORTRAK*) within Mid Yorkshire Hospitals NHS Trust.

• The origin of patient referral (clinical speciality and referral source) • Reasons for CORTRAK* placement • Nutritional status and preparation of the patient • Duration of placement procedure • Successful placement rates • X-ray confirmation requests due to inconclusive final images

CLIENT

PROJECT

WORK TYPE

Avanos

Print marketing materials

• Editorial Layouts • E-Marketing Designs • PowerPoint Presentations

ENSURING ACCURATE PLACEMENT

Success rate for post-pyloric placement in children for CORTRAK* vs 39.0–76.3% for blind placement1–3

Significantly fewer abdominal x-rays required to check placement (0.6–1.3 for CORTRAK* vs 1.63–2.4 for blind placement)1,2

1. NICE. Medtech Innovation briefing. Available from: www.nice.org.uk/advice/mib48/resources/cortrak-2-enteral-access-system-for-placing-nasoenteral-feeding-tubes-pdf-63499172779717. Last accessed August 2020; 2. Goggans M, et al. Nutr Clin Pract 2017;32(2):233–7; 3. Prashant J, et al. Crit Care Med 2019;47(1):211.

CORTRAK* NJ FEEDING

REDUCING RISK, REDUCING COST FOR NJ FEEDING IN CHILDREN GETTING IT RIGHT FIRST TIME

Journal of Human Nutrition and Dietetics 2010;23:61–68

Retrospective review of CORTRAK* use across first 14 months at two hospitals

36 29 20 7 3

container

• Document as per25°C local policy

LOT

5.5

5.0 5.5

aspHirate

6.0

5.0

4.5

6.0

• Place 2 –3 drops of the aspirate from the syringe on the each pad of the indicator strip o Ensure each pad is completely wetted, allowing excess aspirate to run off the indicator strip onto an absorbent towel

pH test strips for the semi-quantitative • Compare the colours on tube the indicator strip with the scale on the indication of pH in human gastric aspirate for the assessment of correct the tubestrip has been removed from o Always use the container placement.

1.5–1.7 HOURS Time to successful post-pyloric placement in children for CORTRAK* vs 4.6–21.0 hours for blind placement1,2 • A study with experienced paediatric nurses reported time to placement of 3 mins vs 20 mins for CORTRAK* vs blindplacement3

82.0– 100% CORTRAK* virtually eliminates the risk of tube misplacement (0% vs. 1.77% misplacements with conventional methods)†,2 • However, tube misplacements can occur if healthcare professionals are not suitably trained7

Windle EM, et al.

≤ 3.5

2 30 sec

CORTRAK* allows visualisation at bedside and immediate identification of misplaced tubes to minimise the risk of complications, such as lung placements1,6

PUBLICATION DISCUSSION GUIDE

Method for testing

2 - 3 drops

Delayed gastric emptying (DGE) occurs in up to 60–70% of intensive care patients and can prevent adequate enteral nutrition3,4

2. Smithard D, et al. Dysphagia 2015;30:275–85

5. Corkins MR, et al. J Parenteral Enteral Nutr 2014;38(2):186–95

Method for testing

Studies suggest that inadvertent placement into the bronchi occurs in 2–4% of blind placements2 • Equates to 5,000–110,000 misplaced tubes per annum in the UK, with the potential to cause significant morbidity and mortality2

Average time to placement of post-pyloric tubes for CORTRAK* vs 42 mins for blind placement†,2

3. FDA. Feeding tube placement systems. Available from: https://www.fda. gov/medical-devices/letters-health-care-providers/feeding-tube-placement-systems-letter-health-care-providers. Last accessed August 2020 4. Tappenden KA, et al. J Acad Nutrition Dietetics 2013;113(9):1219–37

Reduction in the time between order for tube placement and initiation of feeding1

60-70%

1. Windle E, et al. J Hum Nutr Diet 2010;23:61–8

CORTRAK*: PROVIDING SOLUTIONS TO CHALLENGES PROVIDING TIMELY FEEDING

PROVIDING TIMELY FEEDING

GETTING IT RIGHT FIRST TIME

An additional 1/3 will develop malnutrition during their stay4

ENSURING ACCURATE PLACEMENT

CLIENT

Nature’s Creations

CBD PROTEINS

CBD OILS AND TOPICALS

An exceptional range of 100% natural CBD products created to elevate your wellbeing.

N AT U R E ’ S P O W E R Tastes delicious, builds muscle and supports recovery.

CLIENT

PROJECT

WORK TYPE

Nature’s Creations Ltd

Huna product launch

• Editorial Layouts • New Business Visualisations • E-Marketing Designs • Website Design • Product and Packaging

We’re meticulous when it comes to producing CBD. Our hemp experts oversee every stage of the process bringing you pure unadulterated Huna. Whether you’re looking for

CLIENT

calming 6% CBD drops to help you snooze or powerful 26% CBD potency to support you through

Nature’s Creations

health challenges, we have a product you’ll love.

LAB TESTED

PURE

NON-GMO

GLUTEN-FREE

From our shop SEE ALL PRODUCTS

A F O R C E O F N AT U R E

Exceptional CBD products that connect you with the awe-inspiring power of nature. SHOP NOW

CBD Oil 6%

CBD Oil 12%

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor.

BUY NOW

£XX.XX

CBD power for everyone Huna means living in optimal health in harmony with nature. We’re meticulous when it comes to producing CBD. Our hemp experts oversee every stage of the process bringing you pure unadulterated Huna. Whether you’re looking for calming 6% CBD drops to help you snooze or powerful 26% CBD potency to support you through health challenges, we have a

CBD Oil 6%

CBD Oil 12%

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor.

BUY NOW

£XX.XX

product you’ll love. A F O R C E O F N AT U R E

Exceptional CBD products that connect you with the awe-inspiring power of nature.

A S F E AT U R E D I N

LAB TESTED

PURE

NON-GMO

GLUTEN-FREE

SHOP NOW

CBD power for everyone

From our shop SEE ALL PRODUCTS

Get exclusive access to our new product launches.

Huna means living in optimal health in harmony with nature. A F O R C E O F N AT U R E

We’re meticulous when it comes to producing CBD. Our hemp experts

Exceptional CBD products that

oversee every stage of the process bringing you pure unadulterated

connect you with the awe-inspiring power of nature.

Huna. Whether you’re looking for calming 6% CBD drops to help you snooze or powerful 26% CBD potency to support you through health challenges, we have a

SHOP NOW

product you’ll love.

LAB TESTED

CLIENT

Nature’s Creations Ltd

NON-GMO

About Shop

CBD Oil 6%

CBD Oil 12%

News

£XX.XX

FAQ

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor.

Contact

BUY NOW

£XX.XX

GLUTEN-FREE

PROJECT

CBD Oil 6%

CBD Oil 12%

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor.

BUY NOW

£XX.XX

Huna product launch From our shop SEE ALL PRODUCTS

PURE

CBD Oil 6%

Cart

PURE

WORK TYPE £XX.XX

CBD Oil 12%

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud.

• Editorial Layouts • New Business Visualisations • E-Marketing Designs • Website Design • Product and Packaging

A S F E AT U R E D I N

LAB TESTED

JOIN

e for

CLIENT

CooperVision Getting started with myopia management in practice

Managing myopia matters

uccessfully 8 and

What can we do?

In the UK, the number of children aged 10-16 with myopia has more than doubled over the last 50 years. Today, children are becoming myopic at a younger age meaning that they are more likely to progress faster and have higher levels of myopia.1

ws both axial length

Everyone with myopia has potential for significant ocular health risk, including increased risk of:2

Incidence of myopia in 10—16 year olds has more than doubled in the UK in the past 50 years1

⦿ Retinal detachment

Slowing progression of myopia by one dioptre in children can lower risk of myopic maculopathy by 40%3

Everyone with myopia has potential for significant ocular health risk2

⦿ Myopic maculopathy

1. Assess the risk for myopia

Myopia is a significant and increasing public health issue

• Children with myopic parents are more likely to become myopic themselves5 • Age six is a key milestone for predicting risk: +0.75D or less of hyperopia may suggest a myopic future, regardless of family history6

By 2050, 50% of the global population will develop myopia1

50%

2. Behavioural management

⦿ Glaucoma

• Spending time outdoors is protective for myopia development, but the mechanism is poorly understood7

⦿ Cataracts

• A minimum of 10 hours per week outdoors is an achievable recommendation7

Risk of myopia: How to raise parental awareness A YouGov survey commissioned by CooperVision identified that parents:4*

In Western Europe, 56% of the population are predicted to be myopic by 20501

56%

hrs

Myopia increases the risk of serious, sight-threatening eye diseases, such as:2

3. Getting started • Start building experience fitting young children with contact lenses and have your practice environment set up appropriately

Myopic maculopathy

• Adapt your approach to exams and ensure staff are well trained, especially for teach appointments

Retinal detachment

Glaucoma

Cataracts

• Provide parent and child friendly resources Are mostly unaware that the progression of myopia can be slowed

Are unaware of the health risks associated with myopia

Believe that eye care professionals should provide them with information about all options for myopia management

Parents are twice as likely to consider contact lenses for their child if recommended by an ECP

• Be friendly and use positive body language

Together we can help change the future ofchildhood myopia

• Take a look at the MiSight® 1 day website at coopervision.co.uk/contact-lenses/ misight-1-day

Introducing MiSight® 1 day daily disposable contact lenses, proven to slow the progression of childhood myopia. In a clinical study over three years, MiSight® 1 day demonstrated:3

4. Consider MiSight® 1 day MiSight® 1 day is the first daily disposable contact lens proven to slow the progression of myopia in children8*

In a robust, randomised controlled clinical study, currently in its seventh year and published in a peer-reviewed journal, MiSight® 1 day reduced the rate of myopia progression by 59% and reduced axial elongation by 52%8*

2-60. 3. Bulliomore M & 7–31. 5. McCullough S 1): 115–121. 7. Gifford lline J, Jones L, Sinnott

59%

52%

41%

reduction in myopia progression

reduction in axial elongation

showed no meaningful progression in refractive error vs. 4% using standard single-vision one-day lenses

ts subsidiaries. *The online survey selected 280 British adults. The survey included questions concerning the opinions of parents regarding contact lenses, the role of ECPs, their feelings about their child’s diagnosis, their attitudes towards their child wearing contact lenses (given different scenarios), and their understanding of myopia and its management.4

*Compared with a single-vision, one-day lens over a three-year period in children aged 8–15 years on a recommended minimum wearing time: 6+ days per week, 10+ hours per day.

THE PATIENT JOURNEY

Consider growth of the eye and the increased risk this poses to visual impairment. Drag the line to show the risk of visual impairment associated with axial elongation.

Click on each step in the patient journey to review the key actions and the support tools on offer. APPOINTMENT

<26mm:

ACTIONS

100% 3.8% risk of visual impairment

..................................................................

RECAP OF VISUAL IMPAIRMENT AND AXIAL LENGTH

Comprehensive eye exam • Symptoms and history • Habitual visual acuity (distance and near) • Autorefraction and keratometry • Manifest refraction (cyclo recommended) • Best corrected visual acuity (distance and near) • Binocular status • Ocular health • Document myopia management advice given based on findings and risk assessment guide • Demonstrate myopia with Vision Simulator • Provide Guide to Myopia Management to parents

START

40 PREVIOUS

• Vision simulator • Parent/Patient Guide to Myopia Management • Risk Assessment Guide • Axial length estimator (advanced support) • Centile-based eye growth and refractive error charts (advanced support)

Ensure glasses condition is checked and records kept at all appointments

“MiSight 1 day contact lenses can provide long-term benefits to your child’s sight – it is important to slow short-sightedness progression early! ®

How to manag e child’s screen your time during lockdown: 1. Take a bre ak from online learning and use books or other printed resources 2. Set aside times to unp lug and write by hand 3. Keep active throughout the day 4. Spend tim e outdoors 5. Stop usin g digital dev ices at least an hou r before bed

...........................

TOOLS

Indie Grewal Optometrist and President of the British Contact Lens Association

Look familiar? With Coopervision, kids can enjoy the benefits of spectacle free vision

Don’t let your child’s prescription limit their ambition”

CLIENT

PROJECT

WORK TYPE

CooperVision

MiSight and Brilliant Futures marketing material

• Editorial Layouts • Social Media Content • Gifs

• New Business Visualisations • E-Marketing Designs • Infographics

MiSight® 1 day reduces short-sightedness progression in children by

59% on average

CLIENT

European Migraine & Headache Alliance (EMHA)

I AMMORE THAN MY MIGRAINE

#morethanmymigraine

CLIENT

PROJECT

WORK TYPE

European Migraine & Headache Alliance (EMHA)

Various marketing materials

• Editorial Layouts • Social Media Content • New Business Visualisations • E-Marketing Designs

CLIENT

Swedish Orphan Biovitrum (Sobi) Introduction & tips

PAIN IN HAEMOPHILIA What is pain?

A new partner

my voice: talking with others about haemophilia

my voice, my care

Pain is the body’s way of saying something isn’t quite right – a warning sign that damage is occurring or about to happen.1,2 1,2

for people living with haemophilia

Many people with haemophilia have their own personal experience of pain.11However, it should not be considered the ‘norm’. Pain can be managed and prevented.1

Your partner’s family New friends and peers

le pouvoir du jeu

Types of pain Pain in haemophilia is often related to bleeding into joints. There are two types – although hard at times, it’s important to tell them apart as they are managed differently.1

Acute pain

Chronic pain

• Sudden short-term pain, lasting hours or days

• Persistent longerterm pain, lasting months or longer

• May feel like throbbing, sharp pain or tenderness

• May feel like aching, stiffness or ongoing discomfort

1,3–5

People at work

A guide to talking with your healthcare team about what you want to achieve and what you want your treatment and care to do for you.

Pain sites

Ce guide est conçu pour aider votre enfant à mener une vie saine et heureuse grâce à l'activité physique

Pain can occur where bleeds happen.1 The most common bleeding sites in haemophilia are the hinge joints (ankles, knees and elbows).6

1,3–5

HOW CAN PAIN BE MANAGED? Healthcare professionals

1•

As they have different causes, acute and chronic pain are managed differently. There are medical and non-medical approaches to help treat both types.1

Acute pain

Chronic pain R.I.C.E method

Relaxation techniques4

(within 24 to 48 hours)4,5,7,8 Protects from further injury and helps reduce bleeding and swelling.

Help reduce tension and stress.

Prompt treatment1,8 Acute pain caused by a bleed* typically lessens after treatment with clotting factor therapy.

Surgery 1,9,10

*Pain can also occur without a bleed.

Top tips to help take control of your haemophilia

To restore or correct the affected joint.

Working and Travelling around the World with Haemophilia

Both pain types

May 7, 2020

As people who live with haemophilia every day, we bring a unique level of expertise and knowledge that can, and should, shape the healthcare that we receive. We live in a time when modern healthcare systems are trying to move towards more personalised and patient-centred forms of medicine, with aims to empower people to have more of a say in all of the aspects that affect their health. The European Patients Forum describes patient empowerment as enabling patients “to be involved in the decision-making and management of their condition according to their preference.”

Growing up, I was often worried about how my haemophilia might impact my ability to travel the world… with bulky boxes of Factor 8, vials that needed to be kept in a fridge, never mind thinking about needles and airport security! My first experience of travelling abroad with haemophilia came whilst I was at university. As part of my studies, I had the opportunity to apply for an Erasmus+ placement in Slovakia, to work on, and learn from, a project developing nature conservation and eco-tourism. It was quite a leap to go from never having been out of the country before to travelling on my own to live and work in a new country for 6 weeks!

But what does this actually mean for us as people with haemophilia? What can you do to become empowered? Here’s some of my experiences…

Protection from bleeds1,8

Be informed One of the greatest ways that I’ve found to be empowered to have more control over my health and haemophilia is to learn more about it – this has been called ‘health literacy’. It might seem slightly contradictory that I’m suggesting that ‘living life beyond haemophilia’ involves engaging with it more. However, from my own experience, I’ve found that having the knowledge, understanding and confidence to ask relevant questions during meetings with clinicians can be crucial to becoming an active partner in decision-making processes and accessing the kind of treatment that I want. Challenging the status quo of today’s haemophilia care is about being able to ask for what you want and knowing what this might be. We’re lucky to live at a time when the accessibility of information is greater than ever before, and have routes to learn about our treatment options from a wide range of sources. The World Federation of Haemophilia is a great place to start, for example.

Be part of the haemophilia community Following on from this, we’re also living in a time when it’s easier than ever to connect with other people with (or affected by) haemophilia. As someone with no family history of haemophilia, no siblings with haemophilia, and having attended small clinics my whole life, it’s rare that I’ve had a chance to discuss my experiences with others. However, with the internet, whole communities of people living with haemophilia have formed, allowing us to explore topics of concern together, empowering one another through sharing similar stories and questions. Online platforms and haemophilia patient forums (e.g. Reddit) are a fantastic source of advice, solidarity, and current developments. Similarly, there is also a thriving community of people with haemophilia on Twitter. The main challenges here are whether to search for an Americanised or anglicised spelling! Being part of these communities have shaped my experiences of my own haemophilia and my sense of wellbeing in knowing I’m not alone. It’s also given me access to learn from, and discuss haemophilia, with a range of different people – including other people with haemophilia, of different ages and geographic contexts, clinicians with different perspectives and expertise, and researchers at the cutting edge of haemophilia. It’s meant having my own preconceptions about haemophilia challenged, learning and being inspired by the achievements of others. Doing this empowers me to have greater control over the decisions and actions affecting my haemophilia, and enables me to be confident that I can live my life beyond haemophilia.

Pain relievers5,8

Physical therapy 4,8,11

Over-the-counter or prescription pain relief medicines may be appropriate.

Future bleeds can be prevented with prophylactic therapy.

Helps manage pain and restore joint function.

Building a nature trail through wetland forest in Slovakia

Calculating the right amount of treatment to take was a challenge, and looking back, I’m not sure I got my maths right! Towards the end of the 6th week, I was running very short on treatment. It was certainly a learning experience though, and has taught me valuable lessons about always overestimating the amount of treatment I need, factoring in for bleeds, and even taking extra needles for when an initial attempt to find a vein goes wrong. The Haemophilia Society in the UK recommends taking ‘2-3 times the amount of factor you normally need’ when travelling – though for long trips, this can quickly take up a huge amount of space in your luggage. Particularly when the advice is often to stash treatment in your hand luggage, so that it doesn’t get lost or damaged in the hold.

COPING WITH PAIN

Since then, I’ve been lucky enough to travel around the world, though am always much more careful to have extra treatment with me after my initial close-call! My earlier anxieties about being stopped at security have never actually been realised – in fact, my iPad has caused me more trouble at security than my medication ever has! Though, following the World Federation of Haemophilia’s tips of travellers, I always make sure I have a letter from my clinicians to explain why I’m carrying treatment – just in case.

Pain is not just a physical discomfort, it’s also an emotional experience1,2 that can have an impact on:

Be involved in research The role played by people with haemophilia in research is changing. Scientific and healthcare researchers are increasingly keen to actively involve patients in research, doing research ‘with’ people affected by the research, rather than ‘to’, ‘about’ or ‘for’ them. Whilst haemophilia doesn’t have the same culture of involvement as other health conditions, this is growing, and will be a vital part of the future of haemophilia. Seizing these new opportunities and being involved in research allows us, as people with haemophilia, to set the agenda, and have a say on the kinds of questions that we think are important priorities and should be addressed. Examples include, The Bleeding Disorders Priority Setting Partnership, where people with haemophilia contributed to producing a list of the most pressing questions for our community, as defined by us. The People in Research website, along with The Haemophilia Society’s research page, are good places to keep an eye on for opportunities to be empowered to shape the future of haemophilia research, treatment, and care.

Estonia and Arizona – two places that my work has taken me to – something that, when I was younger, I would never have dreamed would be possible with my haemophilia.

James Gorman

30, severe haemophilia A

Daily life12

Connecting with others12,13

Being less able to carry out everyday tasks.

Wanting to socialise less with others. Having a low mood (feeling irritable, tense or withdrawn) that impacts relationships.

Personal growth12,13 Enjoying yourself 12

Feeling less productive and needing to take time off work or study.

Being less involved in usual leisure activities.

There are ways to help you cope.

STAYING ON TOP OF MENTAL HEALTH Everyone experiences and copes with pain differently.1 Pain can lead to negative emotions,5,13 which in turn can cause pain to feel worse.1,14 Below are some tips that could help you keep on top of things.

October, 2020 October, 2020

Thought Leaders: Adhering to exercise plan during the COVID-19 pandemic

Dear XXXXX Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque ultricies sit amet quam in hendrerit. Donec pulvinar lacus eget lacinia maximus. Phasellus pretium, metus eu pharetra mollis, turpis augue suscipit augue, quis aliquet libero lectus in ex. Maecenas porttitor, sem sed laoreet porttitor, ipsum tortor auctor erat, eu viverra enim arcu et mauris. Vivamus non velit at arcu rutrum efficitur sit amet eget elit. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Sed venenatis, ligula in volutpat elementum, purus sem posuere augue, at consequat elit lacus gravida dolor. Sed commodo gravida nisi, at eleifend felis pellentesque ac. Phasellus at leo laoreet, ultricies

1 1 Quality of life

Physical activity and treatment adherence during Covid-19 and the need to continue to do so

Engage in low-intensity exercise4,11,14 Easing into a routine that suits you can help improve mood, mobility and pain.

“

Find a way to relax and reduce tension4,14

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque ultricies sit amet quam in hendrerit.

Quality of life Physical activity and treatment adherence during Covid-19 and the need to continue to do so

SELF-HELP & WAYS TO TAKE CHARGE

Sleep well14,15 A good night’s sleep boosts mood. If you struggle to sleep because of pain, ask your healthcare team for support.

Meditating or breathing exercises won’t necessarily make the pain go away but may help you cope.

”

Stay in control1,13 Unhealthy behaviours to help cope with pain (for example, becoming dependent on substances) can lead to other health issues. If you relate to this, speak with your doctor as soon as possible.

Leadership Articles

Leadership Articles DOWNLOAD

DOWNLOAD

Get your team involved

2 The future of Haemophilia care post Covid-19:

You should not feel like you have to ‘put up’ with pain or face it alone. Try to open up with your haemophilia care team about how you are feeling. They can help provide psychological support and may prescribe medicine to help.8,13,16

Case studies

The future of Haemophilia care post Covid-19:

VIEW

technologies, ways of working, how Sobi can support the community

If you would like to learn more about how to live well with haemophilia, you can explore information, advice and stories at www.LiberateLife.eu <local markets to update with relevant URL>. Any medical information is for informational purposes only and is not a replacement for advice given by a physician or other medical professionals.

REFERENCES Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) © 2020 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden, +46(0)8 697 20 00 NP-9769 | Date of preparation: March 2020

Physical activity and treatment adherence during Covid-19 and the need to continue to do so

Video Media

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque ultricies sit amet quam in hendrerit. Donec pulvinar lacus eget lacinia maximus. Phasellus pretium, metus eu pharetra mollis, turpis augue suscipit augue, quis aliquet libero lectus in ex. Maecenas porttitor, sem sed laoreet porttitor, ipsum tortor

WATCH

CLIENT

PROJECT

Swedish Orphan Biovitrum (Sobi)

Print and digital marketing materials

Understanding the post-Covid patient:

WORK TYPE

keeping up health during COVID, connecting with others and resources available on the Sobi website (LiberateLife.eu) to help communities and care teams keep in touch

Lorem Ipsum Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque ultricies sit amet quam in hendrerit. WATCH

3 Understanding the post-Covid patient: keeping up health during COVID, connecting with others and resources available on the Sobi website (LiberateLife.eu) to help communities and care teams keep in touch

• Editorial Layouts • Social Media Content • Gifs • New Business Visualisations

• E-Marketing Designs • Website Design • Infographics

CLIENT

Siemens

CLIENT

PROJECT

WORK TYPE

Siemens

Financial Services Brochure Mastercard Booklet

Print Design Marketing Collateral

CLIENT

SAS - Scandinavian Airlines

CLIENT

PROJECT

WORK TYPE

Scandinavian Airlines (SAS)

Scandinavian Airlines in China

Brand localization Magazine Advertisements Online Marketing

CLIENT

SAS - Scandinavian Airlines

CLIENT

PROJECT

WORK TYPE

Scandinavian Airlines (SAS)

Beijing-Stockholm Direct Flights

Brand localization Magazine Advertisements Marketing Material Event Management

CLIENT

The Association of MBAs

IS THE GOOD OF SOCIETY INTEGRAL TO GOOD BUSINESS? BRIGHT MINDS WANTED TO SHAPE THE FUTURE OF MANAGEMENT

MBA STUDENT OF THE YEAR

AWARD 2012 NOMINATIONS NOW OPEN. ASK YOUR SCHOOL FOR DETAILS

Our previous MBA Student of the Year winners are all high achievers and ambassadors for the MBA, but another thing they have in common is the way they have utilised their MBA for the greater good. How are you planning to use your MBA? We are looking for highly-skilled and highly-motivated MBAs for the most sought-after accolade in the business education arena. The MBA Student of the Year Award comes with intense media exposure, the role of ambassador for the MBA and for the Association of MBAs and a £1,000 cash prize for the winner (£500 for the runners-up). Ask your school for details on the nominating process.

www.mbaworld.com/soty

3 3 3 3

Fr ee

Meet admissions officers

Scholarships & funding information

en try !

Accredited MBA programmes only Free informative sessions

The Accredited

MBA FAIR L O N D O N

2 0 1 2

Saturday 21 April Park Plaza Victoria Hotel, London, SW1V 1EQ Free sessions on MBA study from experts (including London Business School), advice on how to choose the right MBA programme for you, scholarships & funding, taking the GMAT, what employers look for in an MBA, PLUS prize giveaways. Register now: www.mbaworld.com/mbafair

Organised by:

INSPIRING GLOBAL EXCELLENCE

In association with: